

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :		A1	(11) International Publication Number: WO 99/52875
C07D 215/12, A61K 31/47, C07D 215/14, 215/18, 215/20, 215/42, 215/58, 401/06, 401/10, 401/14, 403/06, 405/06, 409/10, 413/06, 413/14, 417/06, 417/14, 471/10			(43) International Publication Date: 21 October 1999 (21.10.99)
(21) International Application Number: PCT/JP99/01871		(74) Agents: ASAHIWA, Tadao et al.; Osaka Plant of Takeda Chemical Industries, Ltd., 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-0024 (JP).	
(22) International Filing Date: 8 April 1999 (08.04.99)			
(30) Priority Data: 10/96422 8 April 1998 (08.04.98) JP 10/345328 4 December 1998 (04.12.98) JP		(81) Designated States: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): TAKEDA CHEMICAL INDUSTRIES, LTD. [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP).		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(72) Inventors; and (75) Inventors/Applicants (for US only): SUZUKI, Nobuhiro [JP/JP]; 1077-50, Oaza-yatabe, Tsukuba-shi, Ibaraki 305-0861 (JP). KATO, Kaneyoshi [JP/JP]; 2-40, Manuyamada 2-chome, Kawanishi-shi, Hyogo 666-0152 (JP). TAKEKAWA, Shiro [JP/JP]; 5-3-B305, Umezono 2-chome, Tsukuba-shi, Ibaraki 305-0045 (JP). TER-AUCHI, Jun [JP/JP]; 3-5-204, Hachizuka 3-chome, Ikeda-shi, Osaka 563-0024 (JP). ENDO, Satoshi [JP/JP]; 10-6-103, Kamihamuro 1-chome, Takatsuki-shi, Osaka 569-1044 (JP).			
(54) Title: AMINE COMPOUNDS, THEIR PRODUCTION AND THEIR USE AS SOMATOSTATIN RECEPTOR ANTAGONISTS OR AGONISTS			
<p style="text-align: center;">(I)</p>			
(57) Abstract			
<p>The present invention provides a compound of formula (I) wherein Ar represents an aromatic group which may be substituted; X represents methylene, S, SO, SO₂ or CO; Y represents a spacer having a main chain of 2 to 5 atoms; n represents an integer of 1 to 5; i) R¹ and R² each represents a hydrogen atom or a lower alkyl which may be substituted, ii) R¹ and R² form, taken together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic ring which may be substituted, or iii) R¹ or R² together with -(CH₂)_n-N= form, bonded to a component atom of Ring B, a spiro-ring which may be substituted; Ring A represents an aromatic Ring which may be substituted; Ring B represents a 4- to 7-membered nitrogen-containing non-aromatic ring which may be further substituted by alkyl or acyl, with a proviso that X represents S, SO, SO₂ or CO when Ring A has as a substituent a group represented by the formula: -NHCOR¹¹ where R¹¹ represents alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or a group represented by the formula: -NHR¹² where R¹² represents alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl, or a salt thereof; which has an excellent somatostatin receptor binding inhibition action.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CI	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DESCRIPTION**AMINE COMPOUNDS, THEIR PRODUCTION AND THEIR USE AS SOMATOSTATIN RECEPTOR ANTAGONISTS OR AGONISTS****5 TECHNICAL FIELD**

The present invention relates to novel amine compounds, production thereof and a pharmaceutical composition comprising them. In further detail, the present invention relates to a compound which has a somatostatin receptor binding inhibition activity, and is useful for preventing and/or treating diseases associated with somatostatin.

BACKGROUND ART

Somatostatin was found to be a growth hormone inhibiting factor (somatotropin release inhibiting factor; SRIF) in 1973.

Somatostatin receptors were found to comprise five subtypes and named as SSTR1, SSTR2, SSTR3, SSTR4 and SSTR5 respectively (e.g., Endocrinology, vol. 136, pp. 3695-3697, 1995; Trends in Pharmacological Sciences, pp. 87-94, 1997; Life Science, Vol. 57, pp. 1249-1265, 1995).


Somatostatin is known to inhibit production and/or secretion of various hormones, growth factors, and physiologically active substances. As the hormones inhibited by somatostatin, mentioned are growth hormone (GH), thyroid-stimulating hormones (TSH), prolactin, insulin, and glucagon. Therefore, somatostatin has various functions in endocrine systems, exocrine systems and nerve systems, and drugs targeting somatostatin are being developed (e.g., Endocrinology, vol. 136, p. 3695-3697, 1995; Trends in Pharmacological Sciences, pp. 87-94, vol. 18, 1997).

Diseases caused by somatostatin include life-style related diseases such as diabetes; central nervous system diseases; immune system diseases, and hormone-dependent tumors. Trials to develop somatostatin itself or

somatostatin analogues as a drug have been conducted. For instance, octreotide known as a somatostatin receptor agonist has been marketed as a drug for treating hormone-dependent tumors.


5

As a compound having a somatostatin receptor binding activity, especially a selective SSTR1 antagonist activity, there is known a compound represented by the formula:



10 wherein X represents O or H, H; Y represents -CH₂- , -O-, -NH- or -S-; R₁ represents H or C₁₋₄ alkyl; R₂ represents H, benzyl, etc.; R₃ represents H, C₁₋₄ alkyl, etc.; R₄ represents hydrogen atom or halogen (WO97/03054).


15 As a compound which has a selective SSTR4 binding activity and is expected to have a glaucoma treating activity, there is known a compound represented by the formula:



(J. Am. Chem. Soc., vol.120, pp.1368-1373, 1998;
20 WO97/43728).

On the other hand, the following compounds are known as amine compounds.


1) J. Med. Chem., vol.34, pp.2624-2633, 1991 describes, as a compound having a weak analgesic activity, a compound represented by the following formula:



2) JP-A 8(1996)-176087 describes 3-(N,N-dimethylaminomethyl)-1,2,3,4-tetrahydroquinoline as a synthetic intermediate of a compound represented by the formula:


$$\begin{array}{c}
 \text{R}_4 \text{---} \text{N}(\text{H}) \text{---} \text{C}(\text{R}_5) \text{---} \text{C}(\text{R}_6) \text{---} \text{C}(\text{R}_7) \text{---} \text{NH} \text{---} \text{R}'_8 \\
 | \qquad \qquad \qquad | \qquad \qquad \qquad | \\
 \text{R}_1 \text{---} \text{X} \text{---} \text{C}(\text{R}_2) \text{---} \text{C}(\text{R}_3) \text{---} \text{C}(=\text{O}) \text{---}
 \end{array}$$

 wherein R_1 represents arylamino such as



A represents a direct bond, methylene, ethylene, imino, oxy or thio; R_9 represents C_{1-4} alkoxy carbonylamino- C_{1-4} alkyl, etc.; R_{10} represents hydrogen or C_{1-4} alkyl; R_{11} represents hydrogen or halogen; etc.; X represents carbonyl, etc.; R_2 and R_3 represent hydrogen, etc.; R_5 represents hydroxyl, etc.; R_6 represents hydrogen, etc.; R_7 represents hydrogen, etc.; R'_8 represents aliphatic group, etc., which is described to be useful in the treatment of hypertension.

3) WO97/12860 describes, as a compound having an acyl-coenzyme A: cholesterol acyltransferase inhibiting activity and a lipid peroxidation inhibiting activity, a heterocyclic compound represented by the formula:




wherein at least one of R₁, R₂ and R₅ represents alkyl or alkenyl which is substituted by hydroxy, an acidic group, alkoxycarbonyl or -NR₉R₁₀, wherein R₉ and R₁₀ respectively represent hydrogen atom or lower alkyl, etc., and the remaining two groups independently represent hydrogen atom, lower alkyl or lower alkoxy; either of R₂ and R₅ represents a group represented by the formula: -NHCOR, wherein R, represents alkyl, etc., and the remaining groups represent hydrogen atom, lower alkyl or lower alkoxy; R₆ represents alkyl, alkenyl, alkoxylalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl or arylalkyl; Z represents nitrogen atom substituted by R₆; or a combined group forming 5-membered ring or 6-membered ring together with a carbon atom of benzene ring attached to the nitrogen atom and a carbon atom adjacent to the carbon atom, or a pharmaceutically acceptable salt thereof.

Conventional somatostatin and its analogues are all peptides. They are problematic in their oral absorbability, pharmacokinetics, etc. and are therefore unsatisfactory as medicines. It is desired to develop a compound which is different from conventional known compounds in its chemical structure, and which has a selective or nonselective affinity to somatostatin receptor subtypes, or an excellent somatostatin receptor binding inhibiting activity, and which has satisfactory properties as a medicine.

DISCLOSURE OF INVENTION

The present inventors have studied various compounds having a somatostatin receptor binding inhibiting activity,

and, as a result, have succeeded in, for the first time, the production of a compound represented by the formula (I):



wherein Ar represents an aromatic group which may be substituted;

X represents methylene, S, SO, SO₂ or CO;

Y represents a spacer having a main chain of 2 to 5 atoms;

n represents an integer of 1 to 5;

i) R¹ and R² each represents a hydrogen atom or a lower alkyl which may be substituted,

ii) R¹ and R² form, taken together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic ring which may be substituted, or

iii) R¹ or R², together with -(CH₂)_n-N= form, bonded to a component atom of Ring B, a spiro-ring which may be substituted;

Ring A represents an aromatic ring which may be substituted;

Ring B represents a 4- to 7-membered nitrogen-containing non-aromatic ring which may be further substituted by alkyl or acyl,

with a proviso that X represents S, SO, SO₂ or CO when Ring A has as a substituent a group represented by the formula:

-NHCOR¹¹ where R¹¹ represents alkyl, alkoxyalkyl,

alkylthioalkyl, cycloalkyl, cycloalkylalkyl, aryl,

arylalkyl or a group represented by the formula: -NHR¹² where


R¹² represents alkyl, cycloalkyl, cycloalkylalkyl, aryl or

arylalkyl, or a salt thereof [hereafter sometimes referred

to as compound (I)], which is characterized by the chemical

structure in that the nitrogen atom of Ring B in the skeletal

structure represented by the formula:




wherein symbols have the same meanings as above, is substituted by the group represented by the formula: - X-Y-Ar where each symbol has the same meaning as above.

5

We have found for the first time that based on its specific chemical structure, compound (I) has an unexpectedly excellent somatostatin receptor binding inhibiting activity, etc.,

10

that a compound of the formula (I'):



15

wherein X' represents methylene, S, SO, SO₂ or CO; other symbols have the same meanings as above; or a salt thereof [hereinafter sometimes referred to as compound (I')] also has an unexpectedly excellent somatostatin receptor binding inhibiting activity, and that these compounds have low toxicity and are therefore satisfactory as medicines. Compound (I) is within the scope of compound (I'). On the basis of these findings, the inventors have completed the present invention.

20

Specifically, the present invention relates to:

25

(1) compound (I),

(2) a compound of the above (1), wherein Ring B

25

represents a 4- to 7-membered nitrogen-containing non-aromatic ring which may be substituted by alkyl;

30

(3) a compound of the above (1), wherein Ar represents an aromatic ring assembly group which may be substituted or a fused aromatic group which may be substituted;

(4) a compound of the above (1), wherein X represents

(1) CO_2 ;

(2) a compound of the above (1), wherein Y represents a C_{2-5} alkylene which may be substituted;

(3) a compound of the above (2), wherein the substituent of the C_{2-5} alkylene represented by Y is acylamino;

(4) a compound of the above (1), wherein n represents 1 or 2;

(5) a compound of the above (1), wherein the substituent of the C_{2-5} alkylene represented by Y is acylamino;

(6) a compound of the above (5), wherein the substituent of the C_{2-5} alkylene represented by Y is acylamino;

(7) a compound of the above (1), wherein n represents 1 or 2;


(8) a compound of the above (1), wherein R^1 and R^2 each represents a hydrogen atom or a lower alkyl which may be substituted;

(9) a compound of the above (1), wherein R^1 and R^2 form, taken together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic ring which may be substituted;

(10) a compound of the above (9), wherein the nitrogen-containing heterocyclic ring is pyrrolidine, piperidine, piperazine or morpholine;

(11) a compound of the above (1), wherein Ring A is a benzene ring which may be substituted;

(12) a compound of the above (1), which is a compound of the formula:



wherein Ring A' is a benzene ring which may be substituted; Z represents methylene or imino which may be substituted; the other symbols have the same meanings as in the above (1), or a salt thereof;

(13) a compound of the above (12), wherein Z is methylene;

(14) a compound of the above (1), wherein Ar represents


(i) phenyl; 2-, 4- or 5-thiazolyl; 2-, 4- or 5-oxazolyl; 2-, 3- or 4-pyridyl; or 1,2,4- or 1,3,4-oxadiazolyl;

(ii) 2-, 3- or 4-biphenyl; 3-(1-naphthyl)-1,2,4-oxadiazol-5-yl; 3-(2-naphthyl)-1,2,4-oxadiazol-5-yl; 3-(2-benzofuranyl)-1,2,4-oxadiazol-5-yl; 3-phenyl-1,2,4-oxadiazol-5-yl; 3-(2-benzoxazolyl)-1,2,4-oxadiazol-5-yl; 3-(3-indolyl)-1,2,4-oxadiazol-5-yl; 3-(2-indolyl)-1,2,4-oxadiazol-5-yl; 4-phenylthiazol-2-yl; 4-(2-benzofuranyl)thiazol-2-yl; 4-phenyl-1,3-oxazol-5-yl; 5-phenyl-oxazol-2-yl; 4-(2-thienyl)phenyl; 4-(3-pyridyl)phenyl; 4-(2-naphthyl)phenyl; or 4,4'-terphenyl; or


(iii) 2-, 3- or 4-quinolyl; or 1-, 2- or 3-indolyl; each of which (i), (ii) and (iii) may be substituted by a group selected from the group consisting of halogen atom; C₁₋₃ alkyleneoxy; optionally halogenated C₁₋₆ alkyl; C₆₋₁₀ aryloxy-C₁₋₆ alkyl; C₁₋₆ alkyl-C₆₋₁₀ aryl-C₂₋₆ alkenyl; C₁₋₆ aralkyl; optionally substituted by halogen atom or C₁₋₆ alkoxy; hydroxy; C₆₋₁₀ aryloxy; optionally substituted by halogen atom or C₁₋₆ alkoxy; optionally halogenated C₁₋₆ alkyl-carbonyl; C₁₋₆ alkoxy-carbonyl; C₆₋₁₀ aryl-carbonyl and C₆₋₁₀ arylsulfonyl optionally substituted by C₁₋₆ alkyl; X represents methylene, CO or SO₂; Y represents

(a) C₂₋₅ alkylene which may be substituted by


- ① cyano,
- ② C₆₋₁₀ aryl,
- ③ a group represented by the formula:



wherein J¹ and J² each represents CH; C(OH) or N; Q¹ and Q² each represents -(CH₂)_p- or -(CH₂)_p-CO-(CH₂)_q- where p and q each represents an integer of 0 to 3;





represents (i) a group represented by the formula:



wherein W^1 represents halogen atom, cyano, optionally halogenated C_{1-6} alkyl, optionally halogenated C_{1-6} alkoxy, optionally halogenated C_{1-6} alkyl-carbonyl, nitro or C_{6-10} aryl;

(ii) pyridyl, or pyrimidinyl; or

(iii) a group represented by the formula:



wherein W^3 represents hydrogen atom or optionally halogenated C_{1-6} alkyl,


④ C_{1-6} aralkyloxy-carboxamido,

⑤ amino,

⑥ C_{1-6} aralkyl-carboxamido,

⑦ C_{1-6} alkoxy-carbonyl-piperazinyl-carboxamido; or

⑧ a group represented by the formula:



wherein W^2 represents optionally halogenated C_{1-6} alkoxy;

(b) C_{2-5} alkenylene,

(c) $-(CH)_m-Y^{1a}-$ wherein m represents an integer of 1 to 4, Y^{1a} represents O or NR^{8a} where R^{8a} represents hydrogen atom

or C_{6-10} arylsulfonyl which may be substituted by C_{1-6} alkyl,
or


(d) $-\text{NH}-(\text{CH}_2)_r-$ wherein r represents an integer of 1 to 4;
n represents 1 or 2;

5 i) R^1 and R^2 each represents a hydrogen atom or C_{1-6} alkyl
which may be substituted by C_{6-10} aryl,

ii) R^1 and R^2 form, taken together with the adjacent
nitrogen atom, morpholine, piperidine, piperazine or
pyrrolidine, each of which may be substituted by C_{6-10} aryl,

10 or



iii) R^1 together with $-(\text{CH}_2)_n-\text{N}(R^2)-$ forms, bonded to a
component atom of Ring B, a 6-membered spiro-ring
represented by the formula:




15 wherein R^2 represents C_{1-6} alkyl;

Ring A represents benzene ring which may be substituted by
 C_{1-6} alkoxy, C_{6-10} aryl- C_{7-16} aralkyloxy, halogen atom, or
optionally halogenated C_{1-6} alkyl-carboxamido; and

Ring B represents



or



20

each of which may be substituted by C_{1-6} alkyl, formyl or
 C_{1-6} alkyl-carbonyl;

(15) a compound of the above (14), wherein Y
represents

25 (a) C_{2-5} alkylene which may be substituted by

① cyano,

② C_{6-10} aryl,

③ C_{7-16} aralkyloxy-carboxamido, or

④ amino,

(b) C₂₋₅ alkenylene,

(c) -(CH)_m-Y^{1a}- wherein m represents an integer of 1 to 4, Y^{1a} represents O or NR^{8a} where R^{8a} represents hydrogen atom or C₆₋₁₀ arylsulfonyl which may be substituted by C₁₋₆ alkyl, or

(d) -NH-(CH₂)_r- wherein r represents an integer of 1 to 4;

(16) a compound of the above (14), wherein X represents CO;


Y represents

(a) C₂₋₅ alkylene which may be substituted by


① a group represented by the formula:



wherein J¹ and J² each represents CH; C(OH); or N; Q¹ and Q² each represents -(CH₂)_p- or -(CH₂)_p-CO-(CH₂)_q- where p and q each represents an integer of 0 to 3;



represents (i) a group represented by the formula:





wherein W¹ represents halogen atom, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₁₋₆ alkoxy, optionally halogenated C₁₋₆ alkyl-carbonyl, nitro, or C₆.

10. aryl;

(ii) pyridyl, or pyrimidinyl, or

25 (iii) a group represented by the formula:



wherein W³ represents hydrogen atom or optionally halogenated C₁₋₆ alkyl,


② C₇₋₁₆ aralkyloxy-carboxamido,

③ amino,

④ C₇₋₁₆ aralkyl-carboxamido,

⑤ C₁₋₆ alkoxy-carbonyl-piperazinyl-carboxamido, or

⑥ a group represented by the formula:



wherein W² represents optionally halogenated C₁₋₆ alkoxy;

(b) -(CH)_m-Y^{1a}- wherein m represents an integer of 1 to 4,

Y^{1a} represents O or NR^{8a}, where R^{8a} represents hydrogen atom or C₆₋₁₀ arylsulfonyl which may be substituted by C₁₋₆ alkyl, or


(c) -NH-(CH₂)_r- wherein r represents an integer of 1 to 4;

15 n represents 1;

i) R¹ and R² each represents a hydrogen atom or C₁₋₆ alkyl;

Ring A represents benzene ring; and

Ring B represents



20 (17) a compound of the above (16), wherein Ar is 3-indolyl;

(18) a compound of the above (1), which is

3-(R)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-

25 yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline or a salt thereof,

3-(S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-
2-[(R)-(4-phenylpiperazin-1-
yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline
or a salt thereof,

5 3-(R)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-
2-[(R)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-
yl)piperidinocarbonylamino]propanoyl]-1,2,3,4-
tetrahydroquinoline or a salt thereof,

10 3-(S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-
2-[(R)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-
yl)piperidinocarbonylamino]propanoyl]-1,2,3,4-
tetrahydroquinoline or a salt thereof,

15 3-(R)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-
2-[(R)-[4-(2-methyl)phenylpiperazin-1-
yl]carbonylaminopropanoyl]-1,2,3,4-tetrahydroquinoline
or a salt thereof,

20 3-(S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-
2-[(R)-[4-(2-methyl)phenylpiperazin-1-
yl]carbonylaminopropanoyl]-1,2,3,4-tetrahydroquinoline
or a salt thereof,

3-(R,S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-
yl)-2-[(R)-1-benzoyl-4-
piperidinocarbonylamino]propanoyl]-6-methoxy-1,2,3,4-
tetrahydroquinoline or a salt thereof,

25 6-Chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[3-
(indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-
yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline
or a salt thereof,


30 6-Chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[3-
(indol-3-yl)-2-[(R)-4-(2-oxo-2,3-dihydro-1H-
benzimidazol-1-yl)piperidinocarbonylamino]propanoyl]-
1,2,3,4-tetrahydroquinoline or a salt thereof,

35 1-Benzoyl-N-[(R)-2-[6-chloro-3-[(N,N-
dimethylamino)methyl]-1,2,3,4-tetrahydroquinolin-1-yl]-
1-[3-(indol-3-yl)propanoyl]-4-piperidinecarboxamide or a
salt thereof,

1-[3-(4-Biphenylyl)propanoyl]-3-(R)-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline p-toluenesulfonate or a salt thereof, or

1-[3-(4-Biphenylyl)propanoyl]-3-(S)-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline or a salt thereof;

(19) a process for producing a compound of the above (1), which comprises; reacting a compound of the formula:



wherein each symbols has the same meanings as in claim 1, or a salt thereof, with a compound of the formula:

L-X-Y-Ar

wherein L represents a leaving group, and the other symbols have the same meanings as in the above (1), or a salt thereof;

(20) a pharmaceutical composition which comprises a compound of the above (1);

(21) a pharmaceutical composition of the above (20) which is a somatostatin receptor binding inhibitor;

(22) a pharmaceutical composition of the above (21) which is a somatostatin receptor agonist;

(23) a pharmaceutical composition of the above (21) which is a somatostatin receptor antagonist;

(24) a prodrug of a compound of the above (1);

(25) a pharmaceutical composition which comprises a prodrug of the above (24);

(26) a somatostatin receptor binding inhibitor which comprises compound (I');

(27) an inhibitor of the above (26), which is for preventing or treating glaucoma, acromegaly, diabetes, diabetic complications, depression or tumor;

(28) an inhibitor of the above (26), which is an

analgesic agent; etc.

The "hydrocarbon group" in the present specification means a group formed by removing one hydrogen atom from a hydrocarbon compound, as exemplified by acyclic or cyclic hydrocarbon group such as alkyl, alkenyl, alkynyl, cycloalkyl, aryl and aralkyl. Among them, the following C₁₋₁₄ acyclic or cyclic hydrocarbon groups are preferable:

- 10 a) C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, etc.),
- b) C₂₋₆ alkenyl (e.g., vinyl, allyl, isopropenyl, 2-butenyl, etc.),
- c) C₂₋₆ alkynyl (e.g., ethynyl, propargyl, 2-butynyl, etc.),
- d) C₃₋₆ cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.), and C₃₋₆ cycloalkyl being optionally condensed with one benzene ring,
- e) C₆₋₁₄ aryl (e.g., phenyl, 1-naphthyl, 2-naphthyl, 2-indenyl, 2-anthryl, etc.), preferably phenyl,
- f) C₇₋₁₁ aralkyl (e.g., benzyl, phenethyl, diphenylmethyl, triphenylmethyl, 1-naphthylmethyl, 2-naphthylmethyl, 2,2-diphenylethyl, 3-phenylpropyl, 4-phenylbutyl, 5-phenylpentyl, etc.), preferably benzyl.

The "optionally halogenated C₁₋₆ alkyl" in the present specification includes, for example, C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, etc.) optionally having 1 to 5, preferably 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine, etc.). Thus, for example, methyl, chloromethyl, difluoromethyl, trichloromethyl, trifluoromethyl, ethyl, 2-bromoethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, propyl, 3,3,3-trifluoropropyl, isopropyl, butyl, 4,4,4-trifluorobutyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 5,5,5-trifluoropentyl, hexyl, 6,6,6-trifluorohexyl, etc. can be mentioned.

The "optionally halogenated C₃₋₆ cycloalkyl" in the

present specification includes, for example, C₃₋₆ cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.) optionally having 1 to 5, preferably 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine, etc.). Thus, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4,4-dichlorocyclohexyl, 2,2,3,3-tetrafluorocyclopentyl, 4-chlorocyclohexyl, etc. can be mentioned.

The "optionally halogenated C₁₋₆ alkoxy" in the present specification includes, for example, C₁₋₆ alkoxy (e.g., methoxy, ethoxy, propoxy, butoxy, pentyloxy, etc.) optionally having 1 to 5, preferably 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine, etc.). Thus, for example, methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, 2,2,2-trifluoroethoxy, propoxy, isopropoxy, butoxy, 4,4,4-trifluorobutoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy, etc. can be mentioned.

The "optionally halogenated C₁₋₆ alkylthio" in the present specification includes, for example, C₁₋₆ alkylthio (e.g., methylthio, ethylthio, propylthio, isopropylthio, butylthio, sec-butylthio, tert-butylthio, etc.) optionally having 1 to 5, preferably 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine, etc.). Thus, for example, methylthio, difluoromethylthio, trifluoromethylthio, ethylthio, propylthio, isopropylthio, butylthio, 4,4,4-trifluorobutylthio, pentylthio, hexylthio, etc. can be mentioned.

The "optionally halogenated C₁₋₆ alkyl-carbonyl" in the present specification includes, for example, C₁₋₆ alkyl-carbonyl (e.g., acetyl, propanoyl, butanoyl, pentanoyl, hexanoyl, etc.) optionally having 1 to 5, preferably 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine, etc.). Thus, for example, acetyl, monochloroacetyl, trifluoroacetyl, trichloroacetyl, propanoyl, butanoyl, pentanoyl, hexanoyl, etc. can be mentioned.

The "optionally halogenated C₁₋₆ alkylsulfonyl" in the present specification includes, for example, C₁₋₆ alkylsulfonyl (e.g., methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl, etc.) optionally having 1 to 5, preferably 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine, etc.). Thus, for example, methylsulfonyl, difluoromethylsulfonyl, trifluoromethylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, 4,4,4-trifluorobutylsulfonyl, pentylsulfonyl, hexylsulfonyl, etc. can be mentioned.

The "optionally halogenated C₁₋₆ alkyl-carboxamido" in the present specification includes, for example, C₁₋₆ alkyl-carboxamido (e.g., acetamide, etc.) optionally having 1 to 5, preferably 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine, etc.). Thus, for example, acetamido, trifluoroacetamido, propanamido, butanamido, etc. can be mentioned.

In the above-mentioned formulae, the "aromatic group" of the "aromatic group which may be substituted" for Ar includes, for example, a monocyclic aromatic group, an aromatic ring assembly group, a fused aromatic group, etc.

The "monocyclic aromatic group" includes, for example, a monovalent group which is derived by removing an optional hydrogen atom from benzene ring, or a 5- or 6-membered aromatic heterocyclic ring.

The "5- or 6-membered aromatic heterocyclic ring" includes, for example, 5- or 6-membered aromatic heterocyclic rings containing one or more (e.g., 1 to 3) hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms in addition to carbon atoms, etc. Concretely mentioned are thiophene, furan, pyrrole, imidazole, pyrazole, thiazole, oxazole, pyridine, pyrazine, pyrimidine, pyridazine, etc.

Concrete examples of the "monocyclic aromatic group" includes, phenyl; 2- or 3-thienyl; 2- or 3-furyl; 1-, 2- or 3-pyrrolyl; 2- or 4-imidazolyl; 3- or 4-pyrazolyl; 2-, 4- or 5-thiazolyl; 2-, 4- or 5-oxazolyl; 2-, 3- or 4-pyridyl; 2-pyrazinyl; 2-, 4- or 5-pyrimidinyl; 2-, 4- or 5-pyridazinyl; etc.

The "aromatic ring assembly group" includes, for example, a group derived by removing an optional hydrogen atom from aromatic ring assemblies in which two or more, preferably two or three aromatic rings are directly interconnected with each other by single bond(s) and the number of such direct ring junctions is one less than the number of the aromatic rings involved. The "aromatic ring" includes, for example, an aromatic hydrocarbon, an aromatic heterocyclic ring, etc.

The above-mentioned "aromatic hydrocarbon" includes, for example, a C₆₋₁₄ monocyclic or fused polycyclic (bi- or tri-cyclic) aromatic hydrocarbon (e.g., benzene, naphthalene, indene, anthracene, etc.).

The above-mentioned "aromatic heterocyclic ring" includes, for example, 5- to 14-membered, preferably 5- to 10-membered aromatic heterocyclic rings containing one or more (e.g., 1 to 4) hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms in addition to carbon atoms, etc. Concretely mentioned is an aromatic heterocyclic ring, such as thiophene, benzothiophene, benzofuran, benzimidazole, benzoxazole, benzothiazole, benzisothiazole, naphtho[2,3-b]thiophene, furan, phenoxythiin, pyrrole, imidazole, pyrazole, oxazole, isoxazole, 1,2,4-oxadiazole, 1,3,4-oxadiazole, 1,2,4-thiadiazole, 1,3,4-thiadiazole, pyridine, pyrazine, pyrimidine, pyridazine, indole, isoindole, 1H-indazole, purine, 4H-quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, carbazole, β-carboline, phenanthridine,

acridine, phenazine, thiazole, isothiazole, phenothiazine, furazan, phenoxazine, phthalimide, etc.; and a ring as formed through condensation of the above ring, preferably a monocyclic ring, with one or more, preferably one or two aromatic rings (e.g., benzene ring, etc.); etc.

The aromatic ring assemblies in which these rings are directly bonded to each other via a single bond includes, for example, one to be composed of two or three, preferably two aromatic rings selected from the group consisting of benzene ring, naphthalene ring and 5- to 10-membered (preferably 5- or 6-membered) aromatic heterocyclic ring. Preferred examples of the aromatic ring assemblies include one composed of two or three aromatic rings selected from the group consisting of benzene, naphthalene, pyridine, pyrimidine, thiophene, furan, thiazole, isothiazole, oxazole, 1,2,4-oxadiazole, 1,3,4-oxadiazole, 1,2,4-thiadiazole, 1,3,4-thiadiazole, quinoline, isoquinoline, indole, benzothiophene, benzoxazole, benzothiazole, and benzofuran. As specific examples of the aromatic ring assembly group, mentioned are 2-, 3- or 4-biphenyl; 3-(1-naphthyl)-1,2,4-oxadiazol-5-yl; 3-(2-naphthyl)-1,2,4-oxadiazol-5-yl; 3-(2-benzofuranyl)-1,2,4-oxadiazol-5-yl; 3-phenyl-1,2,4-oxadiazol-5-yl; 3-(2-benzoxazolyl)-1,2,4-oxadiazol-5-yl; 3-(3-indolyl)-1,2,4-oxadiazol-5-yl; 3-(3-indolyl)-1,2,4-oxadiazol-5-yl; 4-phenylthiazol-2-yl; 4-(2-benzofuranyl)-thiazol-2-yl; 4-phenyl-1,3-oxazol-5-yl; 5-phenyl-isothiazol-4-yl; 5-phenyloxazol-2-yl; 4-(2-thienyl)phenyl; 4-(3-thienyl)phenyl; 3-(3-pyridyl)phenyl; 4-(3-pyridyl)phenyl; 6-phenyl-3-pyridyl; 5-phenyl-1,3,4-oxadiazol-2-yl; 4-(2-naphthyl)phenyl; 4-(2-benzofuranyl)phenyl; 4,4'-terphenyl; etc.

The "fused aromatic ring" includes, for example, a monovalent group derived by removing an optional hydrogen atom from a fused polycyclic (preferably bi- or tetra-cyclic, preferably bi- or tri-cyclic) aromatic ring. The

"fused polycyclic aromatic ring" includes, for example, a fused polycyclic aromatic hydrocarbon, a fused polycyclic aromatic heterocyclic ring, etc.

The "fused polycyclic aromatic hydrocarbon" includes, for example, a C₉₋₁₄ fused polycyclic (bi- or tri-cyclic) aromatic hydrocarbon (e.g., naphthalene, indene, anthracene, etc.).

The "fused polycyclic aromatic heterocyclic ring" includes, for example, 9- to 14-membered, preferably 9- to 10-membered fused polycyclic aromatic heterocyclic rings containing one or more (e.g., 1 to 4) hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms in addition to carbon atoms, etc. Concretely mentioned is an aromatic heterocyclic ring, such as benzofuran, benzimidazole, benzoxazole, benzothiazole, benzisothiazole, naphtho[2,3-b]thiophene, isoquinoline, quinoline, indole, quinoxaline, phenanthridine, phenothiazine, phenoaxazine, phthalimide, and etc.

Specific examples of the "fused aromatic ring" includes, for example, 1-naphthyl, 2-naphthyl, 2-quinolyl, 3-quinolyl, 4-quinolyl, 2-benzofuranyl, 2-benzothiazolyl, 2-benzimidazolyl, 1-indolyl, 2-indolyl, 3-indolyl, etc.

Among the above groups, those preferred as the aromatic ring for Ar are

- (i) monocyclic aromatic groups such as phenyl; 2-, 4- or 5-thiazolyl; 2-, 4- or 5-oxazolyl; 2-, 3- or 4-pyridyl; 1,2,4- or 1,3,4-oxadiazolyl; and etc.;
- (ii) aromatic ring assembly groups such as 2-, 3- or 4-biphenyl; 3-(1-naphthyl)-1,2,4-oxadiazol-5-yl; 3-(2-naphthyl)-1,2,4-oxadiazol-5-yl; 3-(2-benzofuranyl)-1,2,4-oxadiazol-5-yl; 3-phenyl-1,2,4-oxadiazol-5-yl; 3-(2-benzoxazolyl)-1,2,4-oxadiazol-5-yl; 3-(3-indolyl)-1,2,4-oxadiazol-5-yl; 3-(2-indolyl)-1,2,4-oxadiazol-5-yl; 4-phenylthiazol-2-yl; 4-(2-benzofuranyl)thiazol-2-yl; 4-phenyl-1,3-oxazol-5-yl; 5-phenyloxazol-2-yl; 4-(2-thienyl)phenyl; 4-(3-pyridyl)phenyl; 4-(2-

naphthyl)phenyl; 4,4'-terphenyl; and etc);
(iii) fused aromatic groups such as 2-, 3- or 4-quinolyl;

1-, 2- or 3-indolyl; etc.

The "substituent" for the "aromatic group" which may be substituted includes, for example, halogen atoms (e.g., fluorine, chlorine, bromine, iodine, etc.), C₁₋₃ alkylenedioxy (e.g., methylenedioxy, ethylenedioxy, etc.), nitro, cyano, optionally halogenated C₁₋₆ alkyl, C₆₋₁₀ aryloxy-C₁₋₆ alkyl (e.g., phenoxyethyl, etc.), C₁₋₆ alkyl-C₆₋₁₀ aryl-C₂₋₆ alkenyl (e.g., methylphenylethenyl etc.), optionally halogenated C₁₋₆ cycloalkyl, C₇₋₁₆ aralkyl which may be substituted, optionally halogenated C₁₋₆ alkoxy, optionally halogenated C₁₋₆ alkylthio, hydroxy, C₆₋₁₀ aryloxy which may be substituted, C₆₋₁₀ aryl-C₁₋₆ aralkyloxy (e.g., phenylbenzyloxy etc.), amino, mono-C₁₋₆ alkylamino (e.g., methylamino, ethylamino, propylamino, isopropylamino, butylamino, etc.), di-C₁₋₆ alkylamino (e.g., dimethylamino, diethylamino, dipropylamino, dibutylamino, etc.), ethylmethylamino, etc.), 5- to 7-membered saturated cyclic amino which may be substituted, acyl, acylamino, acyloxy. Among these groups, preferred are halogen atoms, C₁₋₃ alkylenedioxy, optionally halogenated C₁₋₆ alkyl, C₆₋₁₀ aryloxy-C₁₋₆ alkyl, C₁₋₆ alkyl-C₆₋₁₀ aryl-C₂₋₆ alkenyl, C₇₋₁₆ aralkyl which may be substituted, optionally halogenated C₁₋₆ alkoxy, hydroxy, C₆₋₁₀ aryloxy which may be substituted, acyl, acyloxy, etc.

The "aromatic group" may have 1 to 5, preferably 1 to 3 of the above substituents at substitutable positions on the aromatic group. When the number of the substituents is two or more, those substituents may be the same or different.

The "C₇₋₁₆ aralkyl" for the "C₇₋₁₆ aralkyl which may be substituted" includes, for example, benzyl, phenethyl, naphthylmethyl, etc.

The "C₆₋₁₀ aryloxy" for the "C₆₋₁₀ aryloxy which may be

"substituted" includes, for example, phenoxy, naphthoxy, etc.

The "substituent" for these "C₇₋₁₆ aralkyl which may be substituted" and "C₆₋₁₀ aryloxy which may be substituted" includes, for example, 1 to 5 substituents selected from the group consisting of halogen atoms (e.g., fluorine, chlorine, bromine, iodine, etc.), C₁₋₆ alkylenedioxy (e.g., methylenedioxy, ethylenedioxy, etc.), nitro, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₃₋₆ cycloalkyl, optionally halogenated C₁₋₆ alkoxy, optionally halogenated C₁₋₆ alkylthio, hydroxy, amino, mono-C₁₋₆ alkylamino (e.g., methylamino, ethylamino, propylamino, isopropylamino, butylamino, etc.), di-C₁₋₆ alkylamino (e.g., dimethylamino, diethylamino, dipropylamino, dibutylamino, ethylmethylamino, etc.), formyl, carboxy, carbamoyl, optionally halogenated C₁₋₆ alkyl-carbonyl, C₁₋₆ alkoxy-carbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl, etc.), mono-C₁₋₆ alkyl-carbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl, etc.), di-C₁₋₆ alkyl-carbamoyl (e.g., dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl, etc.), optionally halogenated C₁₋₆ alkylsulfonyl, formylamino, optionally halogenated C₁₋₆ alkyl-carboxamido, C₁₋₆ alkoxy-carboxamido (e.g., methoxycarboxamido, ethoxycarboxamido, propoxycarboxamido, butoxycarboxamido, etc.), C₁₋₆ alkylsulfonylamino (e.g., methylsulfonylamino, ethylsulfonylamino, etc.), C₁₋₆ alkyl-carbonyloxy (e.g., acetoxy, propanoyloxy, etc.), C₁₋₆ alkoxy-carbonyloxy (e.g., methoxycarbonyloxy, ethoxycarbonyloxy, propoxycarbonyloxy, butoxycarbonyloxy, etc.), mono-C₁₋₆ alkyl-carbamoyloxy (e.g., methylcarbamoyloxy, ethylcarbamoyloxy, etc.), di-C₁₋₆ alkyl-carbamoyloxy (e.g., dimethylcarbamoyloxy, diethylcarbamoyloxy, etc.).

above "5- to 7-membered saturated cyclic amino which may be substituted" includes, for example, morpholino,

thiomorpholino, piperazin-1-yl, piperidino, pyrrolidin-1-yl, hexamethyleneimin-1-yl, etc.

The "substituent" for the "5- to 7-membered saturated cyclic amino which may be substituted" includes, for example, 1 to 3 substituents selected from the group consisting of C₁₋₆ alkyl; C₆₋₁₄ aryl which may be substituted, C₇₋₁₉ aralkyl which may be substituted, 5- to 10-membered aromatic heterocyclic group which may be substituted, C₆₋₁₄ aryl-carbonyl which may be substituted, optionally halogenated C₁₋₆ alkyl-carbonyl, optionally halogenated C₁₋₆ alkylsulfonyl, etc.

The "C₆₋₁₄ aryl" for the "C₆₋₁₄ aryl which may be substituted" includes, for example, phenyl, 1-naphthyl, 2-naphthyl, 2-indenyl, 2-anthryl, etc. Preferred is phenyl.

The "C₇₋₁₉ aralkyl" for the "C₇₋₁₉ aralkyl which may be substituted" includes, for example, benzyl, phenethyl, diphenylmethyl, triphenylmethyl, 1-naphthylmethyl, 2-naphthylmethyl, 2,2-diphenylmethyl, 3-phenylpropyl, 4-phenylbutyl, 5-phenylpentyl, etc. Preferred is benzyl.

The "5- to 10-membered aromatic heterocyclic group" for the above "5- to 10-membered aromatic heterocyclic group which may be substituted" includes, for example, 2-, 3- or 4-pyridyl; 1-, 2- or 3-indolyl; 2- or 3-thienyl; etc. Preferred are 2-, 3- or 4-pyridyl, etc.

The "C₆₋₁₀ aryl-carbonyl" for the "C₆₋₁₀ aryl-carbonyl which may be substituted" includes, for example, benzoyl, 1-naphthoyl, 2-naphthoyl, etc.

The "substituent" for these "C₆₋₁₄ aryl which may be substituted", "C₇₋₁₉ aralkyl which may be substituted", "5- to 10-membered aromatic heterocyclic group which may be substituted" and "C₆₋₁₀ aryl-carbonyl which may be substituted" includes, for example, 1 to 5 substituents selected from the group consisting of halogen atoms (e.g.,

fluorine, chlorine, bromine, iodine; etc.); C₁₋₆ alkylenedioxy (e.g., methylenedioxy; ethylenedioxy, etc.), nitro, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₃₋₆ cycloalkyl, optionally halogenated C₁₋₆ alkoxy, optionally halogenated C₁₋₆ alkylthio, hydroxy, amino, mono-C₁₋₆ alkylamino (e.g., methylamino, ethylamino, propylamino, isopropylamino, butylamino; etc.), di-C₁₋₆ alkylamino (e.g., dimethylamino, diethylamino, dipropylamino, dibutylamino, ethylmethylamino, etc.), formyl, carboxy, carbamoyl, optionally halogenated C₁₋₆ alkyl-carbonyl, C₁₋₆ alkoxy-carbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl, etc.), mono-C₁₋₆ alkyl-carbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl, etc.), di-C₁₋₆ alkyl-carbamoyl (e.g., dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl, etc.), optionally halogenated C₁₋₆ alkylsulfonyl, formylamino, optionally halogenated C₁₋₆ alkyl-carboxamido, C₁₋₆ alkoxy-carboxamido (e.g., methoxycarboxamido, ethoxycarboxamido, propoxycarboxamido, butoxycarboxamido, etc.), C₁₋₆ alkylsulfonylamino (e.g., methylsulfonylamino, ethylsulfonylamino, etc.), C₁₋₆ alkyl-carbonyloxy (e.g., acetoxy, propanoyloxy, etc.), C₁₋₆ alkoxy-carbonyloxy (e.g., methoxycarbonyloxy, ethoxycarbonyloxy, propoxycarbonyloxy, butoxycarbonyloxy, etc.), mono-C₁₋₆ alkyl-carbamoyloxy (e.g., methylcarbamoyloxy, ethylcarbamoyloxy, etc.), di-C₁₋₆ alkyl-carbamoyloxy (e.g., dimethylcarbamoyloxy, diethylcarbamoyloxy, etc.), etc.

The "acyl" as the "substituent" for the "aromatic group which may be substituted", and the "acyl" in the "acylamino" and the "acyloxy" include, for example, an acyl represented by the formula: -CO-R³, -CO-OR³, -CO-NR³R⁴, -CS-NHR³, -SO₂-R^{3a} or -SO₂-R^{3a}, where R³ is (i) hydrogen, (ii) a hydrocarbon group which may be substituted, for example, a hydrocarbon group which may be substituted by

1 to 5 substituents selected from the group consisting of halogen atoms, C₁₋₃ alkylenedioxy, nitro, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₃₋₆ cycloalkyl, optionally halogenated C₁₋₆ alkoxy, optionally halogenated C₁₋₆ alkylthio, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, 5- to 7-membered cyclic amino which may be substituted, formyl, carboxy, carbamoyl, optionally halogenated C₁₋₆ alkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₀ aryl-carbonyl, C₆₋₁₀ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₀ aryl-carbamoyl, optionally halogenated C₁₋₆ alkylsulfonyl, C₆₋₁₀ arylsulfonyl, formylamino, optionally halogenated C₁₋₆ alkyl-carboxamido, C₆₋₁₀ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino, C₁₋₆ alkyl-carbonyloxy, C₆₋₁₀ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₀ aryl-carbamoyloxy, nicotinoyloxy and C₆₋₁₀ aryloxy, or
(iii) a heterocyclic group which may be substituted, for example, a heterocyclic group which may be substituted by 1 to 5 substituents selected from the group consisting of halogen atoms, C₁₋₃ alkylenedioxy, nitro, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₃₋₆ cycloalkyl, optionally halogenated C₁₋₆ alkoxy, optionally halogenated C₁₋₆ alkylthio, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, 5- to 7-membered cyclic amino which may be substituted, formyl, carboxy, carbamoyl, optionally halogenated C₁₋₆ alkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₀ aryl-carbonyl, C₆₋₁₀ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₀ aryl-carbamoyl, optionally halogenated C₁₋₆ alkylsulfonyl, C₆₋₁₀ arylsulfonyl, formylamino, optionally halogenated C₁₋₆ alkyl-carboxamido, C₆₋₁₀ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino, C₁₋₆ alkyl-carbonyloxy, C₆₋₁₀ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-

carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₀ aryl-carbamoyloxy, nicotinoyloxy and C₆₋₁₀ aryloxy; R^{3a} is (i) a hydrocarbon group which may be substituted, for example, a hydrocarbon group which may be substituted by 1 to 5 substituents selected from the group consisting of halogen atoms, C₁₋₃ alkylenedioxy, nitro, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₃₋₆ cycloalkyl, optionally halogenated C₁₋₆ alkoxy, optionally halogenated C₁₋₆ alkylthio, hydroxy, amino, 10 mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, 5- to 7-membered cyclic amino which may be substituted, formyl, carboxy, carbamoyl, optionally halogenated C₁₋₆ alkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₀ aryl-carbonyl, C₆₋₁₀ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₀ aryl-carbamoyl, optionally 15 halogenated C₁₋₆ alkylsulfonyl, C₆₋₁₀ arylsulfonyl, formylamino, optionally halogenated C₁₋₆ alkyl-carboxamido, C₆₋₁₀ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino, C₁₋₆ alkyl-carbonyloxy, C₆₋₁₀ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₀ aryl-carbamoyloxy, nicotinoyloxy and C₆₋₁₀ aryloxy, or (ii) a heterocyclic group which may be substituted, for example, a heterocyclic group which may be substituted by 20 1 to 5 substituents selected from the group consisting of halogen atoms, C₁₋₃ alkylenedioxy, nitro, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₃₋₆ cycloalkyl, optionally halogenated C₁₋₆ alkoxy, optionally halogenated C₁₋₆ alkylthio, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, 5- to 7-membered cyclic amino which may be substituted, formyl, carboxy, carbamoyl, 25 optionally halogenated C₁₋₆ alkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₀ aryl-carbonyl, C₆₋₁₀ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, C₆₋₁₀ aryl-carbamoyl, optionally 30 halogenated C₁₋₆ alkylsulfonyl, C₆₋₁₀ arylsulfonyl,

formylamino, optionally halogenated C₁₋₆ alkyl-carboxamido, C₆₋₁₀ aryl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino, C₁₋₆ alkyl-carbonyloxy, C₆₋₁₀ aryl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, C₆₋₁₀ aryl-carbamoyloxy, nicotinoyloxy, and C₆₋₁₀ aryloxy; R¹, represents hydrogen atom, or C₁₋₆ alkyl, or R³ and R⁴, taken together with the adjacent nitrogen atom, may form a nitrogen-containing heterocyclic ring.

The "5- to 7-membered cyclic amino which may be substituted" as the substituent for R³ and R⁴, includes the same as those mentioned above for the substituent of the aromatic group for Ar.

The above-mentioned "heterocyclic group" includes, for example, a group derived by removing an optional hydrogen atom from 5- to 14-membered (monocyclic, di- or tri-cyclic) heterocyclic rings containing 1 to 4 of 1 or 2 kinds of hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms in addition to carbon atoms, etc. Preferred examples of the heterocyclic rings include (i) 5- to 14-membered, preferably 5- to 10-membered aromatic heterocyclic rings, (ii) 5- to 10-membered non-aromatic heterocyclic rings, and (iii) 7- to 10-membered bridged heterocyclic rings.

The above-mentioned "5- to 14-membered, preferably 5- to 10-membered aromatic heterocyclic rings" includes, for example, an aromatic heterocyclic ring, such as thiophene, benzothiophene, benzofuran, benzimidazole, benzoxazole, benzothiazole, benzisothiazole, naphtho[2,3-b]thiophene, furan, phenoxathiin, pyrrole, imidazole, pyrazole, oxazole, 1,2,4-oxadiazole, 1,3,4-oxadiazole, 1,2,4-thiadiazole, 1,3,4-thiadiazole, pyridine, pyrazine, pyrimidine, pyridazine, indole, isoindole, 1H-indazole, purine, 4H-quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline,

carbazole, β -carboline, phenanthridine, acridine, phenazine, thiazole, isothiazole, phenothiazine, isoxazole, furazan, phenoxazine, phthalimide, etc.; and a ring as formed through condensation of these rings, preferably monocyclic ring, with one or more, preferably one or two aromatic rings (e.g., benzene ring, etc.), etc.

The above-mentioned "5- to 10-membered non-aromatic heterocyclic rings" includes, for example, pyrrolidine, imidazoline, pyrazolidine, piperidine, piperazine, morpholine, thiomorpholine, etc.

The above-mentioned "7- to 10-membered bridged heterocyclic rings" includes, for example, quinuclidine, 7-azabicyclo[2.2.1]heptane, etc.

The "heterocyclic group" is preferably 5- to 10-membered (monocyclic or dicyclic) heterocyclic groups containing preferably 1 to 4 of 1 or 2 kinds of hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms in addition to carbon atoms, etc. Concretely mentioned are aromatic heterocyclic groups such as 2- or 3-thienyl; 2-, 3- or 4-pyridyl; 2- or 3-furyl; 2-, 3-, 4-, 5- or 8-quinolyl; 4-isoquinolyl; pyrazinyl; 2- or 4-pyrimidinyl; 3-pyrrolyl; 2-imidazolyl; 3-pyridazinyl; 3-isothiazolyl; 3-isooxazoyl; 1-indolyl; 2-indolyl; 2-isoindolyl; and etc.; non-aromatic heterocyclic groups such as 1-, 2- or 3-pyrrolidinyl; 2- or 4-imidazolinyl; 2-, 3- or 4-pyrazolidinyl; piperidino; 2-, 3- or 4-piperidyl; 1- or 2-piperazinyl; morpholino; etc.

Among these groups, 5- or 6-membered heterocyclic groups containing 1 to 3 hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms in addition to carbon atoms, etc. are more preferable. Concretely mentioned are 2-thienyl; 3-thienyl; 2-pyridyl; 3-pyridyl; 4-pyridyl; 2-furyl; 3-furyl; pyrazinyl; 2-pyrimidinyl; 3-pyrrolyl; 3-pyridazinyl; 3-isothiazolyl; 3-isooxazoyl; 1-, 2- or 3-pyrrolidinyl; 2- or 4-

imidazolinyl; 2-, 3- or 4-pyrazolidinyl; piperidino; 2-, 3- or 4-piperidyl; 1- or 2-piperazinyl; morpholino; etc.

The "C₁₋₆ alkyl" for R⁴ includes, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, 5 tert-butyl, pentyl, hexyl, etc.

The "nitrogen-containing heterocyclic ring" as formed by R³ and R⁴ together with the adjacent nitrogen atom includes, for example, 5- to 7-membered nitrogen-containing heterocyclic groups containing at least one nitrogen atom and optionally 1 to 3 hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms in addition to carbon atoms, etc. Concretely mentioned are piperidine, morpholine, thiomorpholine, piperazine, pyrrolidine, etc.

15

Preferred examples of the "acyl" as the "substituent" for the "aromatic group which may be substituted" for Ar include formyl, carboxy, carbamoyl, optionally halogenated C₁₋₆ alkyl-carbonyl, C₁₋₆ alkoxy-carbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl, etc.), C₆₋₁₀ aryl-carbonyl which may be substituted, C₆₋₁₀ aryloxy-carbonyl which may be substituted, C₇₋₁₁ aralkyloxy-carbonyl which may be substituted, 5- or 6-membered heterocyclic-carbonyl which may be substituted, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl (e.g., dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl, etc.), C₆₋₁₀ aryl-carbamoyl which may be substituted, 5- or 6-membered heterocyclic-carbamoyl which may be substituted, optionally halogenated C₁₋₆ alkylsulfonyl, C₆₋₁₀ arylsulfonyl which may be substituted, etc. Among these, preferred are optionally halogenated C₁₋₆ alkyl-carbonyl, C₁₋₆ alkoxy-carbonyl (e.g., ethoxycarbonyl, etc.), C₆₋₁₀ aryl-carbonyl which may be substituted, C₆₋₁₀ arylsulfonyl which may be substituted, etc.

35

The "C₆₋₁₀ aryl-carbonyl" for the above "C₆₋₁₀ aryl-carbonyl which may be substituted" includes, for example,

benzoyl, 1-naphthoyl, 2-naphthoyl, etc.

The "C₆₋₁₀ aryloxy-carbonyl" for the above "C₆₋₁₀ aryloxy-carbonyl which may be substituted" includes, for example, phenoxy carbonyl, etc.

5 The "C₇₋₁₆ aralkyloxy-carbonyl" for the above "C₇₋₁₆ aralkyloxy-carbonyl which may be substituted" includes, for example, benzyl oxycarbonyl, phenethyl oxycarbonyl, etc.

10 The "5- or 6-membered heterocyclic-carbonyl" for the above "5- or 6-membered heterocyclic-carbonyl which may be substituted" includes, for example, nicotinoyl, isonicotinoyl, 2-thenoyl, 3-thenoyl, 2-furoyl, 3-furoyl, morpholinocarbonyl, piperidinocarbonyl, pyrrolidin-1-ylcarbonyl, etc.

15 The "C₆₋₁₀ aryl-carbamoyl" for the above "C₆₋₁₀ aryl-carbamoyl which may be substituted" includes, for example, phenyl carbamoyl, 1-naphthyl carbamoyl, 2-naphthyl carbamoyl, etc.

20 The "5- or 6-membered heterocyclic-carbamoyl" for the above "5- or 6-membered heterocyclic-carbamoyl which may be substituted" includes, for example, 2-pyridyl carbamoyl, 3-pyridyl carbamoyl, 4-pyridyl carbamoyl, 2-thienyl carbamoyl, 3-thienyl carbamoyl, etc.

25 The "C₆₋₁₀ arylsulfonyl" for the above "C₆₋₁₀ arylsulfonyl which may be substituted" includes, for example, benzenesulfonyl, 1-naphthalenesulfonyl, 2-naphthalenesulfonyl, etc.

30 The "substituent" for these "C₆₋₁₀ aryl-carbonyl which may be substituted", "C₆₋₁₀ aryloxy-carbonyl which may be substituted", "C₇₋₁₆ aralkyloxy-carbonyl which may be substituted", "5- or 6-membered heterocyclic-carbonyl which may be substituted", "C₆₋₁₀ aryl-carbamoyl which may be substituted", "5- or 6-membered heterocyclic-carbamoyl which may be substituted" and "C₆₋₁₀ arylsulfonyl which may be substituted" includes, for example, 1 to 5, preferably

1 to 3 substituents selected from the group consisting of halogen atoms, C₁₋₆ alkylenedioxy, nitro, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₁₋₆ alkoxy, optionally halogenated C₁₋₆ alkylthio, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, formyl, carboxy, carbamoyl, optionally halogenated C₁₋₆ alkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, optionally halogenated C₁₋₆ alkylsulfonyl, formylamino, optionally halogenated C₁₋₆ alkyl-carboxamido, C₁₋₆ alkoxy-carboxamido, C₁₋₆ alkylsulfonylamino, C₁₋₆ alkyl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy, di-C₁₋₆ alkyl-carbamoyloxy, and etc. Among these, preferred are halogen atoms, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₁₋₆ alkoxy, etc.

The "acylamino" as the above-mentioned "substituent" for the "aromatic group which may be substituted" for Ar includes, for example, an amino substituted by 1 or 2 "acyl" described in detail in the foregoing referring to the "substituent" for the "aromatic group which may be substituted". Preferred is an acylamino of the formula: -NR⁵-COR⁶, -NR⁵-COOR^{6a}, -NR⁵-SO₂R^{6a}, -NR⁵-CONR^{6a}R^{6b} wherein R⁵ represents hydrogen or C₁₋₆ alkyl, R⁶ has the same meanings as the above R³, R^{6a} has the same meanings as the above R^{3a}, R^{6b} has the same meanings as the above R^{3b}.

The "C₁₋₆ alkyl" for R⁵ and R^{6b} includes the same as "C₁₋₆ alkyl" for R⁴.

Preferred examples of the "acylamino" as the "substituent" for the "aromatic group which may be substituted" for Ar are formylamino, optionally halogenated C₁₋₆ alkyl-carboxamido, C₆₋₁₀ aryl-carboxamido which may be substituted (e.g., phenylcarboxamido, naphthylcarboxamido, etc.), C₁₋₆ alkoxy-carboxamido (e.g., methoxycarboxamido, ethoxycarboxamido, propoxycarboxamido, butoxycarboxamido, etc.), C₁₋₆

alkylsulfonylamino (e.g., methylsulfonylamino, ethylsulfonylamino, etc.), etc.

The "acyloxy" as the "substituent" for the "aromatic group which may be substituted" for Ar includes, for example, an oxy substituted by one "acyl" described in detail in the foregoing referring to the "substituent" for the "aromatic group which may be substituted". Preferred is an acyloxy of the formula: -O-COR', -O-COOR' or -O-CONHR' wherein R' has the same meanings as the above R³.

Preferred examples of the "acyloxy" as the "substituent" for the "aromatic group which may be substituted" for Ar are C₁₋₆ alkyl-carbonyloxy (e.g., acetoxy, propanoyloxy, etc.), C₆₋₁₀ aryl-carbonyloxy which may be substituted (e.g., benzyloxy, 1-naphthoyloxy, 2-naphthoyloxy, etc.), C₁₋₆ alkoxy-carbonyloxy (e.g., methoxycarbonyloxy, ethoxycarbonyloxy, propoxycarbonyloxy, butoxycarbonyloxy, etc.), mono-C₁₋₆ alkyl-carbamoyloxy (e.g., methylcarbamoyloxy, ethylcarbamoyloxy, etc.), di-C₁₋₆ alkyl-carbamoyloxy (e.g., dimethylcarbamoyloxy, diethylcarbamoyloxy, etc.), C₆₋₁₀ aryl-carbamoyloxy which may be substituted (e.g., phenylcarbamoyloxy, naphthylcarbamoyloxy, etc.), nicotinoyloxy, etc.

The "substituent" and "its preferred examples" for the above "C₆₋₁₀ aryl-carboxamido which may be substituted", "C₆₋₁₀ aryl-carbonyloxy which may be substituted" and "C₆₋₁₀ aryl-carbamoyloxy which may be substituted", include the same as those described in the above "C₆₋₁₀ aryl-carbonyl which may be substituted" as the substituent of the aromatic group for Ar.

Among the above-mentioned substituents, preferred examples of the substituent of the aromatic group for Ar are halogen atoms (e.g., fluorine, chlorine, bromine, etc.); C₁₋₃ alkylenedioxy (e.g., methylenedioxy, etc.); optionally halogenated C₁₋₆ alkyl (e.g., methyl, etc.); C₆₋₁₀

aryloxy-C₁₋₆ alkyl (e.g., phenoxyethyl, etc.); C₁₋₆ alkyl-C₆₋₁₀ aryl-C₂₋₆ alkenyl (e.g., methylphenylethenyl, etc.); C₁₋₆ aralkyl (e.g., benzyl, etc.) which may be substituted by halogen atoms (e.g., chlorine, etc.) or C₁₋₆ alkoxy (e.g., methoxy, etc.); optionally halogenated C₁₋₆ alkoxy (e.g., methoxy, etc.); hydroxy; C₆₋₁₀ aryloxy (e.g., phenoxy, etc.) which may be substituted by halogen atoms (e.g., chlorine, etc.) or C₁₋₆ alkoxy (e.g., methoxy, etc.); optionally halogenated C₁₋₆ alkyl-carbonyl (e.g., acetyl, etc.); C₁₋₆ alkoxy-carbonyl (e.g., ethoxycarbonyl, etc.); C₆₋₁₀ aryl-carbonyl; C₆₋₁₀ arylsulfonyl (e.g., phenylsulfonyl, etc.) which may be substituted by C₁₋₆ alkyl (e.g., isopropyl, etc.).

The "spacer having a main chain of 2 to 5 atoms" for Y means a space between X and Ar in which 2 to 5 atoms of a main chain are combined in a straight-chain form. In the present specification, the "number of atoms" is counted so that the number of atoms between X and Ar is minimum.

The "spacer having a main chain of 2 to 5 atoms" includes, for example, divalent groups having a main chain of 2 to 5 atoms, and selected from the group consisting of C₁₋₅ alkylene which may be substituted; C₂₋₅ alkenylene which may be substituted; C₂₋₅ alkynylene which may be substituted; -O-; -S-; -SO-; -SO₂-; and a group represented by the formula: -NR⁸- where R⁸ represents hydrogen, a hydrocarbon group which may be substituted or acyl.

These "divalent groups" may form Y by the combination of 1 to 3 of them, and each group may be the same or different when two or more of these divalent groups are combined.

The "C₁₋₅ alkylene" for the "C₁₋₅ alkylene which may be substituted" includes, for example, -(CH₂)-, -(CH₂)₂-, -(CH₂)₃-, -(CH₂)₄-, -(CH₂)₅-, etc.

The "C₂₋₅ alkenylene" for the "C₂₋₅ alkenylene which may be substituted" includes, for example, -CH=CH-, -CH₂-CH=CH-, -CH₂-CH=CH-CH₂-, -CH₂-CH₂-CH=CH-, -CH=CH-CH=CH-, -CH=CH-

CH₂-CH₂-CH₂-, etc.

The "C₂₋₅ alkynylene" for the "C₂₋₅ alkynylene which may be substituted" includes, for example, -C≡C-, -CH₂-C≡C-, -CH₂-C≡C-CH₂-CH₂-, etc.

5 The "substituent" for these "C₁₋₅ alkylene which may be substituted", "C₂₋₅ alkenylene which may be substituted" and "C₂₋₅ alkynylene which may be substituted"; and the "substituent" for the "hydrocarbon group which may be substituted" for R⁶ includes, for example, 1 to 5, 10 preferably 1 to 3 substituents selected from the group consisting of halogen atoms (e.g., fluorine, chlorine, bromine, etc.); C₁₋₃ alkylenedioxy (e.g., methylenedioxy, etc.); nitro; cyano; optionally halogenated C₁₋₆ alkyl; optionally halogenated C₃₋₆ cycloalkyl; C₆₋₁₀ aryl which may be substituted; 5- to 10-membered aromatic heterocyclic group which may be substituted; optionally halogenated C₁₋₆ alkoxy; optionally halogenated C₁₋₆ alkylthio; hydroxy; amino; mono-C₁₋₆ alkylamino (e.g., methylamino, ethylamino, propylamino, isopropylamino, butylamino, etc.); di-C₁₋₆ 20 alkylamino (e.g., dimethylamino, diethylamino, dipropylamino, dibutylamino, ethylmethyleamino, etc.); formyl; carboxy; carbamoyl; optionally halogenated C₁₋₆ alkyl-carbonyl; C₁₋₆ alkoxy-carbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl, etc.); C₆₋₁₀ aryl-carbonyl which may be substituted; C₆₋₁₀ aryloxy-carbonyl which may be substituted; C₇₋₁₆ aralkyloxy-carbonyl which may be substituted; 5- or 6-membered heterocyclic-carbonyl (e.g., nicotinoyl, isonicotinoyl, 2-thenoyl, 3-thenoyl, 2-furoyl, 3-furoyl, morpholinocarbonyl, piperidinocarbonyl, pyrrolidin-1-ylcarbonyl, etc.); mono-C₁₋₆ alkyl-carbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl, etc.); di-C₁₋₆ 25 alkyl-carbamoyl (e.g., dimethylcarbamoyl, diethylcarbamoyl, ethylmethylecarbamoyl, etc.); C₆₋₁₀ aryl-carbamoyl which may be substituted; 5- or 6-membered 30 35

heterocyclic-carbamoyl' (e.g., 2-pyridylcarbamoyl; 3-pyridylcarbamoyl, 4-pyridylcarbamoyl; 2-thienylcarbamoyl, 3-thienylcarbamoyl, etc.); optionally halogenated C₁₋₆ alkylsulfonyl (e.g., methylsulfonyl, ethylsulfonyl, etc.); C₆₋₁₀ arylsulfonyl which may be substituted; formylamino; acylamino; C₁₋₆ alkyl-carbonyloxy (e.g., acetoxy, propanoyloxy, etc.); C₆₋₁₀ aryl-carbonyloxy which may be substituted; C₁₋₆ alkoxy-carbonyloxy (e.g., methoxycarbonyloxy, ethoxycarbonyloxy, propoxycarbonyloxy, butoxycarbonyloxy, etc.); mono-C₁₋₆ alkyl-carbamoyloxy (e.g., methylcarbamoyloxy, ethylcarbamoyloxy, etc.); di-C₁₋₆ alkyl-carbamoyloxy (e.g., dimethylcarbamoyloxy, diethylcarbamoyloxy, etc.); C₆₋₁₀ aryl-carbamoyloxy which may be substituted; and 15 nicotinoyloxy which may be substituted; etc. When the number of the substituent is 2 or more, these substituents may be the same or different.

The "C₆₋₁₀ aryl" for the above "C₆₋₁₀ aryl which may be substituted" includes, for example, phenyl, 1-naphthyl, 2-naphthyl, etc.

The "5- to 10-membered aromatic heterocyclic group" for the above "5- to 10-membered aromatic heterocyclic group which may be substituted" includes, for example, 2-, 3- or 4-pyridyl; 1-, 2- or 3-indolyl; 2- or 3-thienyl; etc.

The "C₆₋₁₀ aryl-carbonyl" for the above "C₆₋₁₀ aryl-carbonyl which may be substituted" includes, for example, benzoyl, 1-naphthoyl, 2-naphthoyl, etc.

The "C₆₋₁₀ aryloxy-carbonyl" for the above "C₆₋₁₀ aryloxy-carbonyl which may be substituted" includes, for example, phenoxy carbonyl, etc.

The "C₇₋₁₆ aralkyloxy-carbonyl" for the above "C₇₋₁₆ aralkyloxy-carbonyl which may be substituted" includes, for example, benzyloxycarbonyl, phenethyloxycarbonyl, etc.

The "C₆₋₁₀ aryl-carbamoyl" for the above "C₆₋₁₀ aryl-carbamoyl which may be substituted" includes, for example,

phenylcarbamoyl, 1-naphthylcarbamoyl, 2-naphthylcarbamoyl, etc.

The "C₆₋₁₀ arylsulfonyl" for the above "C₆₋₁₀ arylsulfonyl which may be substituted" includes, for example, benzenesulfonyl, 1-naphthalenesulfonyl, 2-naphthalenesulfonyl, etc.

The "C₆₋₁₀ aryl-carbonyloxy" for the above "C₆₋₁₀ aryl-carbonyloxy which may be substituted" includes, for example, benzoyloxy, 1-naphthoyloxy, 2-naphthoyloxy, etc.

The "C₆₋₁₀ aryl-carbamoyloxy" for the above "C₆₋₁₀ aryl-carbamoyloxy which may be substituted" includes, for example, phenylcarbamoyloxy, naphthylcarbamoyloxy, etc.

The "substituent" for these "C₆₋₁₀ aryl which may be substituted", "5- to 10-membered aromatic heterocyclic group which may be substituted", "C₆₋₁₀ aryl-carbonyl which may be substituted", "C₆₋₁₀ aryloxy-carbonyl which may be substituted", "C₆₋₁₀ aralkyloxy-carbonyl which may be substituted", "C₆₋₁₀ aryl-carbamoyl which may be substituted", "C₆₋₁₀ arylsulfonyl which may be substituted", "C₆₋₁₀ aryl-carbonyloxy which may be substituted", "C₆₋₁₀ aryl-carbamoyloxy which may be substituted"; and "nicotinoyloxy which may be substituted" includes, for example, 1 to 5 substituents selected from the group consisting of halogen atoms (e.g., fluorine, chlorine, bromine, iodine, etc.); C₁₋₆ alkylenedioxy (e.g., methylenedioxy, ethylenedioxy, etc.); nitro; cyano; optionally halogenated C₁₋₆ alkyl; optionally halogenated C₃₋₆ cycloalkyl; optionally halogenated C₁₋₆ alkoxy; optionally halogenated C₁₋₆ alkylthio; hydroxy; amino; mono-C₁₋₆ alkylamino (e.g., methylamino, ethylamino, propylamino, isopropylamino, butylamino, etc.); di-C₁₋₆ alkylamino (e.g., dimethylamino, diethylamino, dipropylamino, dibutylamino, ethylmethylamino, etc.); formyl; carboxy; carbamoyl; optionally halogenated C₁₋₆ alkyl-carbonyl; C₁₋₆ alkoxy-carbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-

butoxycarbonyl, etc.); mono-C₁₋₆ alkyl-carbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl, etc.); di-C₁₋₆ alkyl-carbamoyl (e.g., dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl, etc.); optionally halogenated C₁₋₆ alkylsulfonyl; formylamino; optionally halogenated C₁₋₆ alkyl-carboxamido; C₁₋₆ alkoxy-carboxamido (e.g., methoxycarboxamido, ethoxycarboxamido, propoxycarboxamido, butoxycarboxamido, etc.); C₁₋₆ alkylsulfonylamino (e.g., methylsulfonylamino, ethylsulfonylamino, etc.); C₁₋₆ alkyl-carbonyloxy (e.g., acetoxy, propanoyloxy, etc.); C₁₋₆ alkoxy-carbonyloxy (e.g., methoxycarbonyloxy, ethoxycarbonyloxy, propoxycarbonyloxy, butoxycarbonyloxy, etc.); mono-C₁₋₆ alkyl-carbamoyloxy (e.g., methylcarbamoyloxy, ethylcarbamoyloxy, etc.); di-C₁₋₆ alkyl-carbamoyloxy (e.g., dimethylcarbamoyloxy, diethylcarbamoyloxy, etc.); etc.

The "acyl" for R⁸ includes the same as the above-mentioned "acyl" as the "substituent" for the "aromatic group which may be substituted" for Ar.

The "acylamino" as the "substituent" for "C₁₋₆ alkylene which may be substituted", "C₂₋₅" alkenylene which may be substituted" and "C₂₋₅" alkynylene which may be substituted" as the spacer for Y; and the "acylamino" as the "substituent" for the "hydrocarbon group which may be substituted" for R⁸ includes, the same as the above-mentioned "acylamino" as the "substituent" for the "aromatic group which may be substituted" for Ar. Concrete examples of the acylamino include formylamino; optionally halogenated C₁₋₆ alkyl-carboxamido; C₆₋₁₆ aryl-carboxamido which may be substituted (e.g., phenylcarboxamido, naphthylcarboxamido, etc.); C₇₋₁₅ aralkyl-carboxamido (e.g., phenylethylcarboxamido, etc.); C₇₋₁₆ aralkyloxy-carboxamido which may be substituted (e.g., benzyloxycarboxamido, fluorenylmethyloxycarboxamido, etc.); C₁₋₆ alkoxy-carboxamido (e.g., methoxycarboxamido, ethoxycarboxamido, propoxycarboxamido, butoxycarboxamido,

etc.); C_{1-6} alkylsulfonylamino (e.g., methylsulfonylamino, ethylsulfonylamino, etc.); spiro[naphthalene-2,2'-piperidin]-1'-yl-carboxamido which may be substituted by C_{1-6} alkoxy (e.g., methoxy, etc.); a group represented by the formula: $-NR^9-CO-Y^2-(CH_2)_j-R^{10}$ wherein R^9 represents hydrogen or C_{1-6} alkyl, Y^2 represents a bond, O or imino which may be substituted by C_{1-6} alkyl, j represents an integer of 0 to 5, R^{10} represents a group derived by removing one hydrogen atom from a 5- to 7-membered saturated nitrogen-containing cycloalkane; etc. The "substituent" for the " C_{6-10} aryl-carboxamido which may be substituted" and " C_{6-16} aralkyloxy-carboxamido which may be substituted" includes the same as those for the above-mentioned " C_{6-10} aryl which may be substituted". The "group derived by removing one hydrogen atom from a 5- to 7-membered saturated nitrogen-containing cycloalkane, which may be substituted" includes, for example, piperidino, piperazin-1-yl, pyrrolidin-1-yl, piperidin-4-yl, hexamethylenimin-1-yl, etc. The "substituent" for the "group derived by removing one hydrogen atom from a 5- to 7-membered saturated nitrogen-containing cycloalkane" includes, for example, 1 to 3 substituents selected from the group consisting of hydroxy, C_{1-6} alkyl, C_{6-14} aryl which may be substituted, C_{7-19} aralkyl which may be substituted, 5- to 10-membered aromatic heterocyclic group which may be substituted, C_{6-10} aryl-carbonyl which may be substituted, optionally halogenated C_{1-6} alkyl-carbonyl, optionally halogenated C_{1-6} alkylsulfonyl, C_{1-6} alkoxy-carbonyl, etc. The " C_{6-14} aryl" for the " C_{6-14} aryl which may be substituted" includes, for example, phenyl, 1-naphthyl, 2-naphthyl, 2-indenyl, 2-anthryl, etc. The " C_{7-19} aralkyl" for the " C_{7-19} aralkyl which may be substituted" includes, for example, benzyl, phenethyl, diphenylmethyl, triphenylmethyl, 1-naphthylmethyl, 2-naphthylmethyl, 2,2-diphenylethyl, 3-phenylpropyl, 4-

phenylbutyl, 5-phenylpentyl, etc. Preferred are benzyl, etc.

The "5- to 10-membered aromatic heterocyclic group" for the "5- to 10-membered aromatic heterocyclic group which may be substituted" includes, for example, 2-, 3- or 4-pyridyl; 1-, 2- or 3-indolyl; 2- or 3-thienyl; 2-, 4- or 5-pyrimidinyl; 2-oxo-2,3-dihydro-1H-benzimidazol-1-yl; benzotriazol-1-yl; etc. Preferred are 2-, 3- or 4-pyridyl; 2-, 4- or 5-pyrimidinyl; 2-oxo-2,3-dihydro-1H-benzimidazol-1-yl; benzotriazol-1-yl; etc.

The " C_{6-10} aryl-carbonyl" for the " C_{6-10} aryl-carbonyl which may be substituted" includes, for example, benzoyl, 1-naphthoyl, 2-naphthoyl, etc.

The "substituent" for these " C_{6-14} aryl which may be substituted", " C_{7-11} aralkyl which may be substituted", "5- to 10-membered aromatic heterocyclic group which may be substituted" and " C_{6-10} aryl-carbonyl which may be substituted" includes, for example, 1 to 5 substituents selected from the group consisting of halogen atoms (e.g., fluorine, chlorine, bromine, iodine, etc.); C_{1-3} alkylenedioxy (e.g., methylenedioxy, ethylenedioxy, etc.); nitro; cyano; optionally halogenated C_{1-6} alkyl; optionally halogenated C_{3-6} cycloalkyl; optionally halogenated C_{1-6} alkoxy; optionally halogenated C_{1-6} alkylthio; hydroxy; amino; mono- C_{1-6} alkylamino (e.g., methylamino, ethylamino, propylamino, isopropylamino, butylamino, etc.); di- C_{1-6} alkylamino (e.g., dimethylamino, diethylamino, dipropylamino, dibutylamino, ethylmethylamino, etc.); formyl; carboxy; carbamoyl; optionally halogenated C_{1-6} alkyl-carbonyl; C_{1-6} alkoxy-carbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl, etc.); mono- C_{1-6} alkyl-carbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl, etc.); di- C_{1-6} alkyl-carbamoyl (e.g., dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl, etc.); optionally halogenated C_{1-6} alkylsulfonyl; formylamino;

optionally halogenated C₁₋₆ alkyl-carboxamido; C₁₋₆ alkoxy-carboxamido (e.g., methoxycarboxamido, ethoxycarboxamido, propoxycarboxamido, butoxycarboxamido, etc.); C₁₋₆ alkylsulfonylamino (e.g., methylsulfonylamino, 5 ethylsulfonylamino, etc.); C₁₋₆ alkyl-carbonyloxy (e.g., acetoxy, propanoyloxy, etc.); C₁₋₆ alkoxy-carbonyloxy (e.g., methoxycarbonyloxy, ethoxycarbonyloxy, propoxycarbonyloxy, butoxycarbonyloxy, etc.); mono-C₁₋₆ alkyl-carbamoyloxy (e.g., methylcarbamoyloxy, 10 ethylcarbamoyloxy, etc.); di-C₁₋₆ alkyl-carbamoyloxy (e.g., dimethylcarbamoyloxy, diethylcarbamoyloxy, etc.); etc.

Concrete examples of the "spacer having a main chain of 2 to 5 atoms" for Y include, for example, C₂₋₅ alkylene which may be substituted; C₂₋₅ alkenylene which may be substituted; C₂₋₅ alkynylene which may be substituted; divalent groups represented by the formula: -CH₂-Y¹-, -(CH₂)₂-Y¹-, -(CH₂)₃-Y¹-, -(CH₂)₄-Y¹-, -Y¹-CH₂-, -Y¹-(CH₂)₂-, 15 -Y¹-(CH₂)₃-, -Y¹-(CH₂)₄-, -Y¹-CH₂-Y¹-, -Y¹-(CH₂)₂-Y¹-, -Y¹-(CH₂)₃-Y¹-, -CH₂-Y¹-CH₂-, -(CH₂)₂-Y¹-CH₂-, -(CH₂)₃-Y¹-CH₂-, 20 -CH₂-Y¹-(CH₂)₂-, or -CH₂-Y¹-(CH₂)₃- wherein Y¹ represents O, S, SO, SO₂ or NR⁸ where R⁸ has the same meanings as above; etc. When two of Y¹ exist in the same formula, they may be the same or different.

The "C₂₋₅ alkylene" for the "C₂₋₅ alkylene which may be substituted" includes, for example, -(CH₂)₂-, -(CH₂)₃-, -(CH₂)₄-, -(CH₂)₅-, etc.

The "substituent" for the "C₂₋₅ alkylene which may be substituted" includes, for example, the same "substituent" for the above "C₁₋₅ alkylene which may be substituted".

Preferred examples of Y includes, for example,


- (a) C₂₋₅ alkylene which may be substituted by
 - ① cyano,
 - ② C₆₋₁₀ aryl (e.g., phenyl, etc.),
 - ③ a group represented by the formula:



wherein J^1 and J^2 each represents CH , $\text{C}(\text{OH})$ or N ; Q^1 and Q^2 each represents $-(\text{CH}_2)_p-$ or $-(\text{CH}_2)_p-\text{CO}-(\text{CH}_2)_q-$ where p and q each represents an integer of 0 to 3;




represents (i) a group represented by the formula:



wherein W^1 represents halogen atom, cyano, optionally halogenated C_{1-6} alkyl, optionally halogenated C_{1-6} alkoxy, optionally halogenated C_{1-6} alkyl-carbonyl, nitro, or C_6 -aryl;

(ii) 5- or 6-membered nitrogen-containing heterocyclic group which may be substituted (e.g., pyridyl, pyrimidinyl, etc.), or

(iii) a group represented by the formula:



wherein W^3 represents hydrogen atom or optionally halogenated C_{1-6} alkyl,

④ C_{7-16} aralkyloxy-carboxamido which may be substituted


(e.g., fluorenethylmethoxy-carboxamido, etc.),

⑤ amino,

⑥ C_{7-16} aralkyl-carboxamido,

⑦ C_{1-6} alkoxy-carbonyl-piperazinyl-carboxamido, or

⑧ a group represented by the formula:



wherein W^2 represents optionally halogenated C₁₋₆ alkoxy;

(b) C₂₋₅ alkenylene (especially -CH=CH-, etc.),

(c) -(CH)_m-Y¹- wherein m represents an integer of 1 to 4,

Y¹ has the same meanings as above, or

(d) - Y¹-(CH₂)_r- wherein r represents an integer of 1 to 4, Y¹ has the same meanings as above.

Among the above definitions, p and q are preferably

10 0 or 1, especially preferably 0.

As -(CH₂)_p-CO-(CH₂)_q-, -CO- is especially preferable.

W¹ is preferably 1 or 2 substituents selected from the group consisting of halogen atoms (e.g., fluorine, chlorine, etc.), C₁₋₆ alkoxy (e.g., methoxy, etc.), etc.

15 The 5- or 6-membered nitrogen-containing heterocyclic group which may be substituted is preferably pyridyl or pyrimidinyl each of which may be substituted by optionally halogenated C₁₋₆ alkyl (e.g., methyl, trifluoromethyl, etc.) or nitro.

20 W² is preferably 1 or 2 of C₁₋₆ alkoxy (e.g., methoxy, etc.); etc.

The definitions m and r are preferably 1 or 2.

25 Y¹ is preferably 0 or NR⁶. Y¹ is more preferably Y^{1a} wherein Y^{1a} represents 0 or NR^{6a} where R^{6a} represents hydrogen atom or C₆₋₁₀ arylsulfonyl (e.g., phenylsulfonyl, etc.) which may be substituted by C₁₋₆ alkyl (e.g., methyl, etc.). Y¹ is especially preferably 0 or NH.

30 The "lower alkyl" for the "lower alkyl which may be substituted" for R¹ and R² includes, for example, C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl,

isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, etc.).

Preferred are methyl, ethyl and propyl.


The "substituent" for the "lower alkyl which may be substituted" for R¹ and R² includes, for example, 1 to 5, preferably 1 to 3 substituents selected from the "substituent" for the above "hydrocarbon group which may be substituted" for R⁸. These substituents may be the same or different. Among these, preferred is C₆₋₁₀ aryl such as phenyl, etc.

The "nitrogen-containing heterocyclic ring" for the "nitrogen-containing heterocyclic ring which may be substituted" as formed by R¹ and R² together with the adjacent nitrogen atom includes, for example, 3- to 8-membered nitrogen-containing heterocyclic groups containing at least one nitrogen atom and optionally 1 to 3 hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms in addition to carbon atoms. Concretely mentioned are aziridine, azetidine, morpholine, thiomorpholine, piperidine, piperazine, pyrrolidine, hexamethyleneimine, heptamethyleneimine, hexahydropyrimidine, 1,4-diazepane, and unsaturated cyclic amines thereof (e.g., 1,2,5,6-tetrahydropyridine, etc.), etc. Among these, preferred are morpholine, piperidine, piperazine, pyrrolidine, etc.

The "substituent" for the "nitrogen-containing heterocyclic ring which may be substituted" as formed by R¹ and R² together with the adjacent nitrogen atom includes, for example, 1 to 3 substituents selected from the same substituent for the above "5- to 7-membered saturated cyclic amino which may be substituted". Among these, preferred is C₆₋₁₀ aryl such as phenyl, etc.

The "spiro-ring" for the "spiro-ring which may be substituted" as formed by R¹ or R² together with -(CH₂)_n-N= bonded to a component atom of Ring B includes, for example, 5- to 7-membered spiro-ring containing at least one

nitrogen atom and optionally 1 to 3 hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms in addition to carbon atoms. Preferred is a 6-membered spiro-ring. Examples of the bone structure formed by combination of R¹ and a component atom of Ring B include that represented by the formulae:



wherein the symbols have the same meanings as above.

The "substituent" for the "spiro-ring which may be substituted" includes, for example, 1 to 3 substituents selected from the group consisting of oxo, C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, etc.), etc.

The "aromatic ring" for the "aromatic ring which may be substituted" for Ring A includes, for example, an aromatic hydrocarbon, an aromatic heterocyclic ring, etc.

The "aromatic hydrocarbon" includes, for example, a C₆₋₁₄ monocyclic or fused polycyclic (bi- or tri-cyclic) aromatic hydrocarbon (e.g., benzene, naphthalene, indene, anthracene, etc.). Among these, preferred are benzene and naphthalene. More preferred is benzene.

The "aromatic heterocyclic ring" includes, for example, 5- to 14-membered, preferably 5- to 10-membered aromatic heterocyclic rings containing one or more (e.g., 1 to 4) hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms in addition to carbon atoms, etc. Concretely mentioned is an aromatic heterocyclic ring, such as thiophene, benzothiophene, benzofuran, benzimidazole, benzoxazole, benzothiazole, benzisothiazole, naphtho[2,3-b]thiophene, furan, phenoxathiin, pyrrole, imidazole, pyrazole, oxazole, isoxazole, 1,2,4-oxadiazole, 1,3,4-oxadiazole,


1,2,4-thiadiazole, 1,3,4-thiadiazole, pyridine, pyrazine, pyrimidine, pyridazine, indole, isoindole, 1H-indazole, purine, 4H-quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline,

5 cinnoline, carbazole, β -carboline, phenanthridine, acridine, phenazine, thiazole, isothiazole, phenothiazine, isoxazole, furazan, phenoxazine, phthalimide, etc.; and a ring as formed through condensation of the above ring, preferably monocyclic ring, with one or more, preferably 10 one or two aromatic rings (e.g., benzene ring, etc.), etc. Among these, preferred are thiophene, furan, pyrrole, pyridine, pyrimidine, pyridazine, etc.

Among the above rings, Ring A is preferably benzene ring.

15 The "substituent" for the "aromatic ring which may be substituted" for Ring A is the same both in its kind and number as the "substituent" for the above "aromatic group which may be substituted" for Ar. Among these, preferred are C₁₋₆ alkoxy (e.g., methoxy, etc.), C₆₋₁₀ aryl-C₁₋₆ 20 aralkyloxy (e.g., biphenylmethoxy, etc.), halogen atoms (e.g., chlorine, etc.), optionally halogenated C₁₋₆ alkyl-carboxamido (e.g., acetamide, etc.), etc.

The "4- to 7-membered nitrogen-containing non-aromatic ring" for the "4- to 7-membered nitrogen-containing non-aromatic ring which may be further substituted by alkyl or acyl" for Ring B includes, for example, 4- to 7-membered non-aromatic rings containing at least one nitrogen atom and optionally 1 to 3 hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms in addition to carbon atoms, etc. Concrete examples include 4- to 7-membered non-aromatic rings represented by the formulae:




Among these, 6- or 7-membered non-aromatic rings are preferable.

The "alkyl" for the "4- to 7-membered nitrogen-containing non-aromatic ring which may be further substituted by alkyl or acyl" includes preferably 1 to 3 of C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, etc.), etc. Especially preferred is C₁₋₃ alkyl such as methyl, ethyl, etc.

The "acyl" for the "4- to 7-membered nitrogen-containing non-aromatic ring which may be further substituted by alkyl or acyl" includes the same as the "acyl" as the substituent for the aromatic group for the above Ar. Preferred are the above-mentioned formyl, carboxy, carbamoyl, optionally halogenated C₁₋₆ alkyl-carbonyl (e.g., acetyl, etc.), C₁₋₆ alkoxy-carbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl, etc.), C₆₋₁₀ aryl-carbonyl which may be substituted, C₆₋₁₀ aryloxy-carbonyl which may be substituted, C₇₋₁₆ aralkyloxy-carbonyl which may be substituted, 5- or 6-membered heterocyclic-carbonyl which may be substituted, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl (e.g., dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl, etc.), C₆₋₁₀ aryl-carbamoyl which may be substituted, 5- or 6-membered heterocyclic-carbamoyl which may be substituted, optionally halogenated C₁₋₆ alkylsulfonyl, C₆₋₁₀ arylsulfonyl which may be substituted, etc. Among these, optionally halogenated C₁₋₆ alkyl-carbonyl, C₁₋₆ alkoxy-carbonyl (e.g., ethoxycarbonyl, etc.), C₆₋₁₀ aryl-carbonyl which may be substituted, C₆₋₁₀ arylsulfonyl which may be substituted, etc. are preferable. Especially preferred are formyl, C₁₋₆ alkyl-carbonyl


(e.g., acetyl, etc.); etc.

Concrete examples of the fused ring represented by the formula:





5


include



etc. Among these, preferred are



or



, etc.

Ar is preferably an aromatic ring assembly group which

may be substituted or a fused aromatic group which may be substituted.

X is preferably methylene, CO or SO₂. Among these, methylene or CO is preferable. Especially, CO is preferable.


Y is preferably a C₂₋₅ alkylene which may be substituted.

The symbol n is preferably 1 or 2.


R¹ and R², preferably (i) each represents a hydrogen atom or a lower alkyl which may be substituted, or (ii) form, taken together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic ring which may be substituted.

Ring A is preferably a benzene ring which may be substituted, more preferably a benzene ring which may be substituted by a group selected from the group consisting of C₁₋₆ alkoxy (e.g., methoxy, etc.), C₆₋₁₀ aryl-C₇₋₁₆ aralkyloxy (e.g., biphenylmethyloxy, etc.), halogen atoms (e.g., chlorine, etc.), optionally halogenated C₁₋₆ alkyl-carboxamido (e.g., acetamide, etc.), etc.

Ring B is preferably




Preferred examples of the compound (I) include (1) compound (I-I) represented by the formula:



wherein Ring A' is a benzene ring which may be substituted; Z represents methylene or imino which may be substituted;


the other symbols have the same meanings as above;

(2) compound (I-II) represented by the formula:




wherein the symbols have the same meanings as above;

(3) compound (I-III) represented by the formula:



wherein Y^3 represents C_{1-5} alkylene or C_{2-5} alkenylene, the other symbols have the same meanings as above; etc.

(4) compound (I-IV) represented by the formula:



wherein Y^4 represents C_{1-5} alkylene or C_{2-5} alkenylene, each of which may be substituted by acylamino, the other symbols have the same meanings as above; etc.

The "substituent" for the benzene ring for Ring A' includes the same as the substituent for the aromatic ring for Ring A. Concrete examples of the substituent include, for example, 1 to 5 substituents selected from the group consisting of halogen atoms (e.g., fluorine, chlorine, bromine, iodine, etc.); C_{1-3} alkylenedioxy (e.g., methylenedioxy, ethylenedioxy, etc.); nitro; cyano; optionally halogenated C_{1-6} alkyl; optionally halogenated C_{3-6} cycloalkyl; optionally halogenated C_{1-6} alkoxy; optionally halogenated C_{1-6} alkylthio; hydroxy; amino; mono- C_{1-6} alkylamino (e.g., methylamino, ethylamino,

propylamino, isopropylamino, butylamino, etc.); di-C₁₋₆ alkylamino (e.g., dimethylamino, diethylamino, dipropylamino, dibutylamino, ethylmethylethylamino, etc.); formyl; carboxy; carbamoyl; optionally halogenated C₁₋₆ alkyl-carbonyl; C₁₋₆ alkoxy-carbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl, etc.); mono-C₁₋₆ alkyl-carbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl, etc.); di-C₁₋₆ alkyl-carbamoyl (e.g., dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl, etc.); optionally halogenated C₁₋₆ alkylsulfonyl; formylamino; optionally halogenated C₁₋₆ alkyl-carboxamido (e.g., acetamide, etc.); C₁₋₆ alkoxy-carboxamido (e.g., methoxycarboxamido, ethoxycarboxamido, propoxycarboxamido, butoxycarboxamido, etc.); C₁₋₆ alkylsulfonylamino (e.g., methylsulfonylamino, ethylsulfonylamino, etc.); C₁₋₆ alkyl-carbonyloxy (e.g., acetoxy, propanoyloxy, etc.); C₁₋₆ alkoxy-carbonyloxy (e.g., methoxycarbonyloxy, ethoxycarbonyloxy, propoxycarbonyloxy, butoxycarbonyloxy, etc.); mono-C₁₋₆ alkyl-carbamoyloxy (e.g., methylcarbamoyloxy, ethylcarbamoyloxy, etc.); di-C₁₋₆ alkyl-carbamoyloxy (e.g., dimethylcarbamoyloxy, diethylcarbamoyloxy, etc.); and etc. Among these, preferred are C₁₋₆ alkoxy (e.g., methoxy, etc.), C₆₋₁₀ aryl-C₇₋₁₆ aralkyloxy (e.g., biphenylmethoxy, etc.), halogen atoms (e.g., chlorine, etc.), optionally halogenated C₁₋₆ alkyl-carboxamido (e.g., acetamido, etc.), etc.

The substituent for the "imino which may be substituted" for Z includes, for example, optionally halogenated C₁₋₆ alkyl; optionally halogenated C₃₋₆ cycloalkyl; C₇₋₁₆ aralkyl which may be substituted; C₆₋₁₄ aryl which may be substituted; formyl; carboxy; carbamoyl; optionally halogenated C₁₋₆ alkyl-carbonyl; C₁₋₆ alkoxy-carbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl, etc.); C₇₋₁₆

aralkyloxy-carbonyl which may be substituted; mono-C₁₋₆ alkyl-carbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl, etc.); di-C₁₋₆ alkyl-carbamoyl (e.g., dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl, etc.);

optionally halogenated C₁₋₆ alkylsulfonyl; C₆₋₁₄ arylsulfonyl which may be substituted; 5- or 6-membered heterocyclic-carbonyl which may be substituted; etc.

Among these, preferred are formyl, optionally halogenated C₁₋₆ alkyl (e.g., methyl, ethyl, etc.), etc.

The preferred groups for the other symbols are the same as those mentioned above. Especially, preferred is the compound in which Ar is 1-, 2- or 3-indolyl, or aromatic ring assembly group; X is CO; Y is ethylene which is unsubstituted or substituted by acylamino; R¹ and R² are each C₁₋₃ alkyl, or form, taken together with the adjacent nitrogen atom, pyrrolidine.

The C₁₋₅ alkylene and C₂₋₅ alkenylene for Y³ and Y⁴ include the same C₁₋₅ alkylene and C₂₋₅ alkenylene as the spacer for the above Y.

The acylamino which the C₁₋₅ alkylene and C₂₋₅ alkenylene for Y⁴ may have includes the same described as the substituent for the C₁₋₅ alkylene and C₂₋₅ alkenylene as the spacer for the above Y.

Preferred examples of the compound (I) include the followings:

(1) Compound (I-V)

A compound wherein Ar represents (i) phenyl, (ii) 3-pyridyl, (iii) 1,2,4-oxadiazol-5-yl; (iv) 3-quinolyl, (v) 3-indolyl, (vi) 4-biphenylyl, (vii) 4-(2-naphthyl)phenyl, (viii) 4,4'-terphenyl, (ix) 4-(3-pyridyl)phenyl, (x) 4-(2-thienyl)phenyl, (xi) 3-(2-naphthyl)-1,2,4-oxadiazol-5-yl, (xii) 3-(1-naphthyl)-1,2,4-oxadiazol-5-yl, (xiii) 3-(3-indolyl)-1,2,4-oxadiazol-5-yl, (xiv) 3-(2-benzoxazolyl)-1,2,4-

oxadiazol-5-yl, (xv) 3-(2-benzofuranyl)-1,2,4-oxadiazol-5-yl, (xvi) 4-phenylthiazol-2-yl, (xvii) 3-(2-benzofuranyl)thiazol-2-yl, or (xviii) 5-phenyloxazol-2-yl; each of which may be substituted by 1 to 3 substituents selected from the group consisting of halogen atom; C₁₋₃ alkyleneoxy; C₁₋₆ alkyl; C₆₋₁₀ aryloxy-C₁₋₆ alkyl; C₁₋₆ alkyl-C₆₋₁₀ aryl-C₂₋₆ alkenyl; C₇₋₁₆ aralkyl (preferably benzyl), which may be substituted by halogen atom or C₁₋₆ alkoxy; C₁₋₆ alkoxy; hydroxy; C₆₋₁₀ aryloxy optionally substituted by halogen atom or C₁₋₆ alkoxy; C₁₋₆ alkylcarbonyl; and C₁₋₆ alkoxy-carbonyl;

10 X represents methylene or CO;

Y represents:


(i) C₂₋₅ alkylene which may be substituted by 1 or 2 substituents selected from the group consisting of cyano, acylamino and phenyl, (ii) C₂₋₃ alkenylene, (iii) -CH₂-O-, or (iv) a divalent group represented by the formula: -(CH₂)₂-NR⁸- where R⁸ represents hydrogen atom or C₁₋₃ alkyl-phenylsulfonyl;

15 n is 1 or 2;

i) R¹ and R² each represents a hydrogen atom or C₁₋₆ alkyl which may be substituted by C₆₋₁₀ aryl (e.g., phenyl, etc.),


20 ii) R¹ and R² form, taken together with the adjacent nitrogen atom, morpholine, piperidine, piperazine or pyrrolidine, each of which may be substituted by C₆₋₁₀ aryl (e.g., phenyl, etc.), or

25 iii) R¹ forms, bonded to a component atom of Ring B, a 6-membered spiro-ring represented by the formula:




30 wherein R² represents hydrogen atom;
Ring A represents benzene ring which may be substituted by C₁₋₃ alkoxy or phenylbenzyloxy; and

Ring B represents



or




(2) Compound (I-VI)

A compound wherein Ar represents (i) monocyclic aromatic groups such as phenyl; 2-, 4- or 5-thiazolyl; 2-, 4- or 5-oxazolyl; 2-, 3- or 4-pyridyl; and etc.;
 (ii) aromatic ring assembly groups such as 2-, 3- or 4-biphenyl; 3-(1-naphthyl)-1,2,4-oxadiazol-5-yl; 3-(2-naphthyl)-1,2,4-oxadiazol-5-yl; 3-(2-benzofuranyl)-1,2,4-oxadiazol-5-yl; 3-phenyl-1,2,4-oxadiazol-5-yl; 3-(2-benzoxazolyl)-1,2,4-oxadiazol-2-yl; 3-(3-indolyl)-1,2,4-oxadiazol-2-yl; 3-(2-indolyl)-1,2,4-oxadiazol-2-yl; 4-phenylthiazol-2-yl; 4-(2-benzofuranyl)thiazol-2-yl; 4-phenyl-1,3-oxazol-5-yl; 4-(2-thienyl)phenyl; 4-(3-pyridyl)phenyl; 4-(2-naphthyl)phenyl; 4,4'-terphenyl; and etc.; or
 (iii) fused aromatic groups such as 2-, 3- or 4-quinolyl; 1-, 2- or 3-indolyl; and etc.; each of which may be substituted by substituents selected from the group consisting of halogen atoms (e.g., fluorine, chlorine, bromine, etc.); C₁₋₆ alkyleneoxy (e.g., methylenedioxy, etc.); optionally halogenated C₁₋₆ alkyl (e.g., methyl, etc.); C₆₋₁₀ aryloxy-C₁₋₆ alkyl (e.g., phenoxyethyl, etc.); C₁₋₆ alkyl-C₆₋₁₀ aryl-C₂₋₆ alkenyl (e.g., methylphenylethenyl, etc.); C₇₋₁₆ aralkyl (preferably benzyl) which may be substituted by halogen atom (e.g., chlorine, etc.) or C₁₋₆ alkoxy (e.g., methoxy, etc.); optionally halogenated C₁₋₆ alkoxy (e.g., methoxy, etc.); hydroxy; C₆₋₁₀ aryloxy (e.g., phenoxy, etc.) which may be substituted by halogen atom (e.g., chlorine, etc.) or C₁₋₆ alkoxy (e.g., methoxy, etc.); optionally halogenated C₁₋₆ alkylcarbonyl (e.g., acetyl, etc.); C₁₋₆ alkoxy-carbonyl (e.g., ethoxycarbonyl, etc.);


C_{6-10} aryl-carbonyl; C_{6-10} arylsulfonyl (e.g., phenylsulfonyl, etc.) which may be substituted by C_{1-6} alkyl (e.g., isopropyl, etc.); etc.;

X represents methylene, CO or SO₂;

5 Y represents a divalent group represented by
(a) C₂₋₅ alkylene which may be substituted by
① cyano,



wherein J represents CH, C(OH) or N; Q represents $-(CH_2)_p-$ or $-(CH_2)_p-CO-(CH_2)_q-$ where p and q each represents an integer of 0 to 3; the formula:





15. represents (i) a group represented by the formula:




wherein W¹ represents halogen atom, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₁₋₆ alkoxy, optionally halogenated C₁₋₆ alkyl-carbonyl, or nitro;

(ii) 5- or 6-membered nitrogen-containing heterocyclic group which may be substituted (e.g., pyridyl, piperidyl,



wherein W^2 represents C_{1-6} alkoxy, or


④ C₇₋₁₅ aralkyloxycarboxamido which may be substituted
 (e.g., fluorenylmethyloxycarboxamido, etc.),
 (b) C₂₋₅ alkenylene (especially, -CH=CH-, etc.).
 (c) -(CH)_m-Y¹- wherein m represents an integer of 1 to 4,
 5 Y¹ has the same meanings as above, or
 (d) -Y¹-(CH₂)_r- wherein r represents an integer of 1 to
 4, Y¹ has the same meanings as above;
 n represents 1 or 2;
 i) R¹ and R² each represents a hydrogen atom or C₁₋₆ alkyl
 10 which may be substituted by C₆₋₁₀ aryl (e.g., phenyl, etc.),
 ii) R¹ and R² form, taken together with the adjacent
 nitrogen atom, morpholine, piperidine, piperazine or
 pyrrolidine, each of which may be substituted by C₆₋₁₀ aryl
 (e.g., phenyl, etc.), or
 15 iii) R¹ forms, bonded to a component atom of Ring B, a
 6-membered spiro-ring represented by the formula:




wherein R² represents hydrogen atom;

Ring A represents benzene ring which may be substituted by
 20 C₁₋₆ alkoxy (e.g., methoxy, etc.) or C₆₋₁₀ aryl-C₇₋₁₅ aralkyloxy
 (e.g., phenylbenzyloxy, etc.); and

Ring B represents



or



each of which may be substituted by C₁₋₆ alkyl or formyl.


The above compound (I-VI) has an excellent SSTR4
 25 agonistic activity, and is useful especially as an SSTR4
 agonist.

(3) Compound (I-VII)

A compound among the above compound (I-VI), wherein Y represents


(a) C₂₋₅ alkylene which may be substituted by

① a group represented by the formula:




5

wherein J represents CH, C(OH) or N; Q represents -(CH₂)_p- or -(CH₂)_p-CO-(CH₂)_q- where p and q each represents an integer of 0 to 3; the formula:




10 represents (i) a group represented by the formula:



wherein W¹ represents halogen atom, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₁₋₆ alkoxy, optionally halogenated C₁₋₆ alkyl-carbonyl, or nitro;

15 (ii) 5- or 6-membered nitrogen-containing heterocyclic group which may be substituted (e.g., pyridyl, piperidyl, etc.) or

(iii) a group represented by the formula:



20 wherein W² represents C₁₋₆ alkoxy, or

② C₇₋₁₅ aralkyloxycarboxamido which may be substituted (e.g., fluorenylmethyloxycarboxamido, etc.),

(b) -(CH)_m-Y¹- wherein m represents an integer of 1 to 4, Y¹ has the same meanings as above, or

25 (c) - Y¹-(CH₂)_r- wherein r represents an integer of 1 to

4. Y¹ has the same meanings as above.

Among the above, the compound in which:

Ar represents 1-, 2- or 3-indolyl;


X represents CO; and

n represents 1; and

R¹ and R² each represents a hydrogen atom or C₁-alkyl;

Ring A represents benzene ring; and

Ring B represents



The above compound (I-VII) has an excellent SSTR2 binding inhibiting activity and is useful especially as an SSTR2 agonist/antagonist.

(4) Compound (I-VIII)

(i) 3-[(N,N-Dimethylamino)methyl]-1-[3-[3-(1-naphthyl)-1,2,4-oxadiazol-5-yl]propanoyl]-1,2,3,4-tetrahydroquinoline or a salt thereof.

(ii) 1-[3-(4-Biphenylyl)propanoyl]-3-[(N,N-dimethylamino)methyl]-1,2,3,4-tetrahydroquinoline or a salt thereof.

(iii) 1-[3-[3-(2-Benzofuranyl)-1,2,4-oxadiazol-5-yl]propanoyl]-3-(pyrrolidin-1-yl)methyl-1,2,3,4-tetrahydroquinoline or a salt thereof.

(iv) 1-[3-(4-Biphenylyl)propanoyl]-3-(pyrrolidin-1-yl)methyl-1,2,3,4-tetrahydroquinoline or a salt thereof.

(v) 4-[3-(4-Biphenylyl)propanoyl]-2-(pyrrolidin-1-yl)methyl-1,2,3,4-tetrahydroquinoxaline or a salt (especially oxalate) thereof.

(vi) 4-[3-(4-Biphenylyl)propanoyl]-2-(N,N-dimethylamino)methyl-1-formyl-1,2,3,4-tetrahydroquinoxaline or a salt thereof.

(vii) 3-(R,S)-(N,N-Dimethylamino)methyl-1-[3-

(indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline or a salt thereof.

(viii) 3-(R,S)-(N,N-Dimethylamino)methyl-1-[3-

5 (indol-3-yl)-2-[(R)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidinocarbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline or a salt thereof.

(ix) 1-[2-(R)-[4-(2-chlorophenyl)piperazin-1-yl]carbonylamino-3-(R,S)-(N,N-dimethylamino)methyl-3-

10 (indol-3-yl)propanoyl]-1,2,3,4-tetrahydroquinoline or a salt thereof.

(x) 3-(R,S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-

15 yl)-2-(R)-[4-(2-methoxy)phenyl)piperazin-1-yl]carbonylaminopropanoyl]-1,2,3,4-tetrahydroquinoline or a salt thereof.

(xi) 1-[2-(R)-[[4-(4-chlorophenyl)-4-

hydroxypiperidino]carbonyl]amino-3-(indol-3-yl)propanoyl]-3-(R,S)-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline or a salt thereof.

20 Among these compounds, compounds (i) to (vi) have an excellent SSTR4 agonistic activity, and are useful especially as an SSTR4 agonist. Compounds (vii) to (xi) have an excellent SSTR2 binding inhibiting activity and are useful especially as an SSTR2 agonist/antagonist.

25

(5) Compound (I-IX)

(xii) 3-(R)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline or a salt thereof.

(xiii) 3-(S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline or a salt thereof.

30 (xiv) 3-(R)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-

yl)piperidinocarbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline or a salt thereof.

(xv) 3-(S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-2-[R]-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-

5 yl)piperidinocarbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline or a salt thereof.

(xvi) 3-(R)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-2-(R)-[4-(2-methyl)phenylpiperazin-1-

10 yl]carbonylaminopropanoyl]-1,2,3,4-tetrahydroquinoline or a salt thereof.

(xvii) 3-(S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-2-(R)-[4-(2-methyl)phenylpiperazin-1-

15 yl]carbonylaminopropanoyl]-1,2,3,4-tetrahydroquinoline or a salt thereof.

(xviii) 3-(R,S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-1-benzoyl-4-

15 piperidinocarbonylamino]propanoyl]-6-methoxy-1,2,3,4-tetrahydroquinoline or a salt thereof.

(xix) 6-Chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-

20 yl]carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline or a salt thereof.

(xx) 6-Chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-4-(2-oxo-2,3-dihydro-1H-

25 benzimidazol-1-yl)piperidinocarbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline or a salt thereof.

(xxi) 1-Benzoyl-N-[(R)-2-[6-chloro-3-[(N,N-

dimethylamino)methyl]-1,2,3,4-tetrahydroquinolin-1-yl]-1-[3-(indol-3-yl)propanoyl]-4-piperidinecarboxamide or a

30 salt thereof.

(xxii) 1-[3-(4-Biphenylyl)propanoyl]-3-(R)-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline or a salt thereof.

(xxiii) 1-[3-(4-Biphenylyl)propanoyl]-3-(S)-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline or a

35 salt thereof.

Among these compounds, compounds (xii) to (xxi) have an excellent SSTR2 binding inhibiting activity and are useful especially as an SSTR2 agonist/antagonist.

Compounds (xxii) and (xxiii) have an excellent SSTR4 agonistic activity, and are useful especially as an SSTR4 agonist.

As the salts of compound (I) and compound (I'), for example, inorganic salts, ammonium salts, salts with organic bases, salts with inorganic acids, salts with organic acids and salts with basic or acidic amino acids can be mentioned. Preferable examples of inorganic salts include alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salts, magnesium salts and barium salts; aluminum salts, etc. Preferred salts with organic bases are exemplified by salts with trimethylamine, triethylamine, pyridine, picoline, ethanamine, diethanolamine, triethanolamine, dicyclohexylamine, N,N'-dibenzylethylenediamine, etc. Preferred salts with inorganic acids are exemplified by salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, etc. Preferred salts with organic acids are exemplified by salts with formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc. Preferred salts with basic amino acids are exemplified by salts with arginine, lysine, ornithine, etc. Preferred salts with acidic amino acids are exemplified by salts with aspartic acid, glutamic acid, etc.

Among these, pharmaceutically acceptable salts are preferable. Preferable examples include, for example, when compound (I) or (I') has an acidic functional group, inorganic salts such as alkali metal salts (e.g., sodium salt, potassium salt, etc.), alkaline earth metal salts

(e.g., calcium salt, magnesium salt, barium salt, etc.) and ammonium salts; and when compound (I) or (I') has a basic functional group, inorganic salts such as hydrochloride, sulfate, phosphate and hydrobromide; or, organic salts such as acetate, maleate, fumarate, succinate, methanesulfonate, p-toluenesulfonate, citrate and tartrate.

The prodrug of the compound (I) means a compound which is converted into compound (I) under the physiological condition or with a reaction due to an enzyme, a gastric acid, etc. in the living body, that is, a compound which is converted into compound (I) with oxidation, reduction, hydrolysis, etc. enzymatically; a compound which is converted into compound (I) with gastric acid, etc.; etc.

Examples of the prodrug of the compound (I) include a compound wherein an amino group of the compound (I) is substituted with acyl, alkyl, phosphoric acid, etc. (e.g. a compound wherein an amino group of the compound (I) is substituted with eicosanoyl, alanyl, pentylaminocarbonyl, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxycarbonyl, tetrahydrofuryl, pyrrolidylmethyl, pivaloyloxymethyl, tert-butyl, etc.); a compound wherein a hydroxy group of the compound (I) is substituted with acyl, alkyl, phosphoric acid, boric acid, etc. (e.g. a compound wherein a hydroxy group of the compound (I) is substituted with acetyl, palmitoyl, propanoyl, pivaloyl, succinyl, fumaryl, alanyl, dimethylaminomethylcarbonyl, etc.); a compound wherein a carboxyl group of the compound (I) is modified with ester, amide, etc. (e.g. a compound wherein a carboxyl group of the compound (I) is modified with ethyl ester, phenyl ester, carboxymethyl ester, dimethylaminomethyl ester, pivaloyloxymethyl ester, ethoxycarbonyloxyethyl ester, phthalidyl ester, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl ester, cyclohexyloxycarbonylethyl ester, methyl amide, etc.); etc. These prodrugs can be produced

by *per se* known methods from the compound (I).

The prodrug of the compound (I) may be a compound which is converted into the compound (I) under the physiological conditions as described in "Pharmaceutical Research and Development", Vol. 7 (Drug Design), pages 163-198 published in 1990 by Hirokawa Publishing Co. (Tokyo, Japan).

Process for producing compound (I) is mentioned below.


Compound (I) can be produced by *per se* known means, for example, by the methods exemplified by the following schemes, etc. Compound (I') can be produced in accordance with the production of compound (I).

Compounds described in the following schemes include their salts. For their salts, for example, referred to are the same as the salts of compound (I).

"Room temperature" is normally meant to indicate a temperature falling between 0°C and 30°C.

The symbols in chemical structural formulae in the schemes have the same meanings as above unless otherwise specifically described.

[Scheme 1]



Process 1

Compound (II) is subjected to acylation or alkylation to obtain compound (I).

(1) Acylation

When X is SO, SO₂ or CO, compound (II) is subjected to acylation to obtain compound (I).

The "acylation" may be conducted in any *per se* known methods, for example, those described in Organic Functional

Group Preparations, 2nd Ed., Academic Press Inc., 1989.

Concretely mentioned are methods in which (i) compound (II) is reacted with a compound of the formula: $L^1-X-Y-Ar$ wherein L^1 represents a leaving group, the other symbols have the same meanings above, or a salt thereof, (hereafter simply referred to as Process A); or (ii) compound (II) is reacted with a compound of the formula: $HO-X-Y-Ar$ wherein the symbols have the same meanings above, or a salt thereof, in the presence of a dehydrating and condensing agent, (hereafter simply referred to as Process B).

The "leaving group" for L^1 includes, for example, (1) halogen atoms (e.g., chlorine, bromine, iodine, etc.), (2) C_{1-6} alkyl-carbonyloxy (e.g., acetoxy, propionyloxy, butyryloxy, valeryloxy, pivaloyloxy, etc.), (3) C_{1-6} alkoxy-carbonyloxy (e.g., methoxycarbonyloxy, ethoxycarbonyloxy, isopropoxycarbonyloxy, tert-butoxycarbonyloxy, etc.), (4) C_{6-10} aryloxy (e.g., phenoxy, pentachlorophenoxy, pentafluorophenoxy, p-nitrophenoxy, etc.) which may be substituted by 1 to 5 substituents selected from the group consisting of halogen atoms, nitro, optionally halogenated C_{1-6} alkyl and optionally halogenated C_{1-6} alkoxy, (5) (benzotriazol-1-yl)oxy, (6) succinimidoxy, etc. Among these, preferred are halogen atoms, C_{1-6} alkoxy-carbonyloxy, etc.

(i) Process A

Compound (II) is reacted with 1 to 1.5 equivalents of a compound of the formula: $L^1-X-Y-Ar$ wherein the symbols have the same meanings above in the presence of a solvent.

The reaction temperature falls between about -20°C and 100°C, preferably between room temperature and 80°C. The reaction time falls between 0.5 hours and 1 week.

The solvent is not limited as long as it is inert to the reaction (hereafter simply referred to as an inert solvent). For example, mentioned are ethers, halogenated

hydrocarbons, aromatic solvents, nitriles, amides, ketones, sulfoxides, esters, water, etc., which may be used either singly or as a mixture of two or more species. Among these, preferred are tetrahydrofuran (THF), acetonitrile, N,N-dimethylformamide (DMF), acetone, pyridine, ethyl acetate, water, etc.

In the present reaction, a base is used if necessary. The amount of the base used is about 1 to 5 equivalents of compound (II).

The "base" includes, for example;

(1) strong bases such as alkali metal or alkaline earth metal hydrides (e.g., lithium hydride, sodium hydride, potassium hydride, calcium hydride, etc.), alkali metal or alkaline earth metal amides (e.g., lithium amide, sodium amide, lithium diisopropylamide, lithium dicyclohexylamide, lithium hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide, etc.), alkali metal or alkaline earth metal lower-alkoxides (e.g., sodium methoxide, sodium ethoxide, potassium tert-butoxide, etc.).

(2) inorganic bases such as alkali metal or alkaline earth metal hydroxides (e.g., sodium hydroxide, potassium hydroxide, lithium hydroxide, barium hydroxide, etc.), alkali metal or alkaline earth metal carbonates (e.g., sodium carbonate, potassium carbonate, cesium carbonate, etc.), alkali metal or alkaline earth metal hydrogencarbonates (e.g., sodium hydrogencarbonate, potassium hydrogencarbonate, etc.), etc.;

(3) organic bases such as amines e.g., triethylamine, diisopropylethylamine, N-methylmorpholine, dimethylaminopyridine, DBU (1,8-diazabicyclo[5.4.0]-7-undec-7-ene), DBN (1,5-diazabicyclo[4.3.0]non-5-ene), etc., basic heterocyclic compounds, e.g., pyridine, imidazole, 2,6-lutidine, etc. Among these, preferred are potassium carbonate, sodium hydrogencarbonate, triethylamine, N-methylmorpholine, pyridine, etc.

The compound of the formula: $L^1-X-Y-Ar$ wherein symbols have the same meanings above, may be obtained from a compound of the formula: $HO-X-Y-Ar$ wherein symbols have the same meanings above, by a *per se* known method. L^1 is preferably halogen.

The compound of the formula: $HO-X-Y-Ar$ wherein symbols have the same meanings above can be obtained easily, and further, may be produced easily by a *per se* known method.

For example, (3-aryl-1,2,4-oxadiazol-5-yl)acetic acid, 3-(3-aryl-1,2,4-oxadiazol-5-yl)propionic acid, 4-(3-aryl-1,2,4-oxadiazol-5-yl)butyric acid, and their analogues can be produced according to the methods described in Journal of Heterocyclic Chemistry, Vol. 21, pp. 1193-1195 (1984); and 3-(4-aryl-oxazol-5-yl)propionic acid and its analogues can be produced according to the methods described in JP-A-59(1984)-190979.

(ii) Process B

Compound (II); about one equivalent to 5 equivalents of a compound of the formula: $HO-X-Y-Ar$ wherein the symbols have the same meanings above, or a salt thereof; about one equivalent to 2 equivalents of a dehydrating/condensing agent are reacted in an inert solvent under room temperature for about 10 to 24 hours.

The dehydrating/condensing agent includes, for example, dicyclo carbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSC), etc. Among these, WSC is preferable.

The inert solvent include, for example, nitriles (preferably acetonitrile), amides (preferably DMF), halogenated hydrocarbons (preferably dichloromethane), ethers (preferably THF), etc., which may be used either singly or as a mixture of two or more species.

In the present reaction, about one equivalent to 1.5 equivalents of 1-hydroxybenzotriazole (HOBT) and /or about

one equivalent to 5 equivalents of a base (e.g., triethylamine, etc.) may be added if necessary.

(2) **Alkylation**

5 When X is methylene or S, compound (II) is subjected to alkylation to obtain compound (I).

The "alkylation" may be conducted in any *per se* known methods, for example, those described in *Organic Functional Group Preparations*, 2nd Ed., Academic Press Inc., 1989.

10 Concretely mentioned is a method in which compound (II) is reacted with a compound of the formula: $L^2-X-Y-Ar$ wherein represents a leaving group, the symbols have the same meanings above, or a salt thereof.

15 The "leaving group" for L^2 includes, for example, halogen atoms (e.g., chlorine, bromine, iodine, etc.), optionally halogenated C_{1-6} alkylsulfonyloxy (e.g., methanesulfonyloxy, ethanesulfonyloxy, trifluoromethanesulfonyloxy, etc.), C_{6-10} arylsulfonyloxy which may be substituted, etc. The "substituent" for the 20 "C₆₋₁₀ arylsulfonyloxy which may be substituted" includes, for example, 1 to 3 substituents selected from the group consisting of halogen atoms, and optionally halogenated C_{1-6} alkyl or C_{1-6} alkoxy. Specific examples of the "C₆₋₁₀ arylsulfonyloxy which may be substituted" are, 25 benzenesulfonyloxy, p-toluenesulfonyloxy, 1-naphthalenesulfonyloxy, 2-naphthalenesulfonyloxy, etc.

30 Compound (II) is reacted with about 1 to 5 equivalents (preferably 1 to 2 equivalents) of a compound of the formula: $L^2-X-Y-Ar$ wherein L^2 -represents a leaving group, the symbols have the same meanings above, in an inert solvent in the co-existence of a base.

The amount of the base used is normally about 1 to 5 equivalents of compound (II).

35 The "base" includes the above-mentioned "strong bases", "inorganic bases", "organic bases", and etc.

Preferable base includes potassium carbonate, sodium hydride, sodium hydroxide, etc.

The reaction temperature falls between about -20°C and 100°C, preferably between room temperature and 80°C. The reaction time falls between 0.5 hours and 1 day.

The inert solvent includes, for example, alcohols, ethers, halogenated hydrocarbons, aromatic solvents, nitriles, amides, ketones, sulfoxides, water, etc., which may be used either singly or as a mixture of two or more species. Among these, preferred are acetonitrile, N,N-dimethylformamide (DMF), acetone, ethanol, pyridine, water, etc.

In the thus obtained compound (I), intermolecular functional groups can be converted into the desired functional groups by combination of *per se* known chemical reactions. Examples of the chemical reactions include oxidation, reduction, alkylation, hydrolysis, amination, esterification, aryl-coupling reaction, deprotection, etc.

For example, compound (Ia) obtained by the method of scheme 1, and having CO for X in compound (I), may be subjected to reduction to obtain compound (Ib) having methylene for X.

The reduction may be conducted using any *per se* known methods, for example, those described in *Organic Functional Group Preparations*, 2nd Ed., Academic Press Inc., 1989.

Concretely mentioned is a method in which compound (Ia) is reacted with about 1 equivalent to 20 equivalents (preferably about 1 equivalent to 6 equivalents) of a metal hydride in an inert solvent.

The "metal hydride" includes, for example, aluminum hydride, lithium aluminum hydride, sodium borohydride, lithium borohydride, sodium cyanoborohydride, lithium cyanoborohydride, borane complexes (e.g., borane-THF complex, catechol-borane, etc.), dibutyl aluminum hydride, as well as mixtures of these metal hydrides and Lewis acids

(e.g., aluminum chloride, titanium tetrachloride, cobalt chloride, etc.) or phosphorus oxychloride, etc. Preferred metal hydrides are lithium aluminum hydride, aluminum hydride, borane-THE complex, etc.

5 The inert solvent includes, for example, ethers. The reaction temperature varies, depending on the metal hydride used, but normally falls between -70°C and 100°C. Where lithium aluminum hydride is used, the reaction temperature may be between room temperature and 10 80°C. Where borane complex is used, the reaction temperature may be between room temperature and 100°C, preferably between room temperature and 60°C.

The reaction time falls between 0.1 hours and 48 hours.

15 Where a halogen atom (e.g., bromine, iodine, etc.) exists on the intermolecular aromatic ring of compound (I), this halogen atom can be substituted by an aromatic group by an aryl-coupling reaction.

The "aromatic group which may be substituted" includes 20 the same as the above "aromatic group which may be substituted". Preferred are phenyl, 1-naphthyl, 2-naphthyl, 2-biphenylyl, 3-biphenylyl, 4-biphenylyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, etc., each of which may be substituted by 1 to 3 substituents 25 selected from the group consisting of nitro, halogen atoms, cyano, formyl, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₁₋₆ alkoxy, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino and C₁₋₆ alkylcarboxamido.

30 The aryl-coupling reaction can be conducted by any per se known methods, for example, according to the methods described in Acta. Chemica Scandinavica, 221-230 (1993), etc.

35 Concretely, compound (I) having a halogen atom on its intermolecular aromatic ring (simply referred to as compound (Ic)), an aromatic metal compound which may be substituted and a base are reacted in an inert solvent in

the presence of a transition metal catalyst.

The "aromatic metal compound" for the "aromatic metal compound which may be substituted" includes, for example, aryl-boric acid derivatives, aryl di-C₁₋₆ alkylboranes,

aryl-zinc derivatives, aromatic heterocyclic-boric acid derivatives, aromatic heterocyclic di-C₁₋₆ alkylboranes, aromatic heterocyclic-zinc derivatives, etc. The

"substituent" for the "aromatic metal compound which may be substituted" includes, for example, 1 to 5 substituents selected from the group consisting of halogen atoms (e.g.,

fluorine, chlorine, bromine, iodine, etc.); C₁₋₃

alkylenedioxy (e.g., methylenedioxy, ethylenedioxy,

etc.); nitro; cyano; optionally halogenated C₁₋₆ alkyl;

optionally halogenated C₁₋₆ cycloalkyl; optionally

halogenated C₁₋₆ alkoxy; optionally halogenated C₁₋₆

alkylthio; hydroxy; amino; mono-C₁₋₆ alkylamino (e.g.,

methylamino, ethylamino, propylamino, isopropylamino,

butylamino, etc.); di-C₁₋₆ alkylamino (e.g., dimethylamino,

diethylamino, dipropylamino, dibutylamino,

ethylmethylamino, etc.); formyl; carboxy; carbamoyl;

optionally halogenated C₁₋₆ alkyl-carbonyl; C₁₋₆ alkoxy-

carbonyl (e.g., methoxycarbonyl, ethoxycarbonyl,

propoxycarbonyl, tert-butoxycarbonyl, etc.); mono-C₁₋₆

alkyl-carbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl,

etc.); di-C₁₋₆ alkyl-carbamoyl (e.g., dimethylcarbamoyl,

diethylcarbamoyl, ethylmethylcarbamoyl, etc.);

optionally halogenated C₁₋₆ alkylsulfonyl; formylamino;

optionally halogenated C₁₋₆ alkyl-carboxamido (e.g.,

acetamido, etc.); C₁₋₆ alkoxy-carboxamide (e.g.,

methoxycarboxamido, ethoxycarboxamido,

propoxycarboxamido, butoxycarboxamido, etc.); C₁₋₆

alkylsulfonylamino (e.g., methylsulfonylamino,

ethylsulfonylamino, etc.); C₁₋₆ alkyl-carbonyloxy (e.g.,

acetoxy, propanoyloxy, etc.); C₁₋₆ alkoxy-carbonyloxy (e.g.,

methoxycarbonyloxy, ethoxycarbonyloxy,

propoxycarbonyloxy, butoxycarbonyloxy, etc.); mono-C₁₋₆

alkyl-carbamoyloxy (e.g., methylcarbamoyloxy, ethylcarbamoyloxy, etc.); di-C₁₋₆ alkyl-carbamoyloxy (e.g., dimethylcarbamoyloxy, diethylcarbamoyloxy, etc.); etc.

The amount of the "aromatic metal compound which may be substituted" used is about 1 equivalent to 2 equivalents of the compound (Ic).

The "base" includes, for example, sodium carbonate, sodium hydrogencarbonate, etc.

The "transition metal catalyst" includes, for example, palladium catalysts, nickel catalysts, etc. The "palladium catalysts" include, for example, tetrakis(triphenylphosphine)palladium(0), palladium acetate, bis(triphenylphosphine)palladium(II) chloride, palladium-carbon, etc. The "nickel catalysts" include, for example, tetrakis(triphenylphosphine)nickel(0), etc.

The amount of the "transition metal catalyst" used is about 0.01 equivalents to 1 equivalent of the compound (Ic).


The reaction temperature falls between room temperature and 150°C, preferably about 80°C and 150°C. The reaction time falls between about 1 hour and 48 hours.

The inert solvent includes, for example, water, alcohols, aromatic solvents, etc., which may be used either singly or as a mixture of two or more species. Preferably, water, ethanol, toluene, or the like is used either singly or as a mixture of two or more species.

Compound (II) can be produced by any per se known methods or analogous methods thereto. For example, 3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline is a known compound described in JP-A-8(1996)-176087.

Compound (IIa) having, as a fused ring formed by Ring A and Ring B, for example, indoline, 1,2,3,4-tetrahydroquinoline or 2,3,4,5-tetrahydro-1H-1-benzazepine, may be obtained according to the method described in the following scheme 2.

[Scheme 2]



In the above formulae, t represents an integer of 1 to 3.

5 Process 2

Compound (III) is subjected to *per se* known amidation to obtain compound (IV).

Compound (III) can be obtained easily, and further, may be produced easily by a *per se* known method. For example, 2-oxo-1,2,3,4-tetrahydroquinolin-3-acetic acid, 2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine-4-carboxylic acid and its analogues can be produced according to the methods described in Journal of American Chemical Society (J. Am. Chem. Soc.), vol.77, pp.5932-5933, (1995); 2-oxo-1,2,3,4-tetrahydroquinolin-3-carboxylic acid and its analogues can be produced according to the methods described in JP-A-7(1995)-126267.

As amidation, employed is amidation generally used in peptide chemicals, etc. Concretely, it is conducted in the similar manner as acylation described in the above process 1.

Process 3

Compound (IV) is subjected to reduction to obtain compound (IIa).

Reduction can be conducted in the similar manner as in the above reaction to obtain compound (Ib) from compound 5 (Ia).

Concretely, mentioned is a method in which compound (IV) is reacted with about 1 equivalent to 10 equivalents (preferably about 1 equivalent to 6 equivalents) of a metal hydride in an inert solvent.

10 The "metal hydride" includes, for example, aluminum hydride, lithium aluminum hydride, sodium borohydride, lithium borohydride, sodium borohydride cyanide, lithium borohydride cyanide, borane complexes (e.g., borane-THF complex, catechol-borane, etc.), dibutyl aluminum hydride, 15 as well as mixtures of these metal hydrides and Lewis acids (e.g., aluminum chloride, titanium tetrachloride, cobalt chloride, etc.) or phosphorus oxychloride, etc. Preferred metal hydrides are borane complexes, lithium aluminum hydride, aluminum hydride, etc.


20 The reaction temperature varies, depending on the metal hydride used, but normally falls between -70°C and 100°C. Where lithium aluminum hydride is used, the reaction temperature may be between room temperature and 80°C. Where borane complex is used, the reaction 25 temperature may be between room temperature and 100°C, preferably between room temperature and 60°C.

The reaction time falls between 0.1 hours and 48 hours.

The inert solvent includes, for example, ethers.

30 In the production of compound (I), compounds having CO or SO₂ as X can also be produced by combination of acylation and a carbon-carbon binding reaction.

[Scheme 3].



In the above formulae, X^a represents CO or SO_2 , Y^a represents C_{1-4} alkylene, C_{2-4} alkenylene or C_{2-4} alkynylene, L^3 represents the same leaving group as the above L^2 , other symbols have the same meanings as above.

Process 4

Compound (II) is subjected to acylation described in Process 1 to obtain compound (V). The acylating agent includes acetyl chloride, acetic acid anhydride, methanesulfonyl chloride, etc. The reaction conditions are the same as in Process 1.

15 Process 5

Compound (V) obtained in Process 4 is subjected to a carbon-carbon binding reaction. The carbon-carbon binding reaction includes a method using a strong base, etc.. Normally, compound (V) is reacted with 1 to 2 equivalents of a strong base, and then with 1 to 3 equivalents, preferably 1 to 1.5 equivalents of $L^3\text{-}Y^a\text{-}Ar$.

The strong base includes, for example, alkali metal or alkaline earth metal hydrides (e.g., lithium hydride, sodium hydride, potassium hydride, calcium hydride, etc.).



alkali metal or alkaline earth metal amides (e.g., lithium amide, sodium amide, lithium diisopropylamide, lithium dicyclohexylamide, lithium hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide, etc.), alkali metal or alkaline earth metal lower-alkides (e.g., sodium methoxide, sodium ethoxide, potassium tert-butoxide, etc.), etc. Among these, alkali metal amides are preferable.

The inert solvent includes, for example, ethers, amides, halogenated hydrocarbons, which may be used either singly or as a mixture of them.


The reaction temperature may be between -70°C and room temperature, preferably -20°C and room temperature. The reaction time falls between about 0.1 hours and 1 day, preferably about 1 to 5 hours.

Where the spacer Y has acylamino as its substituent, such compound can be produced by the method described in the following scheme 4.

[Scheme 4]



[Scheme 5]



In the above formulae, Y^b represents a spacer without acylamino, L⁴ and L⁵ represent a leaving group, the other symbols have the same meanings as above.

Process 6

Compound (II) is subjected to condensation with natural or synthetic amino acids whose amino is protected with a protective group, then to deprotection to obtain compound (VII).

The condensation is the same as the reaction usually employed in peptide chemistry. Concretely, it is conducted in the similar manner as in the above "acylation". Especially, the method described in "Process A" is preferable.

The amino-protecting group includes that generally employed in peptide chemistry. Concretely, mentioned are C₇₋₁₄ aralkyloxy-carbonyl, trityl, phthaloyl, etc.

The deprotection is conducted according to per se known methods.

Process 7

Compound (VII) is reacted with compound (VIII) in the same manner as in the above acylation.

The above "natural or synthetic amino acids whose amino is protected with a protective group" and compound (VIII) are on the market, or they can be produced in a short process by known techniques using starting materials which can be obtained easily.

Conversion of compound (VII) into compound (IX) can be

conducted by the method described in Scheme 5.

Process 8

Compound (VII) is reacted with 1 to 2 equivalents of L⁴COL⁵ in an inert solvent at room temperature for about 0.5 to 5 hours, then with 1 to 2 equivalents of HY²(CH₂)_n-R¹⁰ or a salt thereof (in the formulae, symbols have the same meanings as above) in an inert solvent at room temperature for about 0.5 to 24 hours. In this reaction, about 1 to 10 5 equivalents of a base (e.g., N-ethyldiisopropylamine, etc.) may be added according to necessity.

The leaving group for L⁴ and L⁵ is preferably, for example, succinimido.

The inert solvent includes, for example, nitriles (preferably acetonitrile), ethers (preferably THF), halogenated hydrocarbons (preferably dichloromethane), which may be used either singly or as a mixture of two or more species.

20 The above "alcohols" includes, for example, methanol, ethanol, isopropanol, tert-butanol, etc.

The above "ethers" includes, for example, diethyl ether, tetrahydrofuran (THF), 1,4-dioxane, 1,2-dimethoxyethane, etc.

25 The above "halogenated hydrocarbons" includes, for example, dichloromethane, chloroform, 1,2-dichloroethane, carbon tetrachloride, etc.

The above "aromatic solvents" includes, for example, benzene, toluene, xylene, pyridine, etc.

30 The above "hydrocarbons" includes, for example, hexane, pentane, cyclohexane, etc.

The above "amides" includes, for example, N,N'-dimethylformamide (DMF), N,N'-dimethylacetamide, N-methylpyrrolidone, etc.

35 The above "ketones" includes, for example, acetone, methyl ethyl ketone, etc.

The above "sulfoxides" includes, for example, dimethylsulfoxide (DMSO), etc.

The above "nitriles" includes, for example, acetonitrile, propionitrile, etc.

The above "esters" includes, for example, ethyl acetate, etc.

In the above-mentioned reactions where the starting compounds are substituted by any of amino, carboxy, hydroxy or carbonyl, those groups may be protected by ordinary protective groups which are generally used in peptide chemistry. The protective groups may be removed after the reaction to give the desired compounds.

The amino-protecting group includes, for example, formyl, C₁₋₆ alkyl-carbonyl (e.g., acetyl, propionyl, etc.), C₁₋₆ alkylloxy-carbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, etc.), benzoyl, C₇₋₁₀ aralkyl-carbonyl (e.g., benzylcarbonyl, etc.), C₇₋₁₄ aralkyloxy-carbonyl (e.g., benzyloxycarbonyl, 9-fluorenylmethoxycarbonyl, etc.), trityl, phthaloyl, N,N-dimethylaminomethylene, silyl (e.g., trimethylsilyl, triethylsilyl, dimethylphenylsilyl, tert-butyl-dimethylsilyl, tert-butyl-diethylsilyl, etc.), C₂₋₆ alkenyl (e.g., 1-allyl, etc.), etc. These groups may be substituted by 1 to 3 substituents of halogen atoms (e.g., fluoro, chloro, bromo, iodo, etc.), C₁₋₆ alkoxy (e.g., methoxy, ethoxy, propoxy, etc.) or nitro, etc.

The carboxy-protecting group includes, for example, C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, etc.), C₇₋₁₁ aralkyl (e.g., benzyl, etc.), phenyl, trityl, silyl (e.g., trimethylsilyl, triethylsilyl, dimethylphenylsilyl, tert-butyl-dimethylsilyl, tert-butyl-diethylsilyl, etc.), C₂₋₆ alkenyl (e.g., 1-allyl, etc.), etc. These groups may be substituted by 1 to 3 substituents of halogen atoms (e.g., fluorine, chlorine, bromine, iodine, etc.), C₁₋₆ alkoxy (e.g., methoxy, ethoxy,

propoxy, etc.) or nitro, etc.

The hydroxy-protecting group includes, for example, C₁₋₆ alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, etc.), phenyl, trityl, C₇₋₁₀ aralkyl (e.g., 5 benzyl, etc.), formyl, C₁₋₆ alkyl-carbonyl (e.g., acetyl, propionyl, etc.), benzoyl, C₇₋₁₀ aralkyl-carbonyl (e.g., benzylcarbonyl, etc.), 2-tetrahydropyranyl, 2-tetrahydrofuranyl, silyl (e.g., trimethylsilyl, triethylsilyl, dimethylphenylsilyl, tert-butyl- 10 dimethylsilyl, tert-butyl-diethylsilyl, etc.), C₂₋₆ alkenyl (e.g., 1-allyl, etc.), etc. These groups may be substituted by 1 to 3 substituents of halogen atoms (e.g., fluorine, chlorine, bromine, iodine, etc.), C₁₋₆ alkyl (e.g., 15 methyl, ethyl, propyl, etc.), C₁₋₆ alkoxy (e.g., methoxy, ethoxy, propoxy, etc.) or nitro, etc.

The carbonyl-protecting group includes, for example, cyclic acetals (e.g., 1,3-dioxane, etc.), acyclic acetals (e.g., di-C₁₋₆ alkylacetals, etc.), etc.

Those protective groups may be removed by any per se 20 known methods, for example, the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons, 1980, etc. For example, the method of removing these protective groups, includes the methods using acids, bases, ultraviolet ray, hydrazine, phenylhydrazine, sodium N-methyldithiocarbamate, tetrabutylammonium fluoride, palladium acetate, trialkylsilylhalide (e.g., trimethylsilyliodide, trimethylsilylbromide, etc.), etc.; and reduction, etc.

30 Compound (I) can be isolated and purified by any known procedures, for example, through solvent extraction, PH adjustment, redistribution, crystallization, recrystallization, chromatography, etc. The starting compounds for compound (I) and their salts can also be 35 isolated and purified according to the same known procedures as above, but without any isolation

procedure, they may be used in the next step while they are in reaction mixtures.

Compound (I) may also be in the form of hydrates or non-hydrates thereof.

Where compound (I) includes optical isomers, stereoisomers, regio isomers and rotational isomers, those are within the scope of compound (I), and can be isolated as their single compound through *per se* known synthesis or separation. For example, where optical isomers of compound (I) exist, those resolved from their mixtures through optical resolution are within the scope of compound (I).

The optical isomers can be produced in any *per se* known methods. Concretely, optically active synthetic intermediates or mixtures of racemate of the final product are subjected to ordinary optical resolution to give the corresponding optical isomers.

For the optical resolution, employable are any *per se* known methods, such as a fractional recrystallization method, a chiral column method, a diastereomer method, etc.

1) Fractional Recrystallization

The method which comprises allowing a racemate to react with an optically active compound (e.g., (+)-mandelic acid, (-)-mandelic acid, (+)-tartaric acid, (-)-tartaric acid, (+)-1-phenethylamine, (-)-1-phenethylamine, cinchonine, (-)-cinchonidine, brucine, etc.) to give a salt, which is then isolated through fractional recrystallization, followed by, when desired, subjecting the isolated compound to neutralization to obtain free optical isomers.

2) Chiral Column Method

The method of separating a racemate or a salt thereof, which comprises utilizing a column for fractionating optical isomers (chiral column). In the case of liquid column chromatography, for example, a mixture of optical


isomers is applied to a chiral column, such as ENANTIO-OVM (manufactured by Tosoh Corp.), CHIRAL SERIES (manufactured by Daicel, Co.), etc., which is then eluted with water, various buffers (e.g., phosphate buffer) and organic solvents (e.g., ethanol, methanol, isopropanol, acetonitrile, trifluoroacetic acid, diethylamine, etc.), singly or as a suitable mixture of them, to isolate the individual optical isomers. In the case of gas chromatography, for example, a chiral column such as CP-Chirasil-DeX CB (manufactured by GL Science Co.), etc. is used for isolation.

3) Diastereomer Method


A racemic mixture is chemically reacted with an optically-active reagent to give a mixture of diastereomer, which is subjected to ordinary separation means (e.g., fractional recrystallization, chromatography, etc.) to give single compounds. The thus-isolated single compounds are then chemically processed, for example, through hydrolysis to thereby remove the optically-active reagent site from the compounds to obtain optical isomers. For example, where compound (I) has a hydroxy group or a primary or secondary amino group in the molecule, it is condensed with an optically-active organic acid (e.g., MPTA [α -methoxy- α -(trifluoromethyl)phenyl-acetic acid], (-)-menthoxyacetic acid, etc.) or the like to give the corresponding ester-type or amide-type diastereomer. On the other hand, where compound (I) has a carboxylic acid group, it is condensed with an optically-active amine or alcohol reagent to give the corresponding amide-type or ester-type diastereomer. The thus-isolated diastereomer is then subjected to acidic or basic hydrolysis, through which it is converted into the optical isomer of the original compound.

35 Compounds (I) and (I') have an excellent somatostatin

receptor binding inhibition activity (namely, somatostatin receptor agonistic and antagonistic activities). Among compound (I), compound (I-I) represented by the formula:




wherein symbols have the same meanings as above, or a salt thereof; especially, compound (I-II), represented by the formula:




wherein symbols have the same meanings as above, or a salt thereof; has an excellent somatostatin receptor agonistic activity/antagonistic activity.

Among compound (I), especially compound (I-III) represented by the formula:



wherein symbols have the same meanings as above, or a salt thereof has an excellent SSTR4 agonistic activity.

Compound (I-IV) represented by the formula:



wherein symbols have the same meanings as above, or a salt thereof has an excellent SSTR2 and SSTR3 receptor affinity.

Compounds (I) and (I') function through various intracellular signal transduction systems with which somatostatin is associated. The "intracellular signal transduction systems" include, for example, that involves adenylate cyclase, K⁺ channels, Ca²⁺ channels, protein phosphatase, phospholipase C/inositol trisphosphate production systems, MAP kinase, Na⁺/H⁺ exchanger, phospholipase A2, a transcription factor such as NF-κB.

The compound (I) modulates a direct or indirect cell proliferation inhibitory action or apoptosis both of which are associated with somatostatin.

Further, compounds (I) and (I') are low in their toxicity, and enhance or inhibit production or secretion of a variety of hormones, growth factors and physiologically active substances by effecting somatostatin receptors in mammals (e.g., human, cattle, horse, dog, cat, monkey, mouse and rat, especially, human).

The "hormones" include, for example, growth hormone (GH), growth hormone-releasing hormone (GHRH), thyroid stimulating hormone (TSH), prolactin, insulin, glucagon, etc. The "growth factors" include, for example, insulin-like growth factor-1 (IGF-1) and vascular endothelial cell growth factor (VEGF). The "physiologically active substances" include, for example, vasoactive intestinal polypeptide (VIP), gastrin, glucagon-like peptide-1, amylin, substance-P, CCK (cholecystokinin), amylase, interleukins such as interleukin-1 (IL-1) and etc., cytokines such as TNF-α and etc., cardiotropin, etc.

Therefore, compounds (I) and (I') are safe, and useful in modulating diseases associated with disorders of the above intracellular signal transduction systems (e.g.,

diseases associated with excess enhancement or inhibition, etc.); disorders of regulation of cell proliferation; diseases associated with disorders of production or secretion of a variety of hormones, growth factors, physiologically active substances and etc.; growth; immune, 5 gastroenteric or metabolic functions, etc.

Compounds (I) and (I') are useful (1) for drugs for treatment of tumors such as acromegaly, TSH-producing tumors, nonsecretory (afunctional) hypophysial tumors, ectopic ACTH (adrenocorticotrophic hormone)-producing tumors, medullar thyroid carcinoma, VIP-producing tumors, glucagon-producing tumors, gastrin-producing tumors, insulinoma and carotinoid tumor, (2) for drugs for treatment of insulin-dependent and non-insulin dependent diabetes mellitus or a variety of diseases associated with them, namely diabetic complications such as diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, Doan syndrome and orthostatic hypotension, (3) for drugs for improvement of hyperinsulinemia or for treatment of obesity caused by inhibition of appetite, and overeating, (4) for drugs for treatment of acute pancreatitis, chronic pancreatitis, pancreatic/intestinal fistula, hemorrhagic ulcer, peptic ulcer, gastritis, hyperchylia, regurgitant esophagitis, (5) for drugs for improvement of various symptoms associated with the *Helicobacter pylori* infection, for example, inhibitors of gastrin hypersecretion, (6) for drugs for inhibition of amylase secretion associated with endoscopic cholangiopancreatography, and drugs for prognostic treatment of surgical operation of pancreas, (7) for drugs for treatment of diarrhea due to intestinal malabsorption, promotion of secretion or dyskinesia of the digestive tracts (for example, short bowel syndrome), diarrhea due to the drugs for cancer chemotherapy, diarrhea due to 10 congenital small intestine atrophy, diarrhea due to neuroendocrine tumors such as VIP-producing tumors, 15 20 25 30 35

diarrhea due to AIDS, diarrhea due to graft versus host reaction associated with bone marrow transplantation, diarrhea due to diabetes mellitus, diarrhea due to celiac plexus blocking, diarrhea due to systemic sclerosis and 5 diarrhea due to eosinophilia, (8) for drugs for treatment of dumping syndrome, irritable colitis, Crohn disease and inflammatory bowel disease, (9) for drugs for treatment of tumors or cancers (e.g., thyroid cancer, large bowel cancer, breast cancer, prostatic cancer, small cell lung cancer, 10 non-small cell cancer, pancreatic cancer, stomach cancer, cholangiocarcinoma, hepatic cancer, vesical cancer, ovarian cancer, melanoma, osteosarcoma, chondrosarcoma, malignant pheochromocytoma, neuro-blastoma, brain tumors, thymoma, renal cancers), leukemia (e.g., leukemia of 15 basophilic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, Hodgkin disease, and non-Hodgkin lymphoma) (drugs for treatment of these cancers can be used for monotherapy or concomitant therapy with other anticancer drugs such as Tamoxifen, LHRH agonists, LHRH antagonists, interferon- α , β and γ , interleukin-2 and etc.), (10) for drugs for prevention and treatment of hypertrophic cardiomyopathy, arteriosclerosis, valvular 20 disease, myocardial infarction (especially, myocardial infarction post percutaneous transluminal coronary antagonists, interventional angioplasty, (11) for drugs for treatment of hemorrhage of esophageal varicosis, cirrhosis and peripheral blood vessel disorders, (12) for drugs for treatment of diseases associated with general or local inflammation; for example, polyarteritis, rheumatoid 25 arthritis, psoriasis, sunburn, eczema and allergy (e.g., asthma, atopic dermatitis and allergic rhinitis) because they inhibit or modulate the secretion of physiologically active substances acting on the immune system (e.g., Substance P, tachykinin and cytokines), (13) for drugs for 30 treatment of dementia (e.g., Alzheimer disease,

Alzheimer-type senile dementia, vascular/multi-infarct dementia), schizophrenia, epilepsy, depression, generalized anxiety disorder, sleep disorder, and multiple sclerosis, because they give influence on the production and secretion of nerve regulators, (14) for drugs for treatment of oculopathy (e.g., glaucoma, etc.), (15) for drugs for prevention and treatment of acute bacterial meningitis, acute virus encephalitis, adult respiratory distress syndrome, bacterial pneumonia, severe systemic mycotic infection, tuberculosis, spinal damage, bone fracture, hepatic failure, pneumonia, alcoholic hepatitis, virus A hepatitis, virus B hepatitis, virus C hepatitis, AIDS infection, human papilloma virus infection, influenza infection, metastasis of cancer, multiple myeloma, osteomalacia, osteoporosis, bone Paget disease, nephritis, renal failure, sepsis, septic shock, hypercalcemia, hypercholesterolemia, hypertriglyceridemia, hyperlipemia, systemic lupus erythematosus, transient ischemic attach and alcoholic hepatitis, (16) for cure of organ transplantation, burns, trauma, and alopecia, (17) as analgesics for chronic or acute pain (e.g., postoperative pain, inflammatory pain, dental pain, bone disease (e.g., arthritis, rheumatism, osteoporosis etc.) derived pain), (18) for imaging of tumors having somatostatin receptors after administering radioactive substance (e.g., ¹²³I, ¹²⁵I, ¹¹¹In, etc.) to compound (I) or (I') either directly or via a suitable spacer, and (19) for targeting tumors with somatostatin receptors using compound (I) or (I') conjugated with anti-cancer drugs directly or using a suitable spacer.

Somatostatin is associated with secretion of growth hormone (especially in the case of SSTR2), therefore, compound (I) or (I'), when it is used directly or for the purpose of promoting secretion of growth hormone, can provide the same effect and use as growth hormone itself.

Thus, compounds having a SSTR2 antagonistic activity or a salt thereof among compound (I-VII) can be used for prevention or treatment of diseases or symptoms caused by insufficiency of growth hormone or IGF-1.

5 The "prevention or treatment of diseases or symptoms caused by insufficiency of growth hormone or IGF-1" includes, for example, treatment of insulin-dependent and non-insulin dependent diabetes mellitus or a variety of diseases associated with them, namely diabetic complications such as diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, Doan syndrome and orthostatic hypotension; prevention of adverse effects caused by disassimilation of glucocorticoid; prevention or treatment of osteoporosis; stimulation of immune system (e.g., promotion of increase in hemocytes such as lymphocyte; strengthening of an antimicrobial activity or an antiviral activity); promotion of cure of burns and trauma; acceleration in the treatment of bone fracture; treatment of acute or chronic renal diseases; treatment or improvement of diseases or symptoms (short stature, delayed growth) associated with insufficiency of growth hormone in adults or infants; treatment of obesity; promotion of recovery after surgical operations; improvement of delayed growth associated with Prader-Willi syndrome and Turner's syndrome; treatment of delayed intrauterine growth and skeletogenous disorders; treatment of peripheral neuropathy; treatment of Noonan's syndrome, schizophrenia and depression; treatment or prevention of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease; treatment of pulmonary insufficiency and ventilation dependence; treatment of malabsorption syndrome; improvement of cachexia or protein loss caused by cancer or AIDS; promotion of weight increase and proteopexis in patients in the case of TPN (total parenteral nutrition); treatment of hyperinsulinemia; promotion of induction of ovulation; improvement of menopausal

10

15

20

25

30

35

disorders; improvement of senile constitution. Further, the compound of the present invention is useful in mammals such as domestic animals for promotion of growth; increase in milk production; strengthening of an antimicrobial and antiviral activity by stimulation of immune system; stimulation in growth of wool in sheeps. In use for the above purposes, for example, in the treatment of osteoporosis, other drugs for treatment of osteoporosis (e.g., bisphosphonates, vitamin D preparations, calcitonin preparations, PTH preparations, Osten, etc.) can be used concomitantly. In the treatment of diabetes mellitus or diseases associated with them, other antidiabetic agents (e.g., thiazolidinediones such as Troglitazone, pioglitazone, Rosiglitazone, and etc.; glucagon antagonists; glucose absorption inhibitors such as acarbose, and etc) can be used concomitantly. Further, other hormones promoting growth hormone secretion (e.g., GHRH), GH or IGF-1 can be used concomitantly. In improvement of menopausal disorders, a hormone supplemental therapy (e.g., therapy by estrogen preparations, Raloxifene, Tamoxifen) can be used concomitantly. In the case in which stimulation of immune system is intended, cytokines or cytokine activity enhancing agents can be used concomitantly.

25

Compounds (I) and (I') can be formulated into pharmaceutical compositions by any *per se* known methods. Compounds (I) and (I'), as they are or as a pharmaceutical composition prepared by optionally admixing with suitable amounts of any pharmaceutically acceptable carriers, can be safely administered either orally or non-orally (for example, topically, rectally, intravenously, etc.). The pharmaceutical composition includes, for example, tablets (including sugar-coated tablets, film-coated tablets), powders, granules, capsules (including soft capsules), liquids, injections, suppositories, sustained release

preparations, etc.

In the pharmaceutical composition of the present invention, the contents of compound (I) or (I') is 0.1 to 100 % by weight of the total weight of the composition. The dose of the composition varies depending on the subject to which the composition is administered, the administration route employed, the disorder of the subject, etc. For example, for the peroral composition for treating glaucoma, its dose may be about 0.1 to 500 mg, preferably about 1 to 10 mg, more preferably 5 to 100 mg, per adult (weighing about 60 kg), in terms of the active ingredient [compound (I) or (I')], and this may be administered once or several times a day.

Any ordinary organic and inorganic carrier substances that are generally used in formulating medicines are usable as the carriers for formulating the pharmaceutical composition of the present invention. For example, employable are ordinary excipients, lubricants, binders, disintegrators, etc. for formulating solid preparations; and solvents, solubilizers, suspending agents, isotonizing agents, buffers, soothing agents, etc. for formulating liquid preparations. If desired, further employable are other additives such as preservatives, antioxidants, colorants, sweeteners, adsorbents, wetting agents, etc.

The excipients include, for example, lactose, white sugar, D-mannitol, starch, corn starch, crystalline cellulose, light silicic anhydride, etc.

The lubricants include, for example, magnesium stearate, calcium stearate, talc, colloidal silica, etc.

The binders include, for example, crystalline cellulose, white sugar, D-mannitol, dextrin, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinyl pyrrolidone, starch, sucrose, gelatin, methyl cellulose, carboxymethyl cellulose sodium, etc.

The disintegrators include, for example, starch, carboxymethyl cellulose, carboxymethyl cellulose calcium,

croscarmellose sodium, carboxymethyl starch sodium, L-hydroxypropyl cellulose, etc.

The solvents include, for example, water for injections, alcohol, propylene glycol, macrogol, sesame oil, corn oil, etc.

The solubilizers include, for example, polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, etc.

The suspending agents include, for example, surfactants such as stearyl triethanolamine, sodium lauryl sulfate, lauryl aminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, glycerin monostearate, etc.; hydrophilic polymers such as polyvinyl alcohol, polyvinyl pyrrolidone, carboxymethyl cellulose sodium, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, etc.

The isotonizing agents include, for example, glucose, D-sorbitol, sodium chloride, glycerin, D-mannitol, etc.

The buffers include, for example, liquid buffers of phosphates, acetates, carbonates, citrates, etc.

The soothing agents include, for example, benzyl alcohol, etc.

The preservatives include, for example, parahydroxybenzoates, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid, etc.

The antioxidants include, for example, sulfites, ascorbic acid, etc.

30 Best mode for carrying out the invention

The present invention will be explained in more detail by the following Reference Examples, Examples, Formulation Example and Experimental Examples. These are mere examples and are not intended to restrict the present invention, and may be modified within the range of not deviating the scope of this invention.

"Room temperature" in the following Reference

Examples and Examples means a temperature of 0°C to 30°C.

For drying an organic solution, anhydrous magnesium sulfate or anhydrous sodium sulfate was employed. Unless otherwise specifically indicated, "%" means percent by weight.

The IR absorption spectra were measured in a diffused reflection method using a Fourier transform infrared spectrophotometer.

10 The meanings of the abbreviations used in the present specification are as follows:

s: singlet

d: doublet

ddd: double double doublet

t: triplet

q: quartet

m: multiplet

br: broad

J: coupling constant

20 Hz: Hertz

CDCl₃: deuterated chloroform

DMSO-d₆: deuterated dimethylsulfoxide

THF: tetrahydrofuran

DMF: N,N-dimethylformamide

25 DMSO: dimethylsulfoxide

WSC: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride

¹H-NMR: proton nuclear magnetic resonance spectrum (generally measured as the free form of each sample

30 in CDCl₃)

IR: infrared absorption spectrum

Me: methyl

Et: Ethyl

HOBt: 1-hydroxy-1H-benzotriazol

LDA: lithium isopropylamide

IPE: diisopropyl ether

Reference Example 1-1**(2-Formylphenyl)oxyacetonitrile**

Bromoacetonitrile (7 g) was added to an acetone solution (500 ml) of salicylaldehyde (36.3 g). To the reaction mixture was added potassium carbonate (82.1 g), which was stirred at room temperature overnight. Water was added to the reaction mixture, which was concentrated. The residue was extracted with ethyl acetate. The organic layer was washed with water and a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was recrystallized from ethyl acetate-IPE to obtain the entitled compound (38.7 g).

m.p. 70-71°C.

15

Reference Example 1-2**(2-Formyl-5-methoxyphenyl)oxyacetonitrile**

The mixture of 2-hydroxy-4-methoxybenzaldehyde (9.50 g), potassium carbonate (17.3 g), bromoacetonitrile (11.2 g) and acetonitrile (100 ml) was stirred at room temperature for 12 hours. Water was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with water and a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by alumina column chromatography (eluent: ethyl acetate), and then recrystallized from ethyl acetate-hexane to obtain the entitled compound (10.7 g).

m.p. 96-101°C.

30 **Reference Example 2**

Benzofuran-2-carbonitrile

Potassium carbonate (65.2 g) was added to a DMF solution (500 ml) of (2-formylphenyl)oxyacetonitrile (38 g), which was stirred at 60 °C for 2.5 hours. Water was added to the reaction mixture, which was extracted with diethyl ether. The organic layer was washed with water and a saturated aqueous sodium chloride solution, then dried

and concentrated. The residue was purified by silica gel column chromatography (eluent: hexane/ethyl acetate=10/1) to obtain the entitled compound (14.5 g).

m.p. 30-33°C (Solvent for recrystallization :

5. hexane).

Reference Example 3

6-Methoxybenzofuran-2-carbonitrile

Potassium carbonate (15.1 g) and molecular sieves 4A (3 g) were added to a DMF solution (100 ml) of (2-formyl-5-methoxyphenyl)oxyacetonitrile (10.4 g), which was stirred at 100 °C for 10 hours. Water was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with water and a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by silica gel column chromatography (ethyl acetate) to obtain the entitled compound (4.65 g).

Amorphous powder.

20. $^1\text{H-NMR}$ δ: 3.88(3H,s), 6.92-7.06(1H,m), 7.01(1H,s), 7.83(1H,s), 7.46-7.58(1H,m).

Reference Example 4

N-Hydroxy-benzofuran-2-carboxyimidamide

25. An aqueous solution (50 ml) of hydroxylamine hydrochloride (35 g) was added to an ethanol solution (100 ml) of benzofuran-2-carbonitrile (14.4 g). To the reaction mixture was added potassium carbonate (26.7 g), which was heated under reflux overnight. The reaction 30 mixture was poured into water (400 ml), which was ice-cooled, and then crystals were collected by filtration. The crystals were washed with ice-cooled ethanol, then dried to obtain the entitled compound (14.7 g).

m.p. 200-201°C.

Example 4.**Reference Example 5****N-Hydroxy-naphthalene-2-carboxyimidamide**

m.p. 115-116°C.

Reference Example 6**N-Hydroxy-naphthalene-1-carboxyimidamide**

m.p. 62-63°C.

Reference Example 7**N-Hydroxy-(4-methoxyphenyl)ethaneimidamide**

10 m.p. 97-98°C.

Reference Example 8**N-Hydroxy-6-methoxy-1-benzofuran-2-****carboxyimidamide**

m.p. 151-153°C.

15

Reference Example 9**3-[3-(4-Methoxyphenyl)methyl-1,2,4-oxadiazol-5-yl]propanoic acid**

3-Methoxycarbonylpropionyl chloride (4.5 g) was added dropwise to a mixed solution of N-hydroxy-2-(4-methoxyphenyl)ethaneimidamide (3 g) in acetonitrile (20 ml) and pyridine (5 ml) under ice-cooling. The reaction mixture was stirred at room temperature for 3 hours, which was diluted with ethyl acetate. The reaction mixture was washed twice with 2N hydrochloric acid and water, then dried and concentrated. The obtained residue was dissolved in pyridine (20 ml) and stirred under heating at 100°C for 18 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (eluent: hexane/ethyl acetate=1/1) to obtain methyl 3-[3-(4-methoxyphenyl)methyl-1,2,4-oxadiazol-5-yl]propionate (2.5 g).

Methyl 3-[3-(4-methoxyphenyl)methyl-1,2,4-oxadiazol-5-yl]propionate (2.4 g) was dissolved in a mixed solvent of ethanol (20 ml) and water (10 ml). Sodium hydroxide (3 g) was added to the reaction mixture, which was stirred at room temperature for one hour. The

reaction mixture was concentrated. 2N hydrochloric acid was added to the residue to become acidic, which was extracted with ethyl acetate. The extract was washed with water, then dried and concentrated. The residue was 5 recrystallized from ethyl acetate-hexane to obtain the entitled compound.

m.p. 82-83°C.

Reference Example 10

10 3-[3-(2-Benzofuranyl)-1,2,4-oxadiazol-5-yl]propionic acid

(1) Methyl 3-[3-(2-benzofuranyl)-1,2,4-oxadiazol-5-yl]propionate

Ethyl acetate (200 ml), potassium carbonate (60 g) and 15 water (270 ml) were added to a THF solution (70 ml) of N-hydroxy-benzofuran-2-carboxyimidamide (10.0 g). To the reaction mixture was added a THF solution (70 ml) of 3-methoxycarbonylpropionyl chloride (7.35 ml), which was stirred for one hour, and the reaction mixture was 20 extracted with ethyl acetate. The organic layer was washed with water and a saturated aqueous sodium chloride solution, then dried and concentrated. A pyridine solution (100 ml) of the residue (15.0 g) was stirred at 100°C overnight. The reaction mixture was concentrated, and the residue was 25 extracted with ethyl acetate. The organic layer was washed subsequently with 1N hydrochloric acid, 10% aqueous potassium carbonate solution and a saturated aqueous sodium chloride solution, and then dried and concentrated. The residue was purified by silica gel column chromatography 30 (eluent: hexane/ethyl acetate=1/1) to obtain methyl 3-[3-(2-benzofuranyl)-1,2,4-oxadiazol-5-yl]propionate (13.2 g).

m.p. 112-113°C (Solvent for recrystallization: ethyl acetate/hexane)

35 (2) 3-[3-(2-Benzofuranyl)-1,2,4-oxadiazol-5-yl]propionic acid

Methanol (180 ml) was added to a THF solution (180 ml)

of methyl 3-[3-(2-benzofuranyl)-1,2,4-oxadiazol-5-yl]propionate (10.0 g). 1N sodium hydroxide (72 ml) was added dropwise to the reaction mixture under ice-cooling.

The reaction mixture was stirred at room temperature for 5 2 hours, and then concentrated. 1N hydrochloric acid (107 ml) was added to the residue, and the precipitated crystals were collected by filtration. The crystals were washed with water and IPE, and dried to obtain the entitled compound (8.0 g).

10 m.p. 154-155°C (Solvent for recrystallization:
methanol/water)

Compounds of the following Reference Example 11 to 17 were synthesized by the similar manner as in Reference 15 Example 10.

Reference Example 11

4-[3-(2-Benzofuranyl)-1,2,4-oxadiazol-5-yl]butyric acid

m.p. 137-139°C.

20 Reference Example 12

2-[3-(2-Benzofuranyl)-1,2,4-oxadiazol-5-yl]acetic acid

m.p. 132-133°C.

Reference Example 13

25 3-[3-(2-Naphthyl)-1,2,4-oxadiazol-5-yl]propionic acid

m.p. 157-158°C.

Reference Example 14

30 3-[3-(1-Naphthyl)-1,2,4-oxadiazol-5-yl]propionic acid

m.p. 117-118°C.

Reference Example 15

3-[3-(Phenoxyethyl)-1,2,4-oxadiazol-5-yl]propionic acid

35 m.p. 80-81°C.

Reference Example 16

3-[3-[(E)-2-(4-methylphenylethenyl)]-1,2,4-

oxadiazol-5-yl]propionic acid

m.p. 139-140°C.

Reference Example 17**3-[3-(6-Methoxybenzofuran-2-yl)-1,2,4-oxadiazol-5-****5-yl]propionic acid**

m.p. 140-142°C.

Reference Example 18**2-Acetylbenzofuran**

10 Bromoacetone (25 g) was added to an acetone solution (500 ml) of salicylaldehyde (20.3 g). To the reaction mixture was added potassium carbonate (45.9 g) at room temperature and the stirring was continued overnight.

15 Water was added to the reaction mixture, which was concentrated. The residue was extracted with ethyl acetate. The organic layer was washed with water and a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was recrystallized from ethyl acetate-IPE to obtain the entitled compound (10 g).

20 m.p. 64-65°C.

Reference Example 19**2-Bromoacetylbenzofuran**

25 Pyridinium bromide perbromide (20 g) was added to a THF solution (200 ml) of 2-acetylbenzofuran (8.35 g). The reaction mixture was stirred at room temperature for 20 minutes. The precipitated crystals were collected by filtration, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (eluent: hexane/ethyl acetate=4/1) to obtain the entitled compound (6.5 g).

30 m.p. 79-80°C.

Reference Example 20**35 Methyl 4-amino-4-thioxobutyrate**

Lawesson's reagent (2.6 g) was added to a toluene (10 ml) solution of methyl succinamate (1.7 g). The

reaction mixture was heated under reflux for 4 hours, cooled, and then concentrated. The residue was purified by silica gel column chromatography (eluent: hexane/ethyl acetate=1/1) to obtain the entitled compound (400 mg) as an oily substance.

¹H-NMR δ: 2.8-3.0(4H,m), 3.70(3H,s), 7.6-8.2(2H,br).

Reference Example 21

3-[4-(2-Benzofuranyl)thiazol-2-yl]propionic acid

(1) Ethyl 3-[4-(2-benzofuranyl)thiazol-2-yl]propionate
2-(Bromoacetyl)benzofuran (650 ml) was added to an ethanol (12 ml) solution of methyl 4-amino-4-thioxobutyrate (400 mg), which was heated under reflux overnight. After cooling, water was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was dried, concentrated, and then purified by silica gel column chromatography (eluent: hexane/ethyl acetate=4/1). The obtained crystals were washed with hexane to obtain ethyl 3-[4-(2-benzofuranyl)thiazol-2-yl]propionate (460 mg).

m.p. 65-66°C (Solvent for recrystallization:
hexane/ethyl acetate)

(2) 3-[4-(2-Benzofuranyl)thiazol-2-yl]propionic acid

1N Sodium hydroxide (3 ml) was added dropwise to a methanol solution (3 ml) of ethyl 3-[4-(2-benzofuranyl)thiazol-2-yl]propionate (460 mg) under ice-cooling. The reaction mixture was stirred at room temperature overnight, to which was added 10% aqueous potassium carbonate solution (10 ml), and the mixture was washed with ethyl acetate. The aqueous layer was made acidic (pH 3) by adding 1N hydrochloric acid and extracted with ethyl acetate. The organic layer was dried and concentrated to obtain the entitled compound (306 mg).

m.p. 203-205°C (Solvent for recrystallization:
methanol/water).

Reference Example 22**3-(4-Phenylthiazol-2-yl)propionic acid**

5 The titled compound was synthesized from phenacyl bromide by the similar manner as in Reference Example 21.

m.p. 72-73°C (Solvent for recrystallization: hexane/IPE).

Reference Example 23**3-(4-Bromophenyl)propionic acid**

Sodium hydride (60% dispersion in oil; 4 g) was added portionwise to an ethanol (100 ml) solution of diethyl malonate (16 g) under ice-cooling. The reaction mixture was stirred at room temperature for 10 minutes, to which 15 was added dropwise a THF (50 ml) solution of p-bromobenzylbromide (12 g) at room temperature. The reaction mixture was stirred at room temperature for 2 hours, and concentrated. Acetic acid (200 ml) and 6N hydrochloric acid (100 ml) were added to the residue. The reaction mixture was stirred under heating at 90°C for 18 hours, and concentrated. Water was added to the residue, which was extracted with ethyl acetate. The organic layer was washed with water, then dried and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate/hexane=1/1), which was recrystallized from IPE to obtain the entitled compound (1.2 g).

m.p. 136-137°C.

Reference Example 24**(4-Biphenylyloxy)acetic acid**

30 Sodium hydride (60% dispersion in oil; 0.8 g) was added portionwise to a DMF (10 ml) solution of 4-hydroxybiphenyl (1.7 g) under ice-cooling. The reaction mixture was stirred at room temperature for 30 minutes, to 35 which was added bromoacetic acid (1.4 g). The reaction mixture was further stirred at room temperature for 18 hours, which was poured into water. 2N hydrochloric acid was added

to the mixture to adjust the pH to 4, which was extracted with ethyl acetate. The organic layer was washed with water, then dried and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate/hexane=1/1), and the crude crystals were

5 recrystallized from IPE to obtain the entitled compound (1.5 g).

m.p. 184-185°C.

10 Reference Example 25

(E)-3-[4-(4-methoxyphenyl)oxyphenyl]propenoic acid
(1) 4-[(4-Methoxyphenyl)oxy]benzenecarbonitrile

Sodium hydride (60 % dispersion in oil; 0.8 g) was added to a DMF (20 ml) solution of 4-methoxyphenol (2.4 g).

15 The reaction mixture was stirred at room temperature for 5 minutes, to which was added 4-fluorobenzene carbonitrile (2.4 g). The reaction mixture was stirred at room temperature for 4 hours, which was further stirred at 50°C for one hour. The reaction mixture was poured into water, which was extracted with toluene. The organic layer was washed with water, then dried and concentrated. The residue was purified by silica gel column chromatography (eluent: hexane/ethyl acetate=1/1), and then recrystallized from toluene-hexane to obtain 4-[(4-

20 methoxyphenyl)oxy]benzenecarbonitrile (2.0 g).

m.p. 102-103°C.

(2) 4-[(4-Methoxyphenyl)oxy]benzenecarboaldehyde

25 A toluene (50 ml) solution of 4-[(4-methoxyphenyl)oxy]benzenecarbonitrile (1.8 g) was cooled to -70°C. Diisobutylaluminum hydride (1M toluene solution; 12 ml) was added dropwise to the reaction mixture. The reaction mixture was stirred at -70°C for one hour, and poured into 2N hydrochloric acid (50 ml). The reaction mixture was further stirred under heating at 50°C for 2 hours, and the organic layer was separated. The organic layer was washed with water, dried, and then concentrated. The residue was purified by silica gel column

chromatography (eluent: hexane/ethyl acetate=1/1), and then recrystallized from hexane-ethyl acetate to obtain 4-[(4-methoxyphenyl)oxy]benzenecarboaldehyde (1.6 g).

m.p. 58-59°C.

5 (3) (E)-3-[4-(4-methoxyphenyl)oxyphenyl]propenoic acid

Sodium hydride (60 % dispersion in oil; 0.36 g) was added to an ethanol (30 ml) solution of ethyl diethylphosphonoacetate (1.4 g) at room temperature. The 10 reaction mixture was stirred at room temperature for 10 minutes, to which was added 4-[(4-methoxyphenyl)oxy]benzenecarboaldehyde (1.2 g). The reaction mixture was stirred at room temperature for 2 hours, which was further stirred at 50°C for 30 minutes. The 15 reaction mixture was cooled, to which were added water (20 ml) and sodium hydroxide (0.5 g). The reaction mixture was stirred at room temperature for 2 hours, and concentrated.

20 2N Hydrochloric acid was added to the residue to become acidic, which was extracted with ethyl acetate. The organic layer was washed with water, then dried and concentrated. The residue was recrystallized from ethyl acetate-hexane to obtain the entitled compound (1.2 g).

m.p. 165-167°C.

25 Reference Example 26

Methyl 4-hydroxyimino-1,2,3,4-tetrahydro-2-naphthalenecarboxylate

Thionyl chloride (5 drops) was added to a methanol (50 ml) solution of 4-oxo-1,2,3,4-tetrahydro-2-naphthalenecarboxylic acid (2.0 g), which was stirred at 30 room temperature for 2 hours. The reaction mixture was poured into water, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium bicarbonate solution, then dried and concentrated. 35 To a methanol (15 ml) solution of the residue was added an aqueous (6 ml) solution of hydroxylamine hydrochloride (850 mg) and sodium acetate (1.0 g), which was heated under

reflux for 12 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium bicarbonate solution, then dried and concentrated. The residue was 5 purified by silica gel column chromatography (eluent: hexane/ethyl acetate=3/1) to obtain the entitled compound (1.62 g).

$^1\text{H-NMR}$ δ : 2.62-3.15(4H, m), 3.34-3.48(1H, m), 3.74(3H, s), 7.14-7.36(3H, m), 7.90(1H, d).

10

Reference Example 27

Methyl 2-oxo-2,3,4,5-tetrahydro-1*H*-1-benzazepine-4-carboxylate

Polyphosphoric acid (20 g) was added to methyl 4-15 hydroxyimino-1,2,3,4-tetrahydro-2-naphthalenecarboxylate (1.6 g), which was stirred at 110°C for 30 minutes. The reaction mixture was ice-cooled, which was added with ice, and then extracted with ethyl acetate. The organic layer was washed with water and a saturated 20 aqueous sodium chloride solution, then dried and concentrated. The residue was purified by silica gel column chromatography (eluent: hexane/ethyl acetate=1/1) to obtain the entitled compound (1.15 g).

m.p. 114-115°C (Solvent for recrystallization: 25 hexane/ethyl acetate).

Reference Example 28

2-Oxo-1,2,3,4-tetrahydro-3-quinolineacetic acid

A concentrated hydrochloric acid (12 ml) solution of 30 methyl 2-oxo-2,3,4,5-tetrahydro-1*H*-1-benzazepine-4-carbonate (960 mg) was heated under reflux for 30 minutes.

The reaction mixture was poured into water, to which was added 1N aqueous sodium hydroxide solution to adjust the pH to 4. The mixture was extracted with a mixed solvent of ethyl acetate-THF (1:1). The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated to obtain the entitled compound (820

mg).

m.p. 145-146°C (Solvent for recrystallization: THF/hexane).

5 Reference Example 29

8-Methoxy-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine-4-carboxylic acid

1N sodium hydroxide (38 ml) was added dropwise to a methanol (40 ml) solution of methyl 8-methoxy-2-oxo-

10 2,3,4,5-tetrahydro-1H-1-benzazepine-4-carbonate (4.8 g) under ice-cooling. The reaction mixture was stirred at room temperature overnight, to which was added dropwise 1N aqueous hydrochloric acid solution (42 ml). The mixture was extracted with a mixed solvent of ethyl acetate-THF (1:1). The organic layer was washed with water and a saturated aqueous sodium chloride solution, then dried and concentrated. The obtained crystals were washed with IPE to obtain the entitled compound (3.27 g).

m.p. 210-212°C (Solvent for recrystallization: THF/IPE).

Reference Example 30

N,N-Dimethyl-2-oxo-1,2,3,4-tetrahydro-3-quinolineacetoamide

25 To the mixed solution of 2-oxo-1,2,3,4-tetrahydro-3-quinolineacetic acid (810 mg) in THF (10 ml) and acetonitrile (10 ml), WSC (1.15 g), HOBt (610 mg), dimethylamine hydrochloride (650 mg) and triethylamine (1.67 ml) were added subsequently, which was stirred at 30 room temperature overnight. Water was added to the reaction mixture, which was extracted with a mixed solvent of ethyl acetate-THF (1:1). The organic layer was washed subsequently with 0.1N aqueous hydrochloric acid solution, a saturated aqueous sodium bicarbonate solution, and a 35 saturated aqueous sodium chloride solution, then dried and concentrated to obtain the entitled compound (620 mg).

m.p. 172-173°C (Solvent for recrystallization: ethyl

acetate/IPE).

Compound of the following Reference Example 31 was synthesized by the similar manner as in Reference Example

5 30.

Reference Example 31

N,N-Dimethyl-8-methoxy-2-oxo-2,3,4,5-tetrahydro-
1*H*-1-benzazepine-4-carboxamide

m.p. 172-173°C (Solvent for recrystallization:
10 ethyl acetate/IPE)

Reference Example 32

3-[2-(N,N-Dimethylamino)ethyl]-1,2,3,4-tetrahydroquinoline

15 Borane-THF complex (1M; 15 ml) was added to N,N-dimethyl-2-oxo-1,2,3,4-tetrahydro-3-quinolineacetoamide (590 mg), which was heated under reflux for 3.5 hours. 6N hydrochloric acid (10 ml) was added to the reaction mixture, which was heated under reflux overnight. 6N sodium 20 hydroxide was added to the reaction mixture to adjust pH to 7 and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium bicarbonate solution and a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by 25 alumina column chromatography (éluent: hexane/ethyl acetate=1/1) to obtain the entitled compound (390 mg) as an oily substance.

¹H-NMR δ: 1.45-1.58(2H, m), 2.24(6H, s), 2.30-2.56(3H, m), 2.75-2.90(1H, m), 2.90-3.04(1H, m), 3.26-3.40(1H, m), 30 3.54-3.74(1H, m), 6.47(1H, d), 6.54-6.66(1H, m), 6.90-7.04(2H, m).

Compound of the following Reference Example 33 was synthesized by the similar manner as in Reference Example

35 32.

Reference Example 33

4-(N,N-Dimethylaminomethyl)-8-methoxy-2,3,4,5-tetrahydro-1H-benzazepine oxalate

m.p. 187-188°C. (Solvent for recrystallization: methanol/IPE).

5

Reference Example 34

Dimethyl 2-[(2-nitrophenyl)methylidene]malonate

A methanol (300 ml) solution of o-nitrobenzaldehyde (103.1 g), dimethyl malonate (90.1 g), acetic acid (1.2 ml) and piperidine (12 ml) was heated under reflux for 25 hours. The reaction mixture was concentrated. Water was added to the mixture, which was extracted with ethyl acetate. The organic layer was washed with 1N hydrochloric acid, water, a saturated aqueous sodium hydrogen carbonate solution and a saturated aqueous sodium chloride solution, then dried and concentrated. The obtained crude crystals were washed with IPE to give the entitled compound (59.79 g). The mother liquor was further purified by silica gel column chromatography (eluent: ethyl acetate/hexane=1/2). The obtained crude crystals were recrystallized from ethyl acetate-hexane to give the entitled compound (34.13 g).

m.p. 67-70°C.

Reference Example 35

Methyl 2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxylate

Sodium borohydride (1.10 g) was added to the mixed solution of dimethyl 2-[(2-nitrophenyl)methylidene]malonate (15.2 g) in ethyl acetate (50 ml) and methanol (200 ml) at 0°C. The reaction mixture was stirred at 0°C for 20 minutes. Water was added to the mixture, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. 5% Palladium-carbon (6.26 g) was added to the mixed solution of the residue in THF (100 ml) and methanol (100 ml), and catalytic hydrogenation was conducted at room temperature

under atmospheric pressure for 3 days. The catalyst was removed by filtration, and the filtrate was concentrated.

The obtained crude crystals were washed with a mixed solution of ethyl acetate/hexane=1/4 to give the entitled compound (9.487 g).

m.p. 165-168°C.

Reference Example 36

2-Oxo-1,2,3,4-tetrahydro-3-quinolinecarboxylic acid

1N Aqueous sodium hydroxide solution (80 ml) was added dropwise to the mixed solution of methyl 2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxylate (8.322 g) in THF (80 ml) and methanol (80 ml) at 0°C. The reaction mixture was stirred at room temperature for 4 hours. 1N Hydrochloric acid (90 ml) was added dropwise to the reaction mixture at 0°C, which was then extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated to obtain crude crystals of the entitled compound (7.032 g). The obtained crude crystals were put to use in the following reaction without purification.

¹H-NMR(DMSO-d₆) δ: 3.11(2H, d), 3.47(1H, t), 6.90(1H, dd), 7.09-7.24(2H, m).

25

Reference Example 37

N,N-Dimethyl-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxamide

2-Oxo-1,2,3,4-tetrahydro-3-quinolinecarboxylic acid (8.56 g), dimethylamine hydrochloride (4.60 g), HOBT (7.18 g), WSC (11.1 g) and triethylamine (20 ml) were added to acetonitrile (400 ml). The reaction mixture was stirred at room temperature for 43 hours. 10 % aqueous citric acid solution was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with water, a saturated aqueous sodium hydrogencarbonate solution and a saturated aqueous sodium chloride solution,

then dried and concentrated. The obtained crude crystals were washed with IPE to give the entitled compound (9.486 g).

m.p. 224-226°C.

5

Compounds of the following Reference Examples 38 to 43 were synthesized by the similar manner as in Reference Example 37.

Reference Example 38

10 N,N-Diethyl-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxamide

m.p. 155-158°C (washed with IPE).

Reference Example 39

15 4-Phenyl-1-[(1,2,3,4-tetrahydro-2-oxoquinolin-3-yl)carbonyl]piperazine

m.p. 225-228°C (Solvent for recrystallization: THF/IPE).

Reference Example 40

20 2-Oxo-3-(pyrrolidin-1-yl)carbonyl-1,2,3,4-tetrahydroquinoline

m.p. 225-228°C (decomposed) (washed with IPE).

Reference Example 41

25 2-Oxo-3-piperidinocarbonyl-1,2,3,4-tetrahydroquinoline

m.p. 179-183°C (washed with IPE).

Reference Example 42

30 2-Oxo-3-morpholinocarbonyl-1,2,3,4-tetrahydroquinoline

m.p. 204-209°C (washed with IPE).

Reference Example 43

35 N-Benzyl-N-methyl-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxamide

m.p. 176-179°C (washed with IPE).

Reference Example 44

3-(N,N-Dimethylamino)methyl-1,2,3,4-tetrahydroquinoline

N,N-Dimethyl-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxamide (9.486 g) was added to 1M Borane-THF complex (200 ml). The reaction mixture was heated under reflux for 45 minutes, and left standing for cooling. The 5 reaction mixture was ice-cooled, to which were added water (20 ml) and 6N hydrochloric acid (50 ml). The mixture was stirred at room temperature for 15 hours, and concentrated. A methanol solution (200 ml) of the residue was heated under reflux for 6 hours, and concentrated. 3N aqueous sodium 10 hydroxide solution was added to the residue to become basic, which was extracted with ethyl acetate. The residue was purified by alumina column chromatography (eluent: ethyl acetate/hexane=1/10). The obtained crude crystals were washed with hexane to give the entitled compound (5.569 g).

15 m.p. 85-89°C.

Compounds of the following Reference Examples 45 to 50 were synthesized by the similar manner as in Reference Example 44.

20 Reference Example 45
3-(N,N-Diethylamino)methyl-1,2,3,4-tetrahydroquinoline
¹H-NMR δ: 1.00(6H, t), 2.01-2.23(1H, m), 2.26-2.62(7H, m), 2.74-3.02(2H, m), 3.36-3.47(1H, m), 6.48(1H, d), 25 6.59(1H, t), 6.91-7.01(2H, m).

Reference Example 46
3-(4-Phenylpiperazin-1-yl)methyl-1,2,3,4-tetrahydroquinoline
m.p. 127-132°C (Solvent for recrystallization: ethyl 30 acetate/hexane).

Reference Example 47
3-(Pyrrolidin-1-yl)methyl-1,2,3,4-tetrahydroquinoline
m.p. 84-87°C (Solvent for recrystallization: ethyl 35 acetate/hexane).
Reference Example 48

3-Piperidinomethyl-1,2,3,4-tetrahydroquinoline
m.p. 65-68°C (Solvent for recrystallization: ethyl acetate/hexane).

Reference Example 49

5 3-Morpholinomethyl-1,2,3,4-tetrahydroquinoline
m.p. 61-65°C (Solvent for recrystallization: ethyl acetate/hexane).

Reference Example 50

10 3-(N-Benzyl-N-methylamino)methyl-1,2,3,4-tetrahydroquinoline

15 $^1\text{H-NMR}$ δ: 2.15-2.52(4H, m), 2.22(3H, s), 2.78-3.00(2H, m), 3.39-3.50(1H, m), 3.50(2H, dd), 6.46(1H, d), 6.60(1H, t), 6.91-7.00(2H, m), 7.18-7.56(5H, m).

15 Reference Example 51

Ethyl 3-(2-nitrobenzyl)-2-oxo-3-piperidinecarboxylate

Sodium hydride (60% dispersion in oil, 2.45 g) was added to ethanol (100 ml), to which was added 3-carboethoxy-2-piperidone (10.0 g). The reaction mixture was stirred for 15 minutes, to which was added 2-nitrobenzyl bromide (13.2 g) at room temperature. The reaction mixture was stirred at 60°C for 3 hours. Water was added to the reaction mixture, which was concentrated. The residue was diluted with water and extracted with ethyl acetate. The organic layer was washed with water and a saturated aqueous sodium chloride solution, then dried and concentrated. The obtained crude crystals were recrystallized from ethyl acetate-hexane to give the entitled compound (14.6 g).

m.p. 137-139°C.

Reference Example 52

Ethyl 3-(2-nitrobenzyl)-2-oxo-1-propyl-3-piperidinecarboxylate

Sodium hydride (60 % dispersion in oil, 1.59 g) was added to a DMF solution (100 ml) of ethyl 3-(2-

nitrobenzyl)-2-oxo-3-piperidinecarboxylate (11.0 g) and propyl iodide (5.79 ml) under ice-cooling. The reaction mixture was stirred at room temperature for 30 minutes. The reaction mixture was diluted with water and extracted with 5 a mixture of ethyl acetate and diethyl ether. The residue was purified by silica gel column chromatography (eluent: ethyl acetate/hexane=1/4 to 1/2) to obtain the entitled compound (10.6 g).

Oily substance.

10 $^1\text{H-NMR}$ δ : 0.87(3H, t), 1.26(3H, t), 1.35-2.23(6H, m), 2.98-3.55(4H, m), 3.68(1H, d), 3.83(1H, d), 4.03-4.35(2H, m), 7.28-7.63(3H, m), 7.77-7.88(1H, m).

Reference Example 53

15 2,2'-Dioxo-1-propyl-1',2',3',4'-tetrahydrospiro[piperidin-3,3'-quinoline]

10 % Palladium- carbon (0.2 g) was added to an ethanol solution (20 ml) of ethyl 3-(2-nitrobenzyl)-2-oxo-1-propyl-3-piperidinecarboxylate (1.00 g), and catalytic 20 hydrogenation was conducted at room temperature under one atmospheric pressure for 6 hours. The catalyst was removed by filtration and the filtrate was concentrated. The residue was dissolved in toluene (20 ml), which was heated under reflux for 12 hours. The reaction mixture was 25 concentrated, and the obtained crude crystals were recrystallized from ethyl acetate-hexane to give the entitled compound (0.55 g).

m.p. 151-154°C.

30 Reference Example 54

1-Propyl-1',2',3',4'-tetrahydrospiro[piperidin-3,3'-quinoline]

In the similar manner as in Reference Example 44, the entitled compound (1.204 g) was synthesized from 2,2'-dioxo-1-propyl-1',2',3',4'-tetrahydrospiro[piperidin-3,3'-quinoline] (1.369 g).

m.p. 85-88°C (washed with hexane).

Reference Example 55

Dimethyl (4-methoxy-2-

5-nitrophenyl)methylidenemalonate

A methanol (125 ml) solution of 4-methoxy-2-nitrobenzaldehyde (21.3 g, described in Org. Synth., volume V, p-139, 1973), dimethyl malonate (16.5 g), piperidine (2.5 ml) and acetic acid (0.25 ml) was heated under reflux 10 for 24 hours. The reaction mixture was concentrated, to which was added 1N hydrochloride, and the mixture was extracted with ethyl acetate. The organic layer was washed with 10% aqueous potassium carbonate solution and a saturated aqueous sodium chloride solution, then dried and 15 concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate/hexane=1/2) to obtain the entitled compound (25 g).

¹H-NMR δ: 3.67(3H, s), 3.88(3H, s), 3.92(3H, s), 7.16(1H, dd), 7.36(1H, d), 7.70(1H, d), 8.14(1H, s).

20

Reference Example 56

Dimethyl (4-methoxy-2-nitrobenzyl)malonate

Sodium borohydride (3.36 g) was added to a methanol (200 ml) solution of dimethyl (4-methoxy-2-25 nitrophenyl)methylidenemalonate (25 g) under ice-cooling.

The reaction mixture was stirred at room temperature for one hour and then neutralized by adding dropwise 1N aqueous hydrochloric acid solution. The reaction mixture was concentrated and extracted with ethyl acetate. The 30 organic layer was washed with water, a saturated aqueous potassium bicarbonate solution and a saturated aqueous sodium chloride solution, then dried and concentrated.

The residue was purified by silica gel column chromatography (eluent: ethyl acetate/hexane=1/4) to 35 obtain the entitled compound (19 g).

¹H-NMR δ: 3.44(2H, d), 3.71(6H, s), 3.86(3H, s),

3.80-4.00(1H, m), 7.08(1H, dd), 7.28(1H, d), 7.52(1H, d).

Reference Example 57

7-Methoxy-2-oxo-1,2,3,4-tetrahydro-3-
5 quinolinecarboxylic acid

10 8 Palladium-carbon (2.0 g) was added to an ethanol
(200 ml) solution of dimethyl (4-methoxy-2-
nitrobenzyl)malonate (19 g); and catalytic hydrogenation
was conducted at room temperature under an atmospheric
10 pressure for 24 hours. The reaction mixture was further
stirred at 80°C for 24 hours. The catalyst was removed by
filtration, and the filtrate was concentrated. The
residue was dissolved in a mixed solvent of THF (250 ml)
and methanol (250 ml), to which was added dropwise 1N
15 aqueous sodium hydroxide solution (126 ml) under ice-
cooling. The reaction mixture was stirred at room
temperature for 72 hours and concentrated. 1N
Hydrochloric acid was added to the residue to make acidic,
and the precipitated crystals were collected by filtration.
20 The obtained crude crystals were washed with acetone to
give the entitled compound (11.7 g).
m.p. 145-146°C (decomposed).

Reference Example 58

25 7-Methoxy-N,N-dimethyl-2-oxo-1,2,3,4-tetrahydro-3-
quinolinecarboxamide

WSC (6.5 g) was added to an acetonitrile solution of
7-methoxy-2-oxo-1,2,3,4-tetrahydro-3-
quinolinecarboxylic acid (3.74 g), dimethylamine
30 hydrochloride (3.44 g), HOBT (2.85 g) and triethylamine
(8.5 g). The reaction mixture was stirred at room
temperature for 24 hours and concentrated. The residue was
diluted with ethyl acetate. The organic layer was washed
with 1N aqueous hydrochloric acid solution, 10% aqueous
35 potassium carbonate solution, and a saturated aqueous
sodium chloride solution, then dried and concentrated.
The obtained crude crystals were recrystallized from ethyl

acetate-hexane to give the entitled compound (1.63 g).
m.p. 209-210°C.

Reference Example 59

5 3-(N,N-Dimethylamino)methyl-7-methoxy-1,2,3,4-tetrahydroquinoline dihydrochloride

1M Borane-THF complex (60 ml) was added to a THF (100 ml) solution of 7-methoxy-N,N-dimethyl-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxamide (1.63 g). The reaction mixture was heated under reflux for 24 hours. The reaction mixture was concentrated and 6N hydrochloric acid (30 ml) was added to the residue, which was heated under reflux for 4 hours. 6N Aqueous sodium hydroxide solution was added to the reaction mixture to make basic, which was extracted with ethyl acetate. The organic layer was washed with 10% aqueous potassium carbonate solution and a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was processed into its dihydrochloride, which was recrystallized from methanol-IPE to obtain the entitled compound (1.27 g).

m.p. 150-151°C.

Reference Example 60

25 3-(N,N-Dimethylamino)methyl-1,2,3,4-tetrahydro-7-quinolinol

48% Hydrobromic acid solution (10 ml) of 3-(N,N-dimethylamino)methyl-7-methoxy-1,2,3,4-tetrahydroquinoline dihydrochloride (1.0 g) was heated under reflux for 4 hours. The reaction mixture was poured into 10% aqueous potassium carbonate solution and extracted with ethyl acetate. The organic layer was dried, and then concentrated. The obtained crude crystals were recrystallized from ethyl acetate-hexane to give the entitled compound (0.81 g).

35 Dihydrochloride salt of the entitled compound showed m.p. of 151-152°C (Solvent for recrystallization: methanol/IPE).

Reference Example 61

7-(4-Biphenyl-*yl*)methoxy-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline hydrochloride

Diethylazodicarboxylic acid (348 mg) was added dropwise to a THF solution (20 ml) of 3-(dimethylamino)methyl-1,2,3,4-tetrahydro-7-quinolinol (344 mg), 4-biphenylmethanol (368 mg), and triphenylphosphine (525 mg). The reaction mixture was stirred at room temperature for one hour, which was poured into 1N hydrochloric acid and washed with ethyl acetate. The aqueous layer was neutralized with 1N aqueous sodium hydroxide solution, to which was added a saturated aqueous sodium bicarbonate solution and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by alumina column chromatography (eluent: ethyl acetate/hexane=1/4), converted into its hydrochloride, and then recrystallized from ethanol-IPE to give the entitled compound (214 mg). m.p.: 183-184°C.

Reference Example 62

3-[1-(2,4-Dichlorobenzyl)indol-3-yl]propionic acid
Sodium hydride (60% dispersion in oil, 0.38 g) was added to the mixed solution of ethyl 3-(indol-3-yl)propionate (1.8 g) in DMF (20 ml) and THF (20 ml) under ice-cooling. The reaction mixture was stirred at room temperature for 10 minutes, to which were added 2,4-dichlorobenzyl bromide (1.8 g) and sodium iodide (0.3 g). The reaction mixture was stirred at room temperature for 3 hours and then poured into water, and the mixture was extracted with IPE. The organic layer was washed with water, then dried and concentrated. The residue was dissolved in ethanol (30 ml), which was stirred at 50°C for 2 hours in the presence of water (10 ml) and sodium hydroxide (1 g).

The reaction mixture was concentrated, made acidic, and then extracted with ethyl acetate. The organic layer was washed with water, then dried and concentrated. The residue was recrystallized from ethyl acetate-IPE to obtain 5 the entitled compound (2.4 g).

m.p. 134-136°C.

Reference Example 63

3-(N,N-Dimethylamino)methyl-1-[2-(6-methoxy-
10 1,2,3,4-tetrahydronaphthalen-2-yl)acetyl]-1,2,3,4-
tetrahydroquinoline oxalate.

The entitled compound was synthesized by the similar manner as in Example 1 hereafter.

Eluent: hexane/ethyl acetate = 3/1 to 2/1

15 m.p. 83-85°C. (Solvent for recrystallization:
THF/diethyl ether).

Reference Example 64

3-(N,N-Dimethylamino)methyl-1-[3-(3-
20 indolyl)acetyl]-1,2,3,4-tetrahydroquinoline
hydrochloride.

The entitled compound was synthesized by the similar manner as in Example 1 hereafter.

Eluent: hexane/ethyl acetate = 2/1.

25 m.p. 231-237°C (Decomposed, Solvent for
recrystallization: methanol/IPE).

Reference Example 65

2-(4-Biphenylyl)ethylthiocyanate

30 Bromine (1.5 ml) was added dropwise to an acetonitrile (60 ml) solution of triphenylphosphine (5 g). After stirring for 5 minutes, an acetonitrile solution (30 ml) of 2-(4-biphenylyl)ethanol (5 g) was added to the reaction mixture. The reaction mixture was stirred at room 35 temperature for one hour and concentrated. Diethyl ether was added to the residue. The supernatant was collected, then dried and concentrated. The residue was purified by

silica gel column chromatography (eluent: IPE) to obtain 2-(4-biphenyl)ethyl bromide (6 g). 2-(4-Biphenyl)ethyl bromide (6 g) was dissolved in methanol (100 ml), which was stirred at 70°C for 48 hours together with potassium thiocyanate (4.0 g). The reaction mixture was concentrated, and the residue was extracted with ethyl acetate. The organic layer was washed with water, then dried and concentrated. The residue was recrystallized from ethyl acetate-hexane to obtain the entitled compound (4.1 g).

m.p. 91-92°C.

Reference Example 66

Ethyl 3,4-dihydro-3-oxo-2-quinoxalinecarboxylate

Diethyl ketomalonate (8 g) was added to an ethanol (100 ml) solution of 1,2-phenylenediamine (5 g). The reaction mixture was stirred at 50°C for 14 hours. The precipitated crystals were filtrated, which was washed with IPE to obtain the entitled compound (8.2 g).

m.p. 169-170°C.

Reference Example 67

Ethyl 4-benzyl-3,4-dihydro-3-oxo-2-

quinoxalinecarboxylate

Sodium hydride (60% dispersion in oil; 0.8 g) was added to a DMF (20 ml) solution of ethyl 3,4-dihydro-3-oxo-2-quinoxalinecarboxylate (4.4 g) under ice-cooling. The reaction mixture was stirred for 10 minutes, to which was added benzyl bromide (2.4 g). The reaction mixture was stirred at room temperature for 3 hours, poured into water, and the mixture was extracted with ethyl acetate. The organic layer was washed with water, then dried and concentrated. The residue was recrystallized from ethyl acetate-hexane to obtain the entitled compound (3.6 g).

m.p. 102-103°C.

Reference Example 68

4-Benzyl-3,4-dihydro-3-oxo-2-quinoxalinecarboxylic acid.

Water (15 ml) and sodium hydroxide (1.3 g) were added to a methanol (30 ml) solution of ethyl 4-benzyl-3,4-dihydro-3-oxo-2-quinoxalinecarboxylate (3.5 g). The reaction mixture was stirred at room temperature for 2 hours and concentrated. 2N Hydrochloric acid was added to the residue to adjust the pH to 4, which was extracted with ethyl acetate. The organic layer was washed with water, then dried and concentrated. The residue was recrystallized from ethyl acetate-hexane to obtain the entitled compound (2.9 g).

m.p. 149-150°C.

15 Reference Example 69

1-Benzyl-3-(pyrrolidin-1-ylcarbonyl)-2(1H)-quinoxaline

Pyrrolidine (0.5 ml) and triethylamine (1 ml) were added to a THF (100 ml) solution of 4-benzyl-3,4-dihydro-3-oxo-2-quinoxalinecarboxylic acid (2 g), WSC (1.4 g) and HOEt (1 g). The reaction mixture was stirred at room temperature for 18 hours and concentrated. The residue was dissolved in ethyl acetate, which was washed with water, and then concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate) to obtain the entitled compound (2.2 g).

m.p. 136-137°C.

Reference Example 70

1-Benzyl-3-(pyrrolidin-1-ylcarbonyl)-3,4-dihydro-2(1H)-quinoxaline

Triethyl silane (4 ml) was added to a trifluoroacetic acid (30 ml) solution of 1-benzyl-3-(pyrrolidin-1-ylcarbonyl)-2(1H)-quinoxaline (2 g). The reaction mixture was stirred at room temperature for 4 hours and concentrated. The residue was recrystallized from ethyl acetate to obtain the entitled compound (1.5 g).

m.p. 162-163°C.

Reference Example 71

4-Benzyl-N,N-dimethyl-3,4-dihydro-3-oxo-2-
5 quinoxalinecarboxamide

Dimethylamine hydrochloride (0.57 g), WSC (1.33 g) and
HOBt (0.86 g) were added to a mixed solution of 4-
benzyl-3,4-dihydro-3-oxo-2-quinoxalinecarboxylic acid
(1.5 g) in THF (30 ml) and acetonitrile (30 ml), to which
10 was added dropwise triethylamine (2.3 ml) under ice-cooling.
The reaction mixture was stirred at room temperature for
15 hours. The precipitated insoluble substances were
removed by filtration and the filtrate was concentrated.
Water was added to the precipitate, which was extracted
15 with ethyl acetate. The ethyl acetate layer was washed with
1N hydrochloric acid, water, a saturated aqueous sodium
hydrogen carbonate solution, and a saturated aqueous sodium
chloride solution, then dried and concentrated. The
residue was recrystallized from ethyl acetate-hexane to
20 obtain the entitled compound (1.47 g).

m.p. 154-155°C.

Reference Example 72

4-Benzyl-1,2,3,4-tetrahydro-N,N-dimethyl-3-oxo-2-
25 quinoxalinecarboxamide

4-Benzyl-N,N-dimethyl-3,4-dihydro-3-oxo-2-
quinoxalinecarboxamide (1.47 g) was added and dissolved in
ice-cooled trifluoroacetic acid (45 ml), to which was
further added triethyl silane (4.6 ml). The reaction
30 mixture was stirred at room temperature for 3 hours, then
concentrated. The residue was dissolved in ethyl acetate
and washed with 10% aqueous potassium carbonate solution,
water and a saturated aqueous sodium chloride solution,
then dried and concentrated. The obtained crystals were
35 washed with IPE to obtain the entitled compound (1.33 g).

m.p. 152-154°C.

Reference Example 73

3-(N,N-Dimethylamino)methyl-1-methylsulfonyl-
1,2,3,4-tetrahydroquinoline

Methanesulfonyl chloride (0.6 g) was added to a THF
5 (20 ml) solution of 3-(N,N-dimethylamino)methyl-
1,2,3,4-tetrahydroquinoline (Reference Example 44; 1 g)
under ice-cooling. The reaction mixture was stirred at
room temperature for 10 minutes, to which was added
triethylamine (2 ml), and the mixture was further stirred
10 at room temperature for 3 hours. The reaction mixture was
diluted with a saturated aqueous potassium bicarbonate
solution and extracted with ethyl acetate. The organic
layer was washed with water, then dried and concentrated.
The residue was purified by alumina column chromatography
15 (eluent: ethyl acetate) and recrystallized from IPE to
obtain the entitled compound (1 g).

m.p. 69-70°C.

Reference Example 74

1-(Methylsulfonyl)-3-(pyrrolidin-1-yl)methyl-
1,2,3,4-tetrahydroquinoline

Methanesulfonyl chloride (0.65 ml) was added dropwise
to an acetonitrile (20 ml) solution of 3-(pyrrolidin-1-
yl)methyl-1,2,3,4-tetrahydroquinoline (Reference Example
25 47; 1.5 g) and triethylamine (2.9 ml) under ice-cooling.
The reaction mixture was stirred at the same temperature
for one hour, to which was added water and the mixture was
extracted with ethyl acetate. The ethyl acetate layer was
washed with a saturated aqueous sodium chloride solution,
30 then dried and concentrated. The residue was purified by
alumina column chromatography (eluent: hexane to
hexane/ethyl acetate = 7/1). The crystals were washed with
IPE to obtain the entitled compound (1.20 g).

m.p. 72-73°C.

35

Reference Example 75

2-(N,N-Dimethylamino)methyl-1-ethyl-1,2,3,4-

tetrahydroquinoxaline trihydrochloride

Borane-dimethylsulfide complex (10M THF solution; 4 ml) was added to a THF (10 ml) solution of 4-benzyl-1,2,3,4-tetrahydro-N,N-dimethyl-3-oxo-2-
5 quinoxalinecarboxamide (2 g) at room temperature. The reaction mixture was stirred at room temperature for 18 hours, then concentrated. Methanol was added to the residue. 6N Hydrochloric acid (10 ml) was added to the reaction mixture, which was stirred at 60°C for 6 hours.
10 The reaction mixture was concentrated, and the residue was neutralized with 2N aqueous sodium hydroxide solution, which was extracted with ethyl acetate. The organic layer was washed with water, dried, then concentrated. The residue was dissolved in pyridine (6 ml) and acetic acid
15 anhydride (1 ml), which was left standing at room temperature for 18 hours, then concentrated. The residue was azeotropically co-distilled twice with toluene and then dissolved in THF (10 ml). Borane-dimethylsulfide complex (10M THF solution; 4 ml) was added to the reaction mixture,
20 which was stirred at room temperature for 18 hours and concentrated. Methanol was added to the residue. 6N Hydrochloric acid (10 ml) was added to the reaction mixture, which was stirred at 60°C for 6 hours. The reaction mixture was concentrated. The residue was neutralized with 2N aqueous sodium hydroxide solution and extracted with ethyl acetate.
25 The residue was dissolved in ethanol, and converted into its hydrochloride by the addition of an excess amount of 4N hydrochloric acid-ethyl acetate, and concentrated. The residue was recrystallized from ethanol-ether to obtain the entitled compound (0.3 g).

m.p. 130-135°C.

Reference Example 76

Diethyl 2-(5-methoxy-2-nitrobenzylidene)malonate

35 The entitled compound was synthesized by the similar manner as in Reference Example 55.

¹H-NMR (CDCl₃) δ: 1.09(3H, t), 1.36(3H, t), 3.88(3H,

s), 4.11(2H, q), 4.35(2H, q), 6.88(1H, d), 6.98(1H, dd), 8.22(1H, s), 8.24(1H, d).

Reference Example 77

5 **Diethyl 2-(5-methoxy-2-nitrobenzyl)malonate**

The entitled compound was synthesized by the similar manner as in Reference Example 56.

10 $^1\text{H-NMR}(\text{CDCl}_3)$ δ : 1.22(6H, t), 3.54(2H, d), 3.87(3H, s), 3.89(1H, t), 4.17(4H, q), 6.80-6.92(2H, m), 8.08-8.20(1H, m).

Reference Example 78

15 **Ethyl 6-methoxy-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxylate**

20 The entitled compound was synthesized by the similar manner as in Reference Example 35.

25 m.p. 158-165°C (Solvent for recrystallization: ethyl acetate/hexane).

20 **Reference Example 79**

25 **6-Methoxy-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxylic acid**

30 The entitled compound was synthesized by the similar manner as in Reference Example 36.

35 m.p. 141-142°C (Decomposed) (Solvent for washing: IPE).

Reference Example 80

30 **N,N-Dimethyl-6-methoxy-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxamide**

35 The entitled compound was synthesized by the similar manner as in Reference Example 30.

40 m.p. 248-250°C (Solvent for washing: ethanol/IPE).

35 **Reference Example 81**

40 **N,N-Dibenzyl-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxamide**

The entitled compound was synthesized by the similar manner as in Reference Example 30.

m.p. 207-208°C (Solvent for recrystallization: IPE).

5 Reference Example 82

3-(R,S)-(N,N-Dibenzylamino)methyl-1,2,3,4-tetrahydroquinoline

The entitled compound was synthesized by the similar manner as in Reference Example 32.

10 $^1\text{H-NMR}(\text{CDCl}_3)$ δ: 2.13-2.43(4H, m), 2.89-2.74(2H, m), 3.36-3.48(1H, m), 3.46(2H, d), 3.67(2H, d), 6.34-6.43(1H, m), 6.57(1H, ddd), 6.86-7.00(2H, m), 7.25-7.43(10, m).

Reference Example 83

15 3-(N,N-Dibenzylamino)methyl-6-methoxy-1,2,3,4-tetrahydroquinoline

The entitled compound was synthesized by the similar manner as in Reference Example 32.

20 $^1\text{H-NMR}(\text{CDCl}_3)$ δ: 2.02-2.56(4H, m), 2.24(6H, s), 2.76-3.02(2H, m), 3.30-3.42(1H, m), 3.72(3H, s), 6.42-6.50(1H, m), 6.54-6.66(2H, m).

Reference Example 84

25 Diethyl 2[(5-chloro-2-nitrophenyl)methylidene]malonate

Potassium hydrogen carbonate (8.12 g) was added to an acetic acid anhydride (18 ml) solution of 5-chloro-2-nitrobenzaldehyde (9.99 g) and diethyl malonate (8.64 g), which was stirred at 110°C for 2 hours. The reaction mixture was added to iced-water and extracted with ethyl acetate. The organic layer was washed with water and a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate/hexane=1/10) to obtain the entitled compound (15.10 g).

$^1\text{H-NMR}$ δ: 1.10(3H, t), 1.36(3H, t), 4.15(2H, q),

4.44(2H, q), 7.42(1H, d), 7.52(1H, dd), 8.11(1H, s),
8.18(1H, d).

Reference Example 85

5 Ethyl 6-chloro-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxylate

Sodium borohydride (1.92 g) was added to an ethanol (100 ml) solution of diethyl 2[(5-chloro-2-nitrophenyl)methylidene]malonate (15.10 g) at 0°C. The reaction mixture was stirred at 0°C for 20 minutes, to which was added water, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. Iron (9.90 g) was added to an acetic acid (150 ml) solution of the residue, which was heated under reflux for 30 minutes. The insoluble substances were removed by filtration, and the filtrate was concentrated. Water was added to the residue, which was extracted with ethyl acetate. The organic layer was washed with water and a saturated aqueous sodium chloride solution, then dried and concentrated. The obtained crude crystals were washed with IPE to give the entitled compound (7.278 g).

m.p. 173-175°C.

25 Reference Example 86

6-Chloro-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxylic acid

1N Aqueous sodium hydroxide solution (30 ml) was added dropwise to a mixed solution of ethyl 6-chloro-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxylate (7.278 g) in THF (90 ml) and methanol (60 ml) at 0°C. The reaction mixture was stirred at room temperature for 18 hours. 1N Hydrochloric acid (30 ml) was added dropwise to the reaction mixture at 0°C, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The obtained crude crystals were washed with diethyl ether to

obtain the entitled compound (6.06 g).

m.p. 134-137°C (Decomposed).

Reference Example 87

5 6-Chloro-N,N-dimethyl-2-oxo-1,2,3,4-tetrahydro-3-
quinolinecarboxamide

10 6-Chloro-2-oxo-1,2,3,4-tetrahydro-3-
quinolinecarboxylic acid (3.00 g), dimethylamine
hydrochloride (1.332 g), HOBT (2.042 g), WSC (3.093 g) and
triethylamine (4.5 ml) were added to acetonitrile (150 ml).
The reaction mixture was stirred at room temperature for
18 hours. 10% Aqueous citric acid solution was added to
the reaction mixture. The precipitated pellets were
collected by filtration and washed with water and IPE to
15 obtain the entitled compound (1.276 g).

m.p. 302-305°C.

Reference Example 88

20 6-Chloro-3-(N,N-dimethylamino)methyl-1,2,3,4-
tetrahydroquinoline

1M Borane/THF complex (33 ml) was added to a THF (300 ml) suspension of 6-chloro-N,N-dimethyl-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxamide (2.135 g). The reaction mixture was heated under reflux for 6 hours, and left standing for cooling. The reaction mixture was ice-cooled, to which was added water (5 ml) and 6N hydrochloric acid (30 ml). The mixture was stirred at room temperature for 15 hours, then concentrated. 3N aqueous sodium hydroxide solution was added to the residue to make basic, which was extracted with ethyl acetate. The organic layer was washed with water and a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by alumina column chromatography (eluent: ethyl acetate/hexane=1/4). The obtained crude crystals were washed with hexane to obtain the entitled compound (1.432 g).

m.p. 94-96°C.

Reference Example 89.

Diethyl 2-[(4-chloro-2-nitrophenyl)methylidene]malonate

5 Potassium hydrogencarbonate (16.57 g) was added to an acetic acid anhydride (36 ml) solution of 4-chloro-2-nitrobenzaldehyde (20.35 g) and diethylmalonate (17.60 g), which was stirred at 110°C for 4 hours. The reaction mixture was added to iced-water, which was extracted with 10 ethyl acetate. The organic layer was washed with water and a saturated aqueous sodium chloride solution, and then dried and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate/hexane=1/4) to obtain the entitled compound (34.92 g).

¹H-NMR δ: 1.10(3H, t), 1.36(3H, t), 4.12(2H, q), 4.35(2H, q), 7.40(1H, d), 7.62(1H, dd), 8.09(1H, s), 8.21(1H, d).

20 Reference Example 90

Ethyl 7-chloro-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxylate

25 Sodium borohydride (2.082 g) was added to an ethanol (200 ml) solution of diethyl 2-[(4-chloro-2-nitrophenyl)methylidene]malonate (34.92 g). The reaction mixture was stirred at 0°C for one hour, to which was added water, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. Iron (26.70 g) was added to an aqueous acetic acid (300 ml) solution of the residue, which was heated under reflux. The reaction mixture was left standing for cooling, and ethyl acetate (300 ml) was added to the reaction mixture. The precipitated insoluble substances were removed by 30 filtration and the filtrate was concentrated. The organic layer was washed with water and a saturated aqueous sodium chloride solution and then dried and concentrated. The

obtained crude crystals were washed with IPE to give the entitled compound (14.50 g).

m.p. 183-185°C.

5 Reference Example 91

7-Chloro-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxylic acid

1N Aqueous sodium hydroxide solution (60 ml) was added dropwise to a mixed solution of ethyl 7-chloro-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxylate (14.39 g) in THF (180 ml) and methanol (120 ml) at 0°C. The reaction mixture was stirred at room temperature for 24 hours. 1N Hydrochloric acid (70 ml) was added dropwise to the reaction mixture at 0°C, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The obtained crude crystals were washed with IPE to obtain the entitled compound (12.15 g).

m.p. 187-189°C.

20

Reference Example 92

7-Chloro-N,N-dimethyl-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxamide

7-Chloro-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxylic acid (11.282 g), dimethylamine hydrochloride (4.936 g), HOBr (7.694 g), WSC (10.63 g), and triethylamine (17 ml) were added to a mixed solution of acetonitrile (100 ml) and THF (100 ml). The reaction mixture was stirred at room temperature for 18 hours. Water was added to the reaction mixture. The precipitated pellets were collected by filtration, washed with water, and diethyl ether to obtain the entitled compound (9.529 g).

m.p. 281-283°C.

35

Reference Example 93

7-Chloro-3-(N,N-dimethylamino)methyl-1,2,3,4-

tetrahydroquinoline

1M Borane/THF complex (80 ml) was added to a THF (180 ml) suspension of 7-chloro-N,N-dimethyl-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxamide (5.055 g). The 5 reaction mixture was heated under reflux and left standing for cooling. The reaction mixture was ice-cooled, to which was added water (5 ml) and 6N hydrochloric acid (50 ml). The mixture was stirred at room temperature for one hour, then concentrated. A methanol solution (100 ml) of the 10 residue was heated under reflux for 75 minutes and then concentrated. 3N Aqueous sodium hydroxide solution was added to the residue to make basic, which was extracted with ethyl acetate. The residue was purified by alumina column chromatography (eluent: ethyl acetate/hexane=1/4). The 15 obtained crude crystals were washed with hexane to give the entitled compound (3.991 g).

m.p. 107-110°C.

Reference Example 94.

20 (S)-(+)-3-(N,N-Dimethylamino)methyl-1,2,3,4-tetrahydroquinoline

3-(N,N-Dimethylamino)methyl-1,2,3,4-tetrahydroquinoline (4.2 g) and (-)-4-(2,4-dichlorophenyl)-5,5-dimethyl-2-hydroxy-1,3,2-dioxaphospholinane 2-oxide ((-)-2,4-Cl₂-CPA; 6.87 g) were 25 dissolved in THF (80 ml) and ethanol (16 ml), which was stirred at room temperature overnight. The precipitated white crystals were filtrated and dried to obtain (-)-2,4-Cl₂-CPA salt (3.92 g) of (+)-3-(N,N-30 dimethylamino)methyl-1,2,3,4-tetrahydroquinoline.

According to the results of HPLC analysis, the optical purity was 94% de. In the same manner, substantially the same operation using 1.0 g (5.3 mmol) of 3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline was 35 conducted to obtain a salt of 92% de (0.91 g).

The above salt (4.83 g) was recrystallized from isopropylalcohol (60 ml) and ethanol (45 ml) to obtain a

salt of 98% de (4.11 g). This salt was stirred in water (35 ml) and 4N sodium hydroxide solution (4.5 ml) at room temperature for 6 hours, which was filtrated, washed with water, and dried to obtain the entitled compound (1.41 g).

5 The absolute structure was determined by X ray crystal analysis of the above salt.

Optical purity: 99%ee.

m.p. 114°C.

10 Specific rotary power: $[\alpha]_D^{26} = +60.19^\circ$ ($c=0.5$; methanol).

Reference Example 95

(R)-(-)-3-(N,N-Dimethylamino)methyl-1,2,3,4-tetrahydroquinoline

15 3-(N,N-Dimethylamino)methyl-1,2,3,4-tetrahydroquinoline (10.3 g) was dissolved in THF (100 ml).

To the mixture was added a mixed solution of (+)-4-(2,4-dichlorophenyl)-5,5-dimethyl-2-hydroxy-1,3,2-dioxaphospholinane 2-oxide ((+)-2,4-Cl₂-CPA; 16.8 g) in THF (100 ml) and ethanol (40 ml), while stirring under heating at 50°C. The reaction mixture was cooled to the room temperature and then stirred for 3 days. The precipitated white crystals were filtrated and dried to obtain (+)-2,4-Cl₂-CPA salt (9.31 g) of (+)-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline.

20 According to the results of HPLC analysis, the optical purity was 92% de.

The above salt (9.31 g) was recrystallized from isopropylalcohol/ethanol (55/45) to obtain a salt of 97% de (7.25 g). The crystal was stirred in water (60 ml), 4N sodium hydroxide solution (7 ml) and ether (30 ml) at room temperature for one hour. The ether layer was combined and the aqueous layer was extracted with 30 ml of ethyl acetate.

35 The organic layers were combined, which was washed with water, then dried and concentrated. The residue was washed with hexane to obtain 2.3 g of white needle crystals.

Optical purity: >99% ee.

m.p. 113-114°C.

Specific rotary power: $[\alpha]_D^{27.4} = -61.2^\circ$ (c=0.5; methanol).

5 Reference Example 96

3-(N-Benzylloxycarbonylamino)methyl-1,2,3,4-tetrahydroquinoline

10 10% Palladium-carbon (150 mg) and concentrated hydrochloric acid (2 ml) were added to a methanol (30 ml) solution of 3-(R,S)-(N,N-dibenzylamino)methyl-1,2,3,4-tetrahydroquinoline (1.5 g), and catalytic hydrogenation was conducted at room temperature under a hydrogen pressure of 4 atmospheric pressure for 2 hours. The catalyst was removed by filtration and the filtrate was concentrated.

15 10% aqueous potassium carbonate solution was added to the residue, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. To a methanol (15 ml) solution of the residue was added 10% palladium-carbon (150 mg), and then an aqueous solution (3 ml) of ammonium formate (300 mg), which was heated under reflux for 2 hours. The catalyst was removed by filtration and the residue was concentrated. The residue was dissolved in THF, then dried, and concentrated.

20 Triethylamine (0.9 ml) was added to a THF (14 ml) solution of the residue, to which was added dropwise benzyl chloroformate (0.5 ml) under ice-cooling. The reaction mixture was stirred at the same temperature for one hour.

25 Water was added to the reaction mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with a saturated aqueous sodium chloride solution, then dried, and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate).

30 The precipitated crystals were washed with hexane to obtain the entitled compound (825 mg).

m.p. 115-116°C.

Reference Example 97

1-[3(4-Biphenylyl)methyl-3-(N-
5 benzyloxycarbonylamino)methyl-1,2,3,4-
tetrahydroquinoline

Oxalyl chloride (0.088 ml) was added dropwise to a THF (3 ml) solution of 3-(4-biphenylyl)propionic acid (183 mg) under ice-cooling. The reaction mixture was stirred at room temperature for one hour and then concentrated. The residue was dissolved in THF (2 ml), which was added dropwise to a THF (3 ml) solution of 3-(N-benzyloxycarbonylamino)methyl-1,2,3,4-tetrahydroquinoline (200 mg) and triethylamine (0.14 ml) under ice-cooling. The reaction mixture was stirred at the same temperature for one hour. Water was added to the mixture, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate/hexane=1/1) to obtain the entitled compound (310 mg).

¹H-NMR(CDCl₃) δ: 2.11-2.35(2H, m), 2.69-3.07(6H, m), 3.09-3.29(1H, m), 3.49-3.65(1H, m), 3.78-3.88(1H, Br), 5.05-5.22(1H, m), 5.09(2H, s), 7.00-7.60(18H, m).

Reference example 98

Diethyl 2-(2,4-dinitrobenzylidene)malonate
The mixture of 2,4-dinitrobenzaldehyde (25 g), diethylmalonate (20.3 g), potassium hydrogencarbonate (19.1 g), and acetic anhydride (50 ml) was stirred at 110°C under nitrogen atmosphere for one hour. The reaction mixture was cooled, diluted with water, and extracted with ethyl acetate. The organic layer was washed with water and a saturated aqueous sodium chloride solution and then dried and concentrated. The residue was purified by alumina column chromatography (eluent: hexane /ethyl acetate =4:

1) to obtain the entitled compound (24 g).

$^1\text{H-NMR}$ (CDCl_3) δ : 1.11(3H, t), 1.37(3H, t), 4.12(2H, q), 4.37(2H, q), 7.67(1H, d), 8.15(1H, s), 8.49(1H, dd), 9.05(1H, d).

5

Reference Example 99

Diethyl 2-(2,4-dinitrobenzyl) malonate

To a ethanol (460 ml) solution of diethyl 2-(2,4-dinitrobenzylidene)malonate (23 g) was added sodium borohydride (1.65 g) while the temperature was kept under -10°C and the mixture was stirred under ice-cooling for 30 minutes. The reaction mixture was made acidic by adding 10% aqueous solution and concentrated. The residue was diluted with 1N hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried and concentrated.

The residue was purified by alumina column chromatography (eluent: hexane / ethyl acetate =4: 1), to obtain the entitled compound (13.9 g).

$^1\text{H-NMR}$ (CDCl_3) δ : 1.24(6H, t), 3.61(2H, d), 3.86(1H, dd), 4.04-4.36(4H, q), 7.70(1H, d), 8.38(1H, dd), 8.86(1H, d).

Reference Example 100

Ethyl 7-amino-2-oxo-1,2,3,4-tetrahydro-3-

quinolinecarboxylate

To a mixed solution diethyl 2-(2,4-dinitrobenzyl) malonate (13 g) in a mixed solution of ethanol (130 ml) and THF (130 ml) was added 10% palladium-Carbon (700 mg). The reaction mixture was stirred under 4 to 5 atmospheric pressure of hydrogen at room temperature for 4 hours. The catalyst was removed by filtration and the filtrate was concentrated. The residue was diluted with ethanol (130 ml), and the mixture was heated under reflux for 12 hours and concentrated. The precipitated crystals were washed with IPE to obtain the entitled compound (7.4 g). The compound recrystallized from ethanol / IPE showed the

following m.p.

m.p.: 182-184°C.

Reference example 101

5 Ethyl 7-benzyloxycarbonylamino-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxylate

To a suspension of ethyl 7-amino-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxylate (2.0 g) in THF(40 ml) was added aqueous sodium carbonate (4.5 g in 40 ml) and 10 cooled, to which benzylchloroformate (1.8ml) was added dropwise. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried, and concentrated. The precipitated crystals were washed 15 with hexane to obtain the entitled compound (3.07 g).

m.p.: 187-189°C.

Reference example 102

20 7-Benzylloxycarbonylamino-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxylic acid

To a solution of ethyl 7-benzyloxycarbonylamino-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxylate (7.8 g) in a mixed solvent of THF (80 ml) and methanol (80 ml) was added 1N aqueous sodium hydroxide (32 ml) under 10°C. The reaction 25 mixture was stirred at room temperature for 4 hours, to which was added 1N hydrochloric acid (35 ml) under 10°C.

The reaction mixture was diluted with a saturated aqueous sodium chloride solution and extracted with ethyl acetate.

The organic layer was washed with a saturated aqueous 30 sodium chloride solution, dried, and concentrated to obtain the entitled compound (7.20 g).

¹H-NMR(CDCl₃) δ: 2.88-3.20(2H, m), 3.34-3.52(1H, m), 5.07(2H, s), 6.78-7.60(9H, m), 9.28(1H, brs).

35 Reference example 103

N,N-Dimethyl-7-benzyloxycarbonylamino-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxamide

To a solution of 7-benzyloxycarbonylamino-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxylic acid (7.0 g) in acetonitrile (80 ml) and THF (80 ml) were added dimethylamine hydrochloride (2.52 g), WSC(5.92 g), HOBT 5 (3.15 g), and triethylamine (18 ml) subsequently at room temperature. The reaction mixture was stirred at room temperature for 10 hours, diluted with water, and extracted with combined solvent of ethyl acetate and THF. The organic layer was washed with 1N hydrochloric acid, water, 10 saturated aqueous sodium hydrogen carbonate, water, saturated aqueous sodium chloride subsequently, dried, and concentrated. The precipitated crystals were washed with IPE to obtain the entitled compound (5.88 g).
m.p.: 218-228°C (decomposed).

15

Reference example 104

N,N-Dimethyl-7-amino-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxamide

To a suspension of N,N-dimethyl-7-benzyloxycarbonylamino-2-oxo-1,2,3,4-tetrahydro-3-quinolinecarboxamide (820 mg) in methanol (8 ml) and THF (8 ml) was added 10% palladium-carbon (100 mg). The reaction mixture was stirred under one atmospheric pressure of hydrogen at room temperature for 4 hours. The catalyst 20 was removed by filtration and the filtrate was concentrated. The precipitated crystals were washed with combined solution of IPE and THF to obtain the entitled compound (480 mg).
m.p.: 219 to 223°C.

30

Reference example 105

7-Amino-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline

To a suspension of N,N-dimethyl-7-amino-2-oxo-35 1,2,3,4-tetrahydro-3-quinolinecarboxamide (450 mg) in THF (15 ml) was added Borane-THF complex (1M, 12 ml) under ice-cooling. The reaction mixture was heated under reflux

for one hour. The reaction mixture was diluted with water (2 ml) under ice-cooling and concentrated. The residue was dissolved in methanol (12 ml), which was heated under reflux with 6N hydrochloric acid (4 ml) for 3 hours. After 5 cooling, the reaction mixture was made basic and extracted with combined solution of THF and ethyl acetate. The organic layer was dried and concentrated. The residue was purified by alumina column chromatography (eluent: ethyl acetate to ethyl acetate / methanol =20: 1) to obtain the 10 entitled compound (380 mg).

¹H-NMR(CDCI₃) δ: 2.00-2.46(4H, m), 2.25(6H, s),
2.66-2.84(1H, m), 2.95(1H, dd), 3.20-3.60(4H, m), 5.86(1H,
d), 6.01(1H, dd), 6.75(1H, d).

15 Reference example 106


7-Acetylamino-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline

To a solution of 7-amino-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline (300 mg) in pyridine (3 ml) was added a solution of acetic anhydride (150 mg) in THF (1 ml) and stirring was continued for 30 minutes. The reaction mixture was purified by alumina column chromatography (eluent: ethyl acetate to ethyl acetate / methanol =20: 1) and the resulting crystals 25 were washed with IPE to obtain the entitled compound (275 mg).

m.p.: 118-123°C.

Example 1

30 3-(N,N-Dimethylamino)methyl-1-[3-[3-(1-naphthyl)-1,2,4-oxadiazol-5-yl]propanoyl]-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




To a THF (10 ml) solution of 3-[3-(1-naphthyl)-1,2,4-oxadiazol-5-yl]propionic acid (compound of Reference Example 14, 381.4 mg) were added dropwise DMF (2 drops) and then oxalyl chloride (0.22 ml) at 0°C. The reaction mixture was stirred at room temperature for one hour, then concentrated. The residue was dissolved in acetonitrile (10 ml), which was added dropwise to an acetonitrile (10 ml) solution of 3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline (190.3 mg) and triethylamine (0.21 ml) at 0°C. The reaction mixture was stirred at room temperature for one hour. 5% Aqueous sodium hydrogencarbonate solution was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by alumina column chromatography (eluent: hexane/ethyl acetate=3/1), which was converted into its p-toluenesulfonate. The mixture was recrystallized from THF/diethyl ether to give the entitled compound (578.3 mg).
m.p. 159-161°C.

Compounds of the following Examples 2 to 68 were synthesized by the similar manner as in Example 1 using the eluent described in the respective Example.

Example 2

3-(N,N-Dimethylamino)methyl-1-[3-(4-methoxyphenyl)propanoyl]-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




Eluent: hexane/ethyl acetate=4/1

m.p. 122-123°C (Solvent for recrystallization: ethyl acetate/diethyl ether).

5

Example 3

3-(N,N-Dimethylamino)methyl-1-(3-phenylpropanoyl)-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




10 Eluent: hexane/ethyl acetate=3/1

m.p. 180-181°C (Solvent for recrystallization: THF/diethyl ether).

Example 4

15 **3-(N,N-Dimethylamino)methyl-1-[3-(3-methoxyphenyl)propanoyl]-1,2,3,4-tetrahydroquinoline p-toluenesulfonate**




Eluent: hexane/ethyl acetate=3/1

20 m.p. 128-129°C (Solvent for recrystallization: THF/diethyl ether).

Example 5

25 **3-(N,N-Dimethylamino)methyl-1-[3-(2-methoxyphenyl)propanoyl]-1,2,3,4-tetrahydroquinoline p-**

toluenesulfonate



Eluent: hexane/ethyl acetate=3/1


m.p. 140-140.5°C (Solvent for recrystallization:

5 THF/diethyl ether)

Example 6

1-[3-(3,4-Dimethoxyphenyl)propanoyl]-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline p-

10 toluenesulfonate



Eluent: hexane/ethyl acetate=2/3


m.p. 138-139°C (Solvent for recrystallization:

THF/diethyl ether)

15

Example 7

3-(N,N-Dimethylamino)methyl-1-[3-(3,4-methylenedioxyphenyl)propanoyl]-1,2,3,4-tetrahydroquinoline p-toluenesulfonate



20


Eluent: hexane/ethyl acetate=3/1

m.p. 143-144°C (Solvent for recrystallization:

THF/diethyl ether)

Example 8

3-(N,N-Dimethylamino)methyl-1-[3-(3,4,5-trimethoxyphenyl)propanoyl]-1,2,3,4-tetrahydroquinoline hydrochloride



Eluent: hexane/ethyl acetate=1/1


Amorphous powder.

¹H-NMR δ: 2.05-2.3(4H, m), 2.20(6H, s), 2.65-3.0(5H, m), 3.22-3.33(1H, m), 3.78(6H, s), 3.81(3H, s), 3.95-4.05(1H, m), 6.33(2H, br), 7.05-7.22(4H, m).

IR(KBr): 1647, 1590, 1508, 1493, 1460, 1422, 1399, 1240, 1127, 1005, 766 cm⁻¹.

Example 9

15 3-(N,N-Dimethylamino)methyl-1-(3,3-diphenylpropanoyl)-1,2,3,4-tetrahydroquinoline oxalate




Eluent: hexane/ethyl acetate=3/1

m.p.: 81-82°C (Solvent for recrystallization:
20 THF/diethyl ether)

Example 10

3-(N,N-Dimethylamino)methyl-1-[3-(4-methylphenyl)propanoyl]-1,2,3,4-tetrahydroquinoline p-25 toluenesulfonate




Eluent: hexane/ethyl acetate=2/1

m.p. 159-160°C (Solvent for recrystallization:
THF/diethyl ether)

5

Example 11

3-(N,N-Dimethylamino)methyl-1-[3-(4-hydroxyphenyl)propanoyl]-1,2,3,4-tetrahydroquinoline hydrochloride



10

Eluent: hexane/ethyl acetate/(methanol)=3/2/(1%)
Amorphous powder.


¹H-NMRδ: 2.22(6H, s), 2.0-2.4(4H, m), 2.7-3.0(5H, m),
3.22-3.32(1H, m), 3.96-4.05(1H, m), 6.69(2H, d), 6.85-

15 7.05(6H, m).

IR(KBr): 1732, 1638, 1613, 1514, 1493, 1458, 1439,
1406, 1227, 1173, 833, 762 cm⁻¹.

Example 12

20 3-(N,N-Dimethylamino)methyl-1-[3-(2-methylphenyl)propanoyl]-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




Eluent: hexane/ethyl acetate=5/1

m.p. 188-190°C (Solvent for recrystallization:
THF/diethyl ether)

Example 13


5 1-[3-(4-Benzoylphenyl)propanoyl]-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline p-toluenesulfonate



10 Eluent: hexane/ethyl acetate=3/1
m.p. 145-150°C (Solvent for recrystallization:
THF/diethyl ether)

Example 14


15 1-[3-(4-Acetoxy-3-methoxyphenyl)propanoyl]-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline p-toluenesulfonate



Eluent: hexane/ethyl acetate=3/1, to 1/1
m.p. 200-204°C (Solvent for recrystallization:
20 THF/diethyl ether)

Example 15

25 3-(N,N-Dimethylamino)methyl-1-[(E)-3-(4-fluorophenyl)propenoyl]-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




Eluent: hexane/ethyl acetate=5/1 to 3/1

m.p. 171-172°C (Solvent for recrystallization: ethyl acetate/diethyl ether)

5

Example 16

1-[(E)-3-(4-Chlorophenyl)propenoyl]-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




10

Eluent: hexane/ethyl acetate=3/1

m.p. 165-166°C (Solvent for recrystallization: THF/diethyl ether)

15 Example 17

1-[3-[4-(4-Chlorophenoxy)phenyl]propanoyl]-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




20

Eluent: hexane/ethyl acetate=3/1

m.p. 167-168°C (Solvent for recrystallization: THF/diethyl ether)

Example 18


3-(N,N-Dimethylamino)methyl-1-[(E)-3-(3,4-methylenedioxyphenyl)propenoyl]-1,2,3,4-tetrahydroquinoline oxalate



5 Eluent: hexane/ethyl acetate=3/1
 m.p. 94-96°C (Solvent for recrystallization:
 THF/diethyl ether)

Example 19


10 3-(N,N-Dimethylamino)methyl-1-[3-(4-methyl-5-phenyloxazol-2-yl)propanoyl]-1,2,3,4-tetrahydroquinoline oxalate



15 Eluent: hexane/ethyl acetate=3/1 to 2/1
 m.p. 129-130°C (Solvent for recrystallization: ethyl acetate/diethyl ether)

Example 20


20 3-(N,N-Dimethylamino)methyl-1-(4-phenylbutanoyl)-1,2,3,4-tetrahydroquinoline oxalate



Eluent: hexane/ethyl acetate=3/1
 m.p. 60-62°C (Solvent for recrystallization:
 THF/diethyl ether)

Example 21

1-[3-[3-(6-Methoxy-2-benzofuranyl)-1,2,4-oxadiazol-5-yl]propanoyl]-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




5

Eluent: hexane/ethyl acetate=1/1
m.p. 108-109°C (Solvent for recrystallization:
ethanol/ethyl acetate)

10 Example 22

3-(N,N-Dimethylamino)methyl-1-[3-[4-(4-fluorophenyl)-2-methyloxazol-5-yl]propanoyl]-1,2,3,4-tetrahydroquinoline oxalate




15

Eluent: hexane/ethyl acetate=3/1 to 2/1
m.p. 120-122°C (Solvent for recrystallization:
THF/diethyl ether)

Example 23

20 1-[3-(4-Biphenylyl)propenoyl]-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




Eluent: hexane/ethyl acetate=1/1
 m.p. 180-182°C (Solvent for recrystallization:
 ethanol/ethyl acetate)

5

Example 24

3-(N,N-Dimethylamino)methyl-1-[3-[3-(phenoxy methyl)-1,2,4-oxadiazol-5-yl]propanoyl]-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




10

Eluent: hexane/ethyl acetate=2/1
 m.p. 146-147°C (Solvent for recrystallization:
 THF/diethyl ether)

15

Example 25

3-(N,N-Dimethylamino)methyl-1-[3-[3-[*(E*)-2-(4-methylphenyl)ethenyl]propanoyl]-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




20

Eluent: hexane/ethyl acetate=4/1 to 3/1
 m.p. 126-128°C (Solvent for recrystallization:
 THF/diethyl ether)

Example 26

5 1-[3-[3-(2-Benzofuranyl)-1,2,4-oxadiazol-5-yl]propanoyl]-3-(N,N-dimethylamino)methyl]-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




Eluent: hexane/ethyl acetate=4/1 to 3/1

m.p. 108-110°C (Solvent for recrystallization:
THF/diethyl ether)

10

Example 27

15 3-(N,N-Dimethylamino)methyl-1-[3-(E)-[4-(4-methoxyphenoxy)phenyl]propenoyl]-1,2,3,4-tetrahydroquinoline oxalate




Eluent: hexane/ethyl acetate=3/1 to 2/1

m.p. 140-143°C (Solvent for recrystallization:
THF/diethyl ether)

20 **Example 28**


3-(N,N-Dimethylamino)methyl-1-[3-(1-methylindol-3-yl)propanoyl]-1,2,3,4-tetrahydroquinoline oxalate



Eluent: hexane/ethyl acetate=3/1 to 2/1
 m.p. 128-129°C (Solvent for recrystallization:
 THF/ethyl acetate)

5 Example 29


1-[3-(4-Biphenylyl)propanoyl]-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline p-toluenesulfonate



10 Eluent: hexane/ethyl acetate=5/1 to 4/1
 m.p. 111-112°C (Solvent for recrystallization:
 THF/diethyl ether)

Example 30


15 3-(N,N-Dimethylamino)methyl-1-[3-(2-methylindol-3-yl)propanoyl]-1,2,3,4-tetrahydroquinoline oxalate



Eluent: hexane/ethyl acetate=3/1 to 2/1
 m.p. 90-94°C (Solvent for recrystallization:
 20 methanol/diethyl ether)

Example 31

25 3-(N,N-Dimethylamino)methyl-1-[3-(2-ethoxycarbonyl-5-methoxyindol-3-yl)propanoyl]-1,2,3,4-tetrahydroquinoline oxalate




Eluent: hexane/ethyl acetate=2/1

m.p. 154-158°C (Solvent for recrystallization:
acetonitrile/THF/diethyl ether)

5

Example 32

1-[3-[(2-Benzoxazolyl)-1,2,4-oxadiazol-5-yl]propanoyl]-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




10

Eluent: hexane/ethyl acetate=4/1 to 3/1

m.p. 109-111°C (Solvent for recrystallization:
ethanol/THF/diethyl ether)

15 Example 33

3-(N,N-Dimethylamino)methyl-1-[3-(E)-(3-quinolynyl)propenoyl]-1,2,3,4-tetrahydroquinoline dioxalate



20 Eluent: hexane/ethyl acetate=4/1 to 3/1


Amorphous powder

IR(KBr): 1719, 1701, 1597, 1493, 1400, 1203, 1111, 966,
764, 721, 588cm⁻¹.

Example 34

3-(N,N-Dimethylamino)methyl-1-[3-(3-quinolynyl)propanoyl]-1,2,3,4-tetrahydroquinoline

5 dioxalate




Eluent: hexane/ethyl acetate=4/1 to 3/1

m.p. 100-101°C (Solvent for recrystallization:
methanol/THF/diethyl ether)

10

Example 35

3-(N,N-Dimethylamino)methyl-1-[3-[1-(4-methylsulfonyl)indol-3-yl]propanoyl]-1,2,3,4-tetrahydroquinoline oxalate



15 Eluent: hexane/ethyl acetate=4/1 to 2/1


Amorphous powder

IR(KBr): 1719, 1649, 1493, 1449, 1402, 1364, 1279,
1173, 1121, 1098, 974, 814, 762, 747, 721, 669, 596, 578,
20 538 cm⁻¹.

Example 36

3-(N,N-Dimethylamino)methyl-1-[3-[3-(3-indolyl)-1,2,4-oxadiazol-5-yl]propanoyl]-1,2,3,4-tetrahydroquinoline


25



Eluent: hexane/ethyl acetate=1/1 to ethyl acetate/methanol=10/1
 m.p. 156-157°C (Solvent for recrystallization: ethyl acetate/diethyl ether).

Example 37

3-(N,N-Dimethylamino)methyl-1-[3-[3-(4-methoxyphenyl)methyl-1,2,4-oxadiazol-5-yl]propanoyl]-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




Eluent: hexane/ethyl acetate=2/1 to 1/1.
 m.p. 143-144°C (Solvent for recrystallization: THF/diethyl ether)

15

Example 38

3-(N,N-Dimethylamino)methyl-1-[3-(4-phenylthiazol-2-yl)propanoyl]-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




20

Eluent: hexane/ethyl acetate=5/1 to 3/1
 m.p. 153-155°C (Solvent for recrystallization: THF/diethyl ether).

Example 39

1-[3-[4-(2-Benzofuranyl)thiazol-2-yl]propanoyl]-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline

5 p-toluenesulfonate


Eluent: hexane/ethyl acetate=5/1 to 4/1

m.p. 149-151°C (Solvent for recrystallization:
THF/diethyl ether)

10

Example 40

1-(4-Biphenylyloxy)acetyl-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




15

Eluent: hexane/ethyl acetate=3/1
m.p. 151-152°C (Solvent for recrystallization:
ethanol/diethyl ether)

20 **Example 41**

3-(N,N-Dimethylamino)methyl-1-[3-[3-(2-naphthyl)-1,2,4-oxadiazol-5-yl]propanoyl]-1,2,3,4-tetrahydroquinoline

150




Eluent: hexane/ethyl acetate=3/1

m.p. 94-95°C (Solvent for recrystallization: diethyl ether).

5

Example 42

3-(N,N-Dimethylamino)methyl-1-[(E)-3-(3-pyridyl)propenoyl]-1,2,3,4-tetrahydroquinoline dioxalate




10

Eluent: hexane/ethyl acetate=1/1

m.p. 155-157°C (Solvent for recrystallization: methanol/ethyl acetate/diethyl ether).

15 Example 43

3-(N,N-Dimethylamino)methyl-1-[3-[N-(3-methoxyphenyl)-N-[(4-methylphenyl)sulfonyl]aminolpropanoyl]-1,2,3,4-tetrahydroquinoline hydrochloride



20

Eluent: hexane/ethyl acetate=3/1 to 1/1


Amorphous powder

IR(KBr): 1649, 1601, 1491, 1402, 1343, 1159, 1092,

1038, 947, 814, 766, 693, 656, 575, 548 cm⁻¹.

Example 44

5 1-[3-[1-(2,4-Dichlorophenyl)methylindol-3-yl]propanoyl]-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline hydrochloride




Eluent: hexane/ethyl acetate=4/1 to 3/1

Amorphous powder

10 IR(KBr): 1647, 1584, 1491, 1466, 1387, 1196, 1181, 1100, 1049, 1013, 959, 833, 743 cm⁻¹.

Example 45

15 1-[4-[3-(2-Benzofuranyl)-1,2,4-oxadiazol-5-yl]butanoyl]-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




Eluent: hexane/ethyl acetate=3/1

20 m.p. 131-132°C (Solvent for recrystallization: diethyl ether).

Example 46

3-(N,N-Dimethylamino)methyl-1-[3-(3-indolyl)propanoyl]-1,2,3,4-tetrahydroquinoline
25 hydrochloride




Eluent: hexane/ethyl acetate=4/1 to 2/1

Amorphous powder

¹H-NMR δ: 1.94-2.32(3H, m), 2.19(6H, s), 2.60-3.34(7H,
5 m), 3.90-4.07(1H, m), 6.92-7.21(7H, m), 7.33(1H, d),
7.42-7.53(1H, m), 7.99(1H, br).

Example 47

10 3-(N,N-Dimethylamino)methyl-1-[4-(3-indolyl)butanoyl]-1,2,3,4-tetrahydroquinoline hydrochloride




Eluent: hexane/ethyl acetate=4/1 to 2/1

Amorphous powder

15 IR(KBr): 3241, 2938, 2676, 1647, 1491, 1458, 1397, 747
cm⁻¹.

Example 48

20 1-(6-Cyano-6,6-diphenylhexanoyl)-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline oxalate




Eluent: hexane/ethyl acetate=4/1

Amorphous powder

IR(KBr): 3036, 2938, 2868, 1655, 1491, 1395, 1192,
5 1179, 758, 700 cm^{-1} .

Example 49

4-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)propanoyl]-8-methoxy-2,3,4,5-tetrahydro-1H-1-benzazepine




Eluent: hexane/ethyl acetate=3/1 to 1/1

m.p. 167-168°C (Solvent for recrystallization: ethyl acetate/diethyl ether).

15

Example 50

4-(N,N-Dimethylamino)methyl-8-methoxy-1-[3-[3-(phenoxy methyl)-1,2,4-oxadiazol-5-yl]propanoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine



20


Eluent: hexane/ethyl acetate=3/1 to 1/1

Oily substance

IR(KBr): 1655, 1611, 1599, 1580, 1443, 1406, 1360,
1346, 1292, 1230, 1217, 1163, 1038, 858, 845, 826, 756, 693
cm⁻¹.

Example 51

1-[3-[3-(2-Benzofuranyl)-1,2,4-oxadiazol-5-yl]propanoyl]-4-(N,N-dimethylamino)methyl-8-methoxy-
10 2,3,4,5-tetrahydro-1H-1-benzazepine p-toluenesulfonate




Eluent: hexane/ethyl acetate=3/1 to 1/1

m.p. 182-184°C (Solvent for recrystallization:
ethanol/THF/diethyl ether).

15

Example 52

1-[3-[3-(2-Benzofuranyl)-1,2,4-oxadiazol-5-yl]propanoyl]-3-(N,N-diethylamino)methyl-1,2,3,4-tetrahydroquinoline



20

Eluent: hexane/ethyl acetate=5/1 to 4/1


Oily substance

¹H-NMR δ: 0.97(6H, t), 2.1-2.6(8H, m), 2.92(1H, dd),
3.0-3.5(5H, m), 3.95-4.15(1H, m), 7.05-7.5(7H, m), 7.61(1H,
d), 7.67(1H, d).

Example 53

1-[3-(4-Biphenylyl)propanoyl]-3-(N,N-

diethylamino)methyl-1,2,3,4-tetrahydroquinoline




Eluent: hexane/ethyl acetate=6/1

Oily substance

5 ¹H-NMR δ: 0.97(6H, t), 2.1-2.6(8H, m), 2.47(4H, q),
2.92(1H, dd), 3.0-3.5(5H, m), 3.95-4.15(1H, m), 7.05-
7.5(7H, m), 7.61(1H, d), 7.67(1H, d).

Example 54

10 1-[3-[3-(2-Benzofuranyl)-1,2,4-oxadiazol-5-
y1]propanoyl]-3-(4-phenylpiperazin-1-yl)methyl-1,2,3,4-
tetrahydroquinoline di-p-toluenesulfonate




Eluent: hexane/ethyl acetate=5/1 to 4/1

15 m.p. 83-85°C (Solvent for recrystallization:
THF/diethyl ether).

Example 55

20 1-[3-(4-Biphenylyl)propanoyl]-3-(4-
phenylpiperazin-1-yl)methyl-1,2,3,4-tetrahydroquinoline
dip-toluenesulfonate




Eluent: hexane/ethyl acetate=6/1 to 5/1
m.p. 176-179°C (Solvent for recrystallization:
THF/diethyl ether)

5

Example 56

1-[3-[3-(2-Benzofuranyl)-1,2,4-oxadiazol-5-yl]propanoyl]-3-(pirrolidin-1-yl)methyl-1,2,3,4-tetrahydroquinoline oxalate




10

Starting compound: compound of Reference Example 10
and compound of Reference Example 47

Eluent: hexane/ethyl acetate=5/1 to 4/1
m.p. 190-192°C (Solvent for recrystallization:
15 THF/ethanol/diethyl ether).

Example 57

1-[3-(4-Biphenylyl)propanoyl]-3-(pirrolidin-1-yl)methyl-1,2,3,4-tetrahydroquinoline oxalate




20

Eluent: hexane/ethyl acetate=6/1
m.p. 156-158°C (Solvent for recrystallization:

THF/diethyl ether)

Example 58

5 1-[3-[3-(2-Benzofuranyl)-1,2,4-oxadiazol-5-yl]propanoyl]-3-[2-(N,N-dimethylamino)ethyl]-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




Eluent: hexane/ethyl acetate=1: 1

m.p. 133-135°C (Solvent for recrystallization:

10 ethanol/IPE).

Example 59

15 1-[3-(4-Biphenylyl)propanoyl]-3-piperidinomethyl-1,2,3,4-tetrahydroquinoline hydrochloride



15

Eluent: hexane/ethyl acetate=1: 1


Amorphous powder

¹H-NMR δ: 1.1-1.8(6H, m), 1.9-2.5(7H, m), 2.6-3.0(6H, m), 3.1-3.4(1H, m), 3.8-4.0(1H, m), 7.05-7.6(13H, m).

20

Example 60

1-[3-[3-(2-Benzofuranyl)-1,2,4-oxadiazol-5-yl]propanoyl]-1,2,3,4-tetrahydro-3-piperidinomethylquinoline




Eluent: hexane/ethyl acetate=2: 1

m.p. 124-128°C (Solvent for recrystallization: ethyl acetate/hexane).

5

Example 61

1-[3-(4-Biphenylyl)propanoyl]-3-morpholinomethyl-1,2,3,4-tetrahydroquinoline hydrochloride



10


Eluent: hexane/ethyl acetate=1: 1

Amorphous powder

¹H-NMR δ: 2.1-2.5(8H, m), 2.6-3.4(5H, m), 3.2-3.6(1H, m), 3.5-3.9(4H, m), 3.8-4.1(1H, m), 7.05-7.6(13H,m).

15 Example 62

1-[3-[3-(2-Benzofuranyl)-1,2,4-oxadiazol-5-yl]propanoyl]-3-morpholinomethyl-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




20

Eluent: hexane/ethyl acetate=1: 1

m.p. 189-194°C (Solvent for recrystallization: methanol).

Example 63

5 1'-(3-(4-Biphenylyl)propanoyl)-1',2',3',4'-tetrahydro-1-propylspiro[piperidin-3,3'-quinoline]oxalate




Eluent: hexane/ethyl acetate=4/1

10 Amorphous powder
IR(KBr): 3027, 2969, 2940, 2878, 1655, 1491, 1397, 762, 700 cm⁻¹.

Example 64

15 1'-(3-[3-(2-Benzofuranyl)-1,2,4-oxadiazol-5-yl]propanoyl)-1',2',3',4'-tetrahydro-1-propylspiro[piperidin-3,3'-quinoline]




Eluent: hexane/ethyl acetate=2/1

20 m.p. 133-135°C (Solvent for recrystallization: ethyl acetate/hexane).

Example 65

160


3-(N-Benzyl-N-methylamino)methyl-1-[3-(4-biphenylyl)propanoyl]-1,2,3,4-tetrahydroquinoline oxalate



5 Eluent: hexane/ethyl acetate=4/1
 Amorphous powder
 IR(KBr): 3027, 1721, 1655, 1491, 1385, 1196, 924, 829, 760, 700 cm⁻¹.

10 Example 66

7-(4-Biphenylyl)methoxy-3-(N,N-dimethylamino)methyl-1-[3-(3-indolyl)propanoyl]-1,2,3,4-tetrahydroquinoline hydrochloride



15 Amorphous powder


¹H-NMR δ: 1.85-2.20(4H, m), 2.17(6H, s), 2.50-2.95(3H, m), 3.05-3.30(3H, m), 3.90-4.05(1H, m), 4.99(2H, s), 6.74(1H, dd), 6.84-7.18(5H, m), 7.22-7.64(11H, m), 8.16(1H, br).

20

Example 67

7-(4-Biphenylyl)methoxy-3-(N,N-dimethylamino)methyl-1-[4-(3-indolyl)butyryl]-1,2,3,4-tetrahydroquinoline hydrochloride


161

**Amorphous powder**

¹H-NMR δ: 1.80-2.20(6H, m), 2.15(6H, s), 2.50-2.95(3H, m), 3.05-3.30(3H, m), 3.90-4.05(1H, m), 4.99(2H, s), 5 6.70-7.18(6H, m), 7.22-7.64(11H, m), 8.20(1H, br).

Example 68


7-(4-Biphenylmethoxy)-3-(N,N-dimethylamino)methyl-1-[3-(5-methoxyindol-3-yl)propanoyl]-1,2,3,4-tetrahydroquinoline hydrochloride

**Amorphous powder**

¹H-NMR δ: 1.80-2.20(4H, m), 2.16(6H, s), 2.50-2.95(3H, m), 3.05-3.30(3H, m), 3.75(3H, s), 3.90-4.05(1H, m), 15 4.97(2H, s), 6.70-7.64(17H, m), 8.26(1H, br).

Example 69

3-(N,N-Dimethylamino)methyl-1-[3-[1-(2,4,6-triisopropylphenylsulfonyl)indol-3-yl]propanoyl]-20 1,2,3,4-tetrahydroquinoline p-toluenesulfonate




Chloroethylcarbonate (184.5 mg) was added dropwise to a THF (10 ml) solution of 3-[1-(2,4,6-triisopropylphenylsulfonyl)indol-3-yl]propionic acid (683.4 mg) and triethylamine (0.32 ml) at 0°C. The reaction mixture was stirred at 0°C for 30 minutes, to which was added dropwise a THF/acetonitrile (2 ml/20 ml) solution of N,N-dimethyl-N-[2-(1,2,3,4-tetrahydro-3-quinolinyl)methyl]amine (190.3 mg). The reaction mixture was stirred at 40°C overnight, then concentrated. 5% Aqueous sodium hydrogencarbonate solution was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by alumina column chromatography (eluent: hexane/ethyl acetate=4/1 to 3/1), which was converted into its p-toluenesulfonate. The mixture was recrystallized from THF/diethyl ether to give the entitled compound (606.0 mg).

m.p. 122-125°C.

Example 70

3-(N,N-Dimethylamino)methyl-1-[3-(5-methoxyindol-3-yl)propanoyl]-1,2,3,4-tetrahydroquinoline hydrochloride



The entitled compound was obtained by the similar manner as in Example 67.


Eluent: hexane/ethyl acetate=4/1 to 1/2

5 Amorphous powder

IR(KBr): 1636, 1582, 1458, 1400, 1219, 1177, 1063, 1028, 802, 762 cm⁻¹.

Example 71

10 1-[3-(4-Bromophenyl)propanoyl]-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




To a THF (20 ml) solution of 3-(4-bromophenyl)propionic acid (2.098 g), were added oxalyl chloride (0.92 ml) and DMF (2 drops) at 0°C. The reaction mixture was stirred at room temperature for 30 minutes, then concentrated. A THF (10 ml) solution of the residue was added dropwise to a THF (20 ml) solution of 3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline (1.321 g) and triethylamine (1.5 ml) at 0°C. The reaction mixture was stirred at 0°C for 30 minutes. Water was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by alumina column chromatography (eluent: ethyl acetate/hexane=1/4). An ethanol solution (10 ml) of p-toluenesulfonic acid monohydrate (1.263 g) was

added to an ethanol (20 ml) solution of the residue, then concentrated. The obtained crude crystals were recrystallized from ethanol/ethyl acetate to give the entitled compound (3.130 g).

5 m.p. 182-187°C.

Example 72

3-(N,N-Dimethylamino)methyl-1-[3-(4-methylphenyl)propanoyl]-1,2,3,4-tetrahydroquinoline p-
10 toluenesulfonate




2M Aqueous sodium carbonate solution (1.25 ml) was added to a suspension of 1-[3-(4-bromophenyl)propanoyl]-3-(N,N-dimethylamino)methyl-
15 1,2,3,4-tetrahydroquinoline p-toluenesulfonate (400 mg) in toluene (10 ml) and ethanol (1.25 ml), which was stirred at room temperature for 10 minutes. 4-Methylbenzene boronic acid (123 mg) and
20 tetrakis(triphenylphosphine)palladium (24 mg) were added to the reaction mixture, which was heated under reflux under an argon atmosphere for 14 hours. Water was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated.
25 The residue was purified by alumina column chromatography (eluent: hexane/ethyl acetate=10/1 to 2/1), which was converted into its p-toluenesulfonate. The mixture was recrystallized from ethyl acetate to give the entitled compound (296 mg).
30 m.p. 107-108°C.

Compounds of the following Examples 73 to 76 were synthesized by the similar manner as in Example 72 using the eluent described in the respective Example.

Example 73


5 3-(N,N-Dimethylamino)methyl-1-[3-[4-(2-naphthyl)phenyl]propanoyl]-1,2,3,4-tetrahydroquinoline p-toluenesulfonate



10 Eluent: hexane/ethyl acetate=10/1 to 2/1
m.p. 152-153°C (Solvent for recrystallization:
ethanol/ethyl acetate)

Example 74


15 3-(N,N-Dimethylamino)methyl-1-[3-[4-methoxyphenyl]phenyl]propanoyl]-1,2,3,4-tetrahydroquinoline p-toluenesulfonate



20 Eluent: hexane/ethyl acetate=10/1 to 2/1
m.p. 93-95°C (Solvent for recrystallization: ethyl acetate).

Example 75

25 1-[3-[4-(2-Chlorothiophen-5-yl)phenyl]propanoyl]-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




Eluent: hexane/ethyl acetate=7/1 to 5/1
m.p. 130.5-132.5°C (Solvent for recrystallization:
ethyl acetate).

5.

Example 76

3-(N,N-Dimethylamino)methyl-1-[3-[4-(4-biphenylyl)phenyl]propanoyl]-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




10

Eluent: hexane/ethyl acetate=10/1 to 2/1
m.p. 186-188°C (Solvent for recrystallization:
ethanol/ethyl acetate).

15 Example 77

3-(N,N-Dimethylamino)methyl-1-[3-[4-(3-pyridyl)phenyl]propanoyl]-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




2M Aqueous sodium carbonate solution (1.25 ml) was added to a suspension of 1-[3-(4-bromophenyl)propanoyl]-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline p-toluenesulfonate (400 mg) in toluene (10 ml) and ethanol (1.25 ml), which was stirred at room temperature for 10 minutes. Diethyl(3-pyridyl)borane (154 mg) and tetrakis(triphenylphosphine)palladium (24 mg) were added to the reaction mixture, which was heated under reflux under an argon atmosphere for 14 hours. Water was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by alumina column chromatography (eluent: hexane/ethyl acetate=10/1 to 2/1), which was converted into its p-toluenesulfonate. The mixture was recrystallized from ethanol-IPE to give the entitled compound (250 mg).

m.p. 98-101°C.

20

Example 78

3-(N-Benzyl-N-methylamino)methyl-1-[3-(4-biphenylyl)propyl]-1,2,3,4-tetrahydroquinoline oxalate




25 3-(N-Benzyl-N-methylamino)methyl-1-[3-(4-biphenylyl)propanoyl]-1,2,3,4-tetrahydroquinoline oxalate (0.800 g) was converted into a free form, which was dissolved in THF (5 ml). 1M Borane-THF complex (3 ml) was added to the reaction mixture, which was heated under reflux for 30 minutes, then left standing for cooling. Water (0.5 ml) and 6N hydrochloric acid (2 ml) were added to the

reaction mixture, which was stirred at room temperature for 12 hours. The reaction mixture was made basic by adding 1N aqueous sodium hydroxide solution and extracted with ethyl acetate. The organic layer was washed with a 5 saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by alumina column chromatography (eluent: ethyl acetate/hexane=1/50). A methanol solution (3 ml) of oxalic acid dihydrate (149 mg) was added to a methanol solution (10 ml) of the residue, 10 which was concentrated. Ethyl acetate was added to the residue, and the precipitates were collected by filtration to give the entitled compound (3.130 g) as an amorphous powder.

IR(KBr): 3029, 2938, 2907, 1725, 1603, 1508, 1466, 15 1260, 1221, 914, 760, 739, 698 cm^{-1} .

Example 79.

3-(N,N-Dimethylamino)methyl-1,2,3,4-tetrahydro-1-[3-(3-indolyl)propyl]quinoline hydrochloride



20


The entitled compound was obtained by the similar manner as in Example 78.

Eluent: hexane/ethyl acetate=4/1

m.p. 152-156°C (Solvent for recrystallization: 25 methanol/ethyl acetate).

Example 80.

3-(N,N-Dimethylamino)methyl-1,2,3,4-tetrahydro-1-[4-(3-indolyl)butyl]quinoline hydrochloride




The entitled compound was obtained by the similar manner as in Example 78.

Eluent: hexane/ethyl acetate=4/1

5 ¹H-NMR δ: 1.52-1.86(4H, m), 2.48-2.70(3H, m), 2.59(6H, s), 2.72-2.86(3H, m), 2.88-3.18(2H, m), 3.28(2H, t), 3.45(1H, d), 6.46-6.68(2H, m), 6.90-7.24(5H, m), 7.36(1H, d), 7.61(1H, d), 7.94(1H, br).

10 Example 81

1-[3-(4-Biphenylyl)propyl]-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydro-quinoline oxalate



15 The entitled compound was obtained by the similar manner as in Example 78.


Eluent: ethyl acetate/hexane=1/10

m.p. 144°C (Solvent for recrystallization: methanol/ethyl acetate).

20

Example 82

1-[3-(4-Biphenylyl)propanoyl]-1,2,3,4-tetrahydro-3-(N-methylamino)methylquinoline oxalate




10% Palladium-carbon (64 mg) was added to a methanol (10 ml) solution of 3-(N-benzyl-N-methylamino)methyl-1-[3-(4-biphenylyl)propanoyl]-1,2,3,4-tetrahydroquinoline (0.302 g) and catalytic hydrogenation was conducted at room temperature under an atmospheric normal pressure for 3 hours. The catalyst was removed by filtration and the filtrate was concentrated. The residue was purified by alumina column chromatography (eluent: ethyl acetate to 10 ethyl acetate/methanol=10/1). A methanol (2 ml) solution of oxalic acid dihydrate (42 mg) was added to a methanol (5 ml) solution of the residue, which was concentrated. Ethyl acetate was added to the residue, and the precipitates were collected by filtration to give the 15 entitled compound (3.130 g) as an amorphous powder.

IR(KBr): 3058, 3029, 2840, 1655, 1489, 1379, 762, 696 cm⁻¹.

Example 83

20 1-[3-(4-Biphenylyl)propyl]-1,2,3,4-tetrahydro-3-(N-methylamino)methylquinoline dihydrochloride




The entitled compound was obtained by the similar manner as in Example 78.

Eluent: ethyl acetate/methanol=10/1

IR(KBr): 2949, 2735, 2118, 1732, 1485, 1468, 1252, 1044, 777, 743 cm⁻¹.

5 Example 84

7-(4-Biphenylyl)methoxy-3-(N,N-dimethylamino)methyl-1-[3-(5-methoxyindol-3-yl)propyl]-1,2,3,4-tetrahydro-quinoline hydrochloride




10 The entitled compound was obtained by the similar manner as in Example 78.

m.p. 202-203°C (Solvent for recrystallization: methanol/IPE).

15 Example 85

1-[2-(4-Biphenylyl)ethylsulfonyl]-3-(pyrrolidin-1-yl)methyl-1,2,3,4-tetrahydroquinoline oxalate



(1) 2-(4-Biphenylyl)-1-ethanesulfonyl chloride

20 2-(4-Biphenylyl)ethylthiocyanate (0.5 g) was suspended in water (15 ml) and acetic acid (15 ml). Chlorine gas was blown into the reaction mixture under ice-cooling. Ten minutes later, ethyl acetate (20 ml) was added to the reaction mixture. Chlorine gas was blown into **25** the reaction mixture at room temperature for 50 minutes,

and the organic layer was separated. The organic layer was washed twice with 10% aqueous potassium chloride solution, then dried and concentrated to give a crude product (0.7 g) of 2-(4-biphenyl)-1-ethanesulfonyl chloride.


5 (2) 1-[2-(4-Biphenyl)ethylsulfonyl]-3-(pyrrolidin-1-yl)methyl-1,2,3,4-tetrahydroquinoline oxalate

An acetonitrile (20 ml) solution of 2-(4-biphenyl)-1-ethanesulfonyl chloride (0.7 g) was added dropwise to an acetonitrile (20 ml) solution of 3-(pyrrolidin-1-yl)methyl-1,2,3,4-tetrahydroquinoline (450 mg) and triethylamine (0.44 ml) at 0°C. The reaction mixture was stirred at room temperature for 3 hours, then left standing for 2 days. 10% Aqueous potassium carbonate solution and water were added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by alumina column chromatography (eluent: hexane/ethyl acetate=10/1), which was converted into its oxalate. The mixture was recrystallized from ethanol-diethyl ether to give the entitled compound (267 mg).

m.p. 115-118°C.

25 Example 86

3-(R,S)-(N,N-Dimethylamino)methyl-1-[2-(R)-(9-fluorenylmethoxy)carbonylamino-3-(indol-3-yl)propanoyl]-1,2,3,4-tetrahydroquinoline




Oxalyl chloride (0.48 ml) was added dropwise to a THF (15 ml) solution of N-(9-fluorenylmethoxycarbonyl)-D-tryptophan (289 mg) and DMF (0.03 ml) at 0°C. The reaction mixture was stirred at room temperature for 30 minutes, then concentrated. The residue was dissolved in ethyl acetate (10 ml), which was added dropwise to the mixture of an ethyl acetate (15 ml) solution of 3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline (298 mg) and a saturated aqueous sodium bicarbonate solution (10 ml) at 0°C. The reaction mixture was stirred at room temperature for one hour, and the organic layer was separated. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate/methanol=10/1) to obtain the entitled compound (797 mg).

IR(KBr): 3295, 2971, 1707, 1647, 1491, 1233, 760, 741 cm⁻¹.

20

Example 87

1-[2-(R)-Amino-3-(indol-3-yl)propanoyl]-3-(R,S)-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline




25 Piperidine (0.66 ml) was added to a methanol (10 ml) solution of 3-(R,S)-(N,N-dimethylamino)methyl-1-[2-(R)-(9-fluorenylmethoxy)carbonylamino-3-(indol-3-yl)propanoyl]-1,2,3,4-tetrahydroquinoline (0.797 g) at room temperature. The reaction mixture was stirred at room 30 temperature for 18 hours, then concentrated. The residue was purified by alumina column chromatography (eluent: ethyl acetate/methanol=10/1) to obtain the entitled

compound (0.382 g).

IR(KBr): 3281, 2938, 1647, 1582, 1493, 1458, 1240, 743
cm⁻¹.

5. Example 88

3-(R,S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline.



10


N,N'-Disuccinimidyl carbonate (45 mg) was added to a THF (5 ml) solution of 1-[2-(R)-amino-3-(indol-3-yl)propanoyl]-3-(R,S)-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline (99 mg) and N-ethyldiisopropylamine (0.1 ml). The reaction mixture was stirred at room temperature for 2 hours, to which were added a THF (3 ml) solution of 1-phenylpiperazine (68 mg) and N-ethyldiisopropylamine (0.1 ml). The reaction mixture was stirred at room temperature for further 3 hours, then concentrated. The residue was purified by alumina column chromatography (eluent: ethyl acetate) to obtain the entitled compound (0.134 g) as an amorphous powder.

IR(KBr): 3297, 2820, 1630, 1493, 1233, 760, 743 cm⁻¹.

25 The following compounds of Examples 89 and 90 were produced by the similar manner as in Example 88.

Example 89


3-(R,S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidinocarbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline



IR(KBr): 3258, 2940, 1692, 1630, 1487, 756, 741 cm⁻¹.

Example 90


5 3-(R,S)-(N,N-Dimethylamino)methyl-1-[2-(R)-
(1,2,3,4-tetrahydro-6,7-dimethoxyspiro[naphthalen-2,2'-
piperidin]-1'-yl)carbonylamino-3-(indol-3-
yl)propanoyl]-1,2,3,4-tetrahydroquinoline



10 IR(KBr): 3299, 2934, 1638, 1514, 1256, 1115, 743 cm⁻¹.

Example 91

15 1-[2-(R)-[4-(2-Chlorophenyl)piperazin-1-
yl]carbonylamino-3-(R,S)-(N,N-dimethylamino)methyl-3-
(indol-3-yl)propanoyl]-1,2,3,4-tetrahydroquinoline



N,N'-Disuccinimidyl carbonate (102 mg) and N-ethyldiisopropylamine (0.14 ml) were added to an acetonitrile (5 ml) solution of 1-[2-(R)-amino-3-(indol-3-yl)propanoyl]-3-(R,S)-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline (150 mg). The reaction mixture was stirred at room temperature for 30 minutes, to which were added an acetonitrile (1 ml) solution of 1-(2-chlorophenyl)piperazine (78 mg) and N-ethyldiisopropylamine (0.07 ml). The reaction mixture was stirred at room temperature for 2 hours. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by alumina column chromatography (eluent: ethyl acetate/hexane=1/1 to 3/1) to obtain the entitled compound (158 mg) as an amorphous powder.


IR(KBr): 3267, 1635, 1230, 760, 744 cm⁻¹.

The following compounds of Examples 92 to 97 were produced by the similar manner as in Example 91.

Example 92

3-(R,S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-2-(R)-[4-(2-methoxy)phenyl]piperazin-1-

25 carbonylaminopropanoyl]-1,2,3,4-tetrahydroquinoline




The similar procedure was conducted using 1-(2-methoxyphenyl)piperazine. The product was purified by aluminum column chromatography (eluent: ethyl acetate/hexane=1/1 to ethyl acetate) to obtain the entitled compound (165 mg) as an amorphous powder.

IR(KBr): 3265, 1635, 1498, 1240, 744 cm⁻¹.

Example 93

5 3-(R,S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-[4-(2-pyridyl)piperazin-1-yl]carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline




The similar procedure was conducted using 1-(2-pyridyl)piperazine. The product was purified by alumina column chromatography (eluent: ethyl acetate/hexane=1/1 to 10 ethyl acetate/methanol=20/1) to obtain the entitled compound (190 mg) as an amorphous powder.

IR(KBr): 3265, 1635, 1491, 1437, 1240, 742 cm⁻¹.

Example 94

15 3-(R,S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-4-[(2-pyrimidinyl)piperazin-1-yl]carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline




20 The similar procedure was conducted using 1-(2-pyrimidinyl)piperazine. The product was purified by alumina column chromatography (eluent: ethyl acetate/hexane=1/1 to ethyl acetate/methanol=20/1) to obtain the entitled compound (175 mg) as an amorphous powder.

25 IR(KBr): 3265, 1635, 1585, 1494, 1248, 983 cm⁻¹.

Example 95

1-[2-(R)-(4-benzylpiperazin-1-yl)carbonylamino-3-(R,S)-(N,N-dimethylamino)methyl-3-(indol-3-yl)propanoyl]-1,2,3,4-tetrahydroquinoline




5

The similar procedure was conducted using 1-benzylpiperazine. The product was purified by aluminum column chromatography (eluent: ethyl acetate/hexane=1/1 to ethyl acetate) to obtain the entitled compound (115 mg) as
10 an amorphous powder.

IR(KBr): 3263, 1635, 1491, 1234, 742 cm⁻¹.

Example 96

15 3-(R,S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-2-(R)-[(4-phenylpiperidino)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline




The similar procedure was conducted using 4-phenylpiperidine. The product was purified by alumina column chromatography (eluent: ethyl acetate/hexane=1/2 to 2/1), to obtain the entitled compound (120 mg) as an amorphous powder.

IR(KBr): 3265, 1635, 1491, 1230, 758, 742 cm⁻¹.

Example 97

1-[2-(R)-[[4-(4-Chlorophenyl)-4-hydroxypiperidino]carbonyl]amino-3-(indol-3-yl)propanoyl]-3-(R,S)-(N,N-dimethylamino)methyl-
 5 1,2,3,4-tetrahydroquinoline




The similar procedure was conducted using 4-(4-chlorophenyl)-4-hydroxypiperidine. The product was purified by alumina column chromatography (eluent: ethyl acetate/hexane=1/1 to ethyl acetate/methanol=20/1) to obtain the entitled compound (200 mg) as an amorphous powder.

IR(KBr): 3298, 1624, 1491, 742 cm⁻¹.

15 Example 98

4-Benzyl-2-(N,N-dimethylamino)methyl-1-formyl-
 1,2,3,4-tetrahydroquinoxaline



Borane-THF complex (1M THF solution; 21 ml) was added dropwise to a THF (30 ml) solution of 4-benzyl-N,N-dimethyl-3-oxo-1,2,3,4-tetrahydro-2-quinoxalinecarboxamide (1.33 g) under ice-cooling. The reaction mixture was stirred at room temperature for 30 minutes, which was heated under reflux for 2 hours. The reaction mixture was cooled to room temperature. Water (5 ml) was added to the reaction mixture, which was stirred for 10 minutes, then concentrated. The residue was

dissolved in methanol (30 ml), which was heated under reflux for an hour together with 6N hydrochloric acid (10 ml). 3N Aqueous sodium hydroxide solution (20 ml) was added to the reaction mixture under ice-cooling for neutralization, 5 which was concentrated. 10% Aqueous potassium carbonate solution was added to the residue, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated to obtain a crude product of N-[(4-benzyl- 10 1,2,3,4-tetrahydro-2-quinoxaliny1)methyl]-N,N-dimethylamine. (Trihydrochloride salt of this compound showed m.p. of 168 to 172°C)


The crude product was dissolved in formic acid (12 ml), to which was added dropwise the mixture (prepared by mixing 15 both and stirring for an hour at 50°C) of formic acid (1.4 ml) and acetic acid anhydride (2.8 ml) under ice-cooling.

The reaction mixture was stirred at room temperature for an hour, then concentrated. The residue was dissolved in ethyl acetate. The mixture was washed with 10% aqueous 20 potassium carbonate solution and a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by alumina column chromatography (eluent: ethyl acetate/hexane=1/1). The obtained crystals were washed with hexane to give the entitled 25 compound (1.16 g).

m.p. 82-84°C.

Example 99

4-[3-(4-Biphenylyl)propanoyl]-2-(N,N-dimethylamino)methyl-1-formyl-1,2,3,4-tetrahydroquinoxaline p-toluenesulfonate



10% Pd-C (175 mg) and concentrated hydrochloric acid (0.3 ml) were added to a methanol (15 ml) solution of 4-benzyl-2-(N,N-dimethylamino)methyl-1-formyl-1,2,3,4-tetrahydroquinoxaline (350 mg). The reaction mixture was subjected to catalytic hydrogenation at room temperature under 4.5 atmospheric pressure for 2 hours. The catalyst was removed by filtration and the filtrate was concentrated.

10 Aqueous potassium carbonate solution was added to the residue, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated to give 2-(N,N-dimethylamino)methyl-1-formyl-1,2,3,4-tetrahydroquinoxaline (190 mg).


15 Oxalyl chloride (0.1 ml) was added to a THF (5 ml) solution of 3-(4-biphenylyl)propionic acid (210 mg) under ice-cooling, to which was further added DMF (one drop). The reaction mixture was stirred at room temperature for 30 minutes and concentrated. The residue was dissolved in THF (5 ml), which was added dropwise to a THF (5 ml) solution of 2-(N,N-dimethylamino)methyl-1-formyl-1,2,3,4-tetrahydroquinoxaline (170 mg) and triethylamine (0.16 ml) under ice-cooling. The reaction mixture was stirred at the same temperature for an hour. Water was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by alumina column chromatography (eluent: hexane to hexane/ethyl acetate=4/1), which was converted into its p-toluenesulfonate. The mixture was

washed with methanol-IPE to obtain the entitled compound (220 mg).

m.p. 195-197°C.

5 Example 100

4-[3-(4-Biphenylyl)propanoyl]-2-(N,N-dimethylamino)methyl-1-ethyl-1,2,3,4-tetrahydroquinoxaline p-toluenesulfonate




10 Oxalyl chloride (0.18 ml) was added to a THF (7 ml) solution of 3-(4-biphenylyl)propionic acid (370 mg) under ice-cooling, to which was added DMF (one drop). The reaction mixture was stirred at room temperature for 30 minutes and concentrated. The residue was again dissolved 15 in THF, which was concentrated. The residue was dissolved in THF (7 ml), which was added dropwise to a THF (7 ml) solution of 2-(N,N-dimethylamino)methyl-1-ethyl-1,2,3,4-tetrahydroquinoxaline (obtained by 10% neutralization of trihydrochloride (450 mg)) and 20 triethylamine (0.29 ml) under ice-cooling. The reaction mixture was stirred at same temperature for an hour. Water was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and 25 concentrated. The residue was purified by alumina column chromatography (eluent: hexane to hexane/ethyl acetate=5/1), which was converted into its p-toluenesulfonate. The mixture was washed with IPE to obtain the entitled compound (620 mg).

30 m.p. 169-172°C.

Example 101

4-Benzyl-1-formyl-2-(pyrrolidin-1-yl)methyl-
1,2,3,4-tetrahydroquinoxaline



5

Borane-THF complex (1M THF solution; 17 ml) was added dropwise to a THF (20 ml) solution of 1-benzyl-3-(pyrrolidin-1-ylcarbonyl)-3,4-dihydro-2(1H)-quinoxaline (Reference Example 70; 1.05 g) under ice-cooling. The reaction mixture was stirred at room temperature for 30 minutes, which was heated under reflux for 2 hours. The reaction mixture was cooled to room temperature. Water (5 ml) was added to the reaction mixture, which was stirred for 10 minutes, then concentrated. The residue was dissolved in methanol (20 ml) and heated under reflux for an hour together with 6 N hydrochloric acid (6 ml). 3 N Aqueous sodium hydroxide solution (12 ml) was added to the reaction mixture under ice-cooling for neutralization, which was concentrated. 10% Aqueous potassium carbonate solution was added to the residue, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated to give a crude product of 1-benzyl-3-(pyrrolidin-1-yl)methyl-1,2,3,4-tetrahydroquinoxaline (Trihydrochloride salt of this compound showed m.p. of 207 to 212°C).


The crude product was dissolved in formic acid (12 ml), to which was added dropwise the mixture (prepared by mixing both and stirring for an hour at 50°C) of formic acid (1.4 ml) and acetic acid anhydride (2.8 ml) under ice-cooling.

The reaction mixture was stirred at room temperature for one hour, then concentrated. The residue was dissolved in

ethyl acetate. The mixture was washed with 10% aqueous potassium carbonate solution and a saturated aqueous sodium chloride solution, then dried and concentrated. The crystals were washed with hexane to give the entitled
 5 compound (800 mg).
 m.p. 94-96°C.

Example 102

10 **4-(3-(4-Biphenylyl)propanoyl)-1-formyl-2-(pyrrolidin-1-yl)methyl-1,2,3,4-tetrahydroquinoxaline oxalate**



10% Pd-C (200 mg) and concentrated hydrochloric acid (0.3 ml) were added to a methanol (25 ml) solution of 15 4-benzyl-1-formyl-2-(pyrrolidin-1-yl)methyl-1,2,3,4-tetrahydroquinoxaline (500 mg). The reaction mixture was subjected to catalytic hydrogenation at room temperature under 4.5 atmospheric pressure for 2 hours. The catalyst was removed by filtration, and the filtrate was concentrated. 10% Aqueous potassium carbonate solution was added to the residue, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated to give 1-formyl-2-(pyrrolidin-1-yl)methyl-1,2,3,4-tetrahydroquinoxaline (360 mg).
 20 Oxalyl chloride (0.19 ml) was added to a THF (5 ml) solution of 3-(4-biphenylyl)propionic acid (410 mg) under ice-cooling, to which was added DMF (one drop). The reaction mixture was stirred at room temperature for 30 minutes, 25 which was concentrated. The residue was again dissolved
 30


in THF, which was concentrated. The residue was dissolved in THF (7 ml), which was added dropwise to a THF (7 ml) solution of 1-formyl-2-(pyrrolidin-1-yl)methyl-1,2,3,4-tetrahydroquinoxaline (360 mg) and triethylamine (0.31 ml) under ice-cooling. The reaction mixture was stirred at the same temperature for one hour. Water was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by alumina column chromatography (eluent: hexane to hexane/ethyl acetate=4/1), which was converted into its oxalate. The crystals were washed with IPE to give the entitled compound (350 mg).

m.p. 144-147°C.

15

Example 103

4-(3-(4-Biphenylyl)propanoyl)-2-(pyrrolidin-1-yl)methyl-1,2,3,4-tetrahydroquinoxaline oxalate



oxalate


20 4N Hydrochloric acid-ethyl acetate (2 ml) was added to a methanol (10 ml) solution of 4-(3-(4-biphenylyl)propanoyl)-1-formyl-2-(pyrrolidin-1-yl)methyl-1,2,3,4-tetrahydroquinoxaline (320 mg). The reaction mixture was stirred at 50°C for one hour, then concentrated. 10% Aqueous potassium carbonate solution was added to the residue, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by alumina column chromatography (eluent: hexane to hexane/ethyl acetate=7/1), which was converted into its oxalate. The

obtained crystals were washed with methanol-IPE to give the entitled compound (250 mg).

m.p.. 196-198° C.

5 Example 104

1-Acetyl-4-benzyl-2-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoxaline




Borane-dimethylsulfide complex (10M-THF solution ; 5 ml) was added to a THF (20 ml) solution of 4-benzyl-N,N-dimethyl-3-oxo-3,4-dihydro-2-quinoxalinecarboxamide (1.5 g). The reaction mixture was stirred at room temperature for one hour, further at 50° C for 18 hours, then concentrated. The residue was dissolved in methanol (30 ml) and the mixture was stirred at 50° C for 20 hours together with 6N hydrochloric acid (10 ml). The reaction mixture was concentrated, and the residue was dissolved in pyridine (10 ml). Acetic anhydride (0.5 ml) was added to the reaction mixture, which was stirred at room temperature for 5 hours. The reaction mixture was concentrated, and the residue was purified by alumina column chromatography (eluent: ethyl acetate/hexane=1/3) to obtain the entitled compound (0.6 g).

¹H-NMR δ: 2.2-2.4(11H, m), 3.4-3.6(2H, m), 4.4-4.6(2H, s), 5.2-5.3(1H, m), 6.5-6.7(2H, m), 6.9-7.1(1H, m), 7.2-7.4(7H, m).

Example 105

1-[2-(4-Biphenylyl)ethyl]sulfonyl-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline




LDA (1.9 M/THF, 1.2 ml) was added dropwise to a THF solution of 3-(*N,N*-dimethylamino)methyl-1-methylsulfonyl-1,2,3,4-tetrahydroquinoline (0.24 g). The reaction mixture was stirred under ice-cooling for 30 minutes. A THF (1 ml) solution of 4-biphenylmethyl bromide (0.16 g) was added to the reaction mixture, which was stirred at room temperature for 3 hours. Water was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with water, then dried and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate), which was further recrystallized from hexane-ethyl acetate to give the entitled compound (30 mg).

m.p. 108-109°C.

Example 106

1-[2-(4-Biphenylyl)ethylsulfonyl]-3-(pyrrolidin-1-yl)methyl-1,2,3,4-tetrahydroquinoline



A THF (10 ml) solution of 1-(methylsulfonyl)-3-(pyrrolidin-1-yl)methyl-1,2,3,4-tetrahydroquinoline (0.6 g) was cooled to -15°C under an argon flow. LDA (1.9 M heptane solution, 2.15 ml) was added dropwise to the


reaction mixture. The reaction mixture was warmed to room temperature, which was stirred for 30 minutes, then cooled to -15°C again. A THF (2 ml) solution of 4-biphenylylmethyl bromide (0.4 g) was added dropwise to the reaction mixture.

5 The reaction mixture was stirred at the same temperature for 30 minutes, which was warmed to 0°C. Water was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and 10 concentrated. The residue was purified by alumina column chromatography (eluent: hexane to hexane/ethyl acetate=10/1) and silica gel column chromatography (eluent: ethyl acetate). The crystals were washed with IPE to give the entitled compound (28 mg).

15 m.p. 107-110°C.

Example 107

1-N-(4-Biphenylyl)methylaminocarbonyl-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline p-toluenesulfonate



To a dichloromethane (4 ml) solution of triphosgene (156 mg) was added dropwise a dichloromethane (2 ml) solution of 3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline (300 mg) and triethylamine (0.44 ml) under ice-cooling. The reaction mixture was stirred for 40 minutes, to which was added dropwise a dichloromethane (3 ml) solution of 4-biphenylylmethylamine (290 mg) and triethylamine (0.44 ml) at the same temperature. The 25 reaction mixture was stirred at room temperature for one hour, to which was added ethyl acetate. The insoluble substances were removed by filtration, then concentrated.


30

The residue was purified by alumina column chromatography (eluent: hexane to hexane/ethyl acetate=3/1), which was converted into its p-toluenesulfonate. The mixture was recrystallized from ethanol-IPE to give the entitled
5 compound (310 mg).

m.p. 167-169°C.

Example 108

10 1-[3-(4-Biphenyl)propanoyl]-6-chloro-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




Oxalyl chloride (0.11 ml) and DMF (one drop) were added to a THF (5 ml) solution of 3-(4-biphenyl)propionic acid (249 mg) at 0°C. The reaction mixture was stirred at room temperature for one hour, then concentrated. The residue was dissolved in THF (5 ml), which was added dropwise to a THF (10 ml) solution of 6-chloro-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline (202 mg) and triethylamine (0.19 ml) at 0°C. The reaction mixture was stirred at room temperature for one hour. 10% Aqueous potassium carbonate solution was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated.
25 The residue was purified by alumina column chromatography (eluent: hexane/ethyl acetate=4/1), which was converted into its p-toluenesulfonate. The mixture was recrystallized from ethanol-diethyl ether to give the entitled compound (466 mg).
30

m.p. 144-146°C.

Example 109

1-[3-[3-(2-Benzofuranyl)-1,2,4-oxadiazol-5-yl]propanoyl]-6-chloro-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline




Synthesis was conducted by the similar manner as in Example 108.

10 m.p. 125-127°C (Solvent for recrystallization: ethyl acetate/hexane).

Example 110

1-[3-(4-Biphenylyl)propanoyl]-3-(N,N-dimethylamino)methyl-6-methoxy-1,2,3,4-tetrahydroquinoline




Synthesis was conducted by the similar manner as in Example 1.

20 m.p. 91-93°C (Solvent for recrystallization: ethyl acetate/hexane).

Example 111

1-[2-(R)-Amino-3-(indol-3-yl)propanoyl]-3-(R,S)-(pyrrolidin-1-yl)methyl-1,2,3,4-tetrahydroquinoline




A THF (15 ml) solution of oxalyl chloride (1.16 ml) was added dropwise to a THF (45 ml) solution of N-(9-fluorenylmethoxycarbonyl)-D-tryptophan (4.73 g) and DMF (0.1 ml) at 0°C. The reaction mixture was stirred at room temperature for 30 minutes, then concentrated. The residue was dissolved in ethyl acetate (30 ml), which was added dropwise to the mixture of an ethyl acetate (40 ml) solution of 3-(R,S)-(pyrrolidin-1-yl)methyl-1,2,3,4-tetrahydroquinoline (800 mg) and 20% aqueous sodium carbonate solution (40 ml), at 0°C. The reaction mixture was stirred at room temperature for one hour, and the organic layer was separated. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by alumina column chromatography (eluent: ethyl acetate/hexane=1:2 to 1:1), then concentrated. The residue was dissolved in methanol (60 ml). Piperidine (2 ml) was added to the mixture, which was stirred at room temperature for 12 hours. The reaction mixture was concentrated, and purified by alumina column chromatography (eluent: ethyl acetate/hexane=1:2 to ethyl acetate/methanol=20:1) to obtain the entitled compound (1.1 g) as an amorphous powder.

IR(KBr): 3287, 2924, 1651, 1582, 1491, 1236, 741 cm⁻¹.

Example 112

1-[2-(R)-Amino-3-(indol-3-yl)propanoyl]-3-(R)-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline




Synthesis was conducted by the similar manner as in Example 111.

IR(KBr): 3279, 2932, 1647, 1580, 1493, 1236, 741 cm⁻¹.

$[\alpha]_D^{20} = -247^\circ$ (C=0.347% in methanol).

Example 113: 1-[2-(R)-Amino-3-(indol-3-yl)propanoyl]-3-(S)-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline




Synthesis was conducted by the similar manner as in Example 111.

IR(KBr): 3287, 2930, 1647, 1582, 1491, 1242, 743 cm⁻¹.

$[\alpha]_D^{20} = -218^\circ$ (C=0.345% in methanol).

Example 114: 1-[2-(R)-Amino-3-(indol-3-yl)propanoyl]-3-(R,S)-(N-benzyl-N-methylamino)methyl-1,2,3,4-tetrahydroquinoline




20

Synthesis was conducted by the similar manner as in Example 111.

IR(KBr): 3285, 2934, 2791, 1651, 1491, 743, 700 cm⁻¹.

Example 115

5 1-[2-(R)-Amino-3-(indol-3-yl)propanoyl]-3-(R,S)-
 (N,N-dibenzylamino)methyl-1,2,3,4-tetrahydroquinoline




Synthesis was conducted by the similar manner as in
 Example 111.

10 IR(KBr): 3287, 2930, 2797, 1645, 1493, 743, 700 cm⁻¹.

Example 116

15 1-[2-(R)-Amino-3-(indol-3-yl)propanoyl]-3-(R,S)-
 (N,N-dimethylamino)methyl-6-methoxy-1,2,3,4-
 tetrahydroquinoline




Synthesis was conducted by the similar manner as in
 Example 111.

20 IR(KBr): 3289, 2934, 1644, 1501, 1456, 1267, 741 cm⁻¹.

Example 117

25 1-[2-(R)-Amino-3-(indol-3-yl)propanoyl]-6-chloro-
 3-(R,S)-(N,N-dimethylamino)methyl-1,2,3,4-
 tetrahydroquinoline




A THF (5 ml) solution of oxalyl chloride (1.5 ml) was added dropwise to a THF (30 ml) solution of N-(9-fluorenylmethoxycarbonyl)-D-tryptophan (5.887 g) and DMF 5 (0.04 ml). The reaction mixture was stirred at 0°C for one hour, then concentrated. The residue was dissolved in a mixed solution of ethyl acetate (15 ml) and THF (15 ml), which was added dropwise to the mixture of an ethyl acetate (30 ml) solution of 6-chloro-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline (1.030 g) and a saturated aqueous sodium bicarbonate solution (20 ml) at 0°C. The reaction mixture was stirred at room temperature for one hour, and the organic layer was separated. The organic layer was washed with a saturated 10 aqueous sodium chloride solution, then dried and concentrated. The residue was purified by alumina column chromatography (eluent: hexane/ethyl acetate=1/1) and silica gel column chromatography (eluent: ethyl acetate/methanol=10/1) to obtain 6-chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[2-(R)-(9-fluorenylmethoxy)carbonylamino-3-(indol-3-yl)propanoyl]-1,2,3,4-tetrahydroquinoline (1.35 g). 15 Piperidine (1.1 ml) was added to a methanol (15 ml) solution of this compound at room temperature. The reaction mixture 20 was stirred at room temperature for 5 hours, then concentrated. The residue was purified by alumina column chromatography (eluent: ethyl acetate/methanol=10/1) to obtain the entitled compound (0.602 g). 25

IR(KBr) : 2938, 1647, 1487, 1458, 1096, 743 cm⁻¹.

The following compounds of Examples 118 to 132 were synthesized by similar manner as in Example 91.

Example 118

3-(R)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-
2-[(R)-(4-phenylpiperazin-1-
yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline




5

IR(KBr): 3266, 2820, 1634, 1493, 1233, 760, 743 cm⁻¹.

$[\alpha]_D^{20} = -158^\circ$ (C=0.475% in methanol).

Example 119

10 3-(S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-
2-[(R)-(4-phenylpiperazin-1-
yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline




IR(KBr): 3266, 2820, 1634, 1493, 1233, 758, 743 cm⁻¹.

15 $[\alpha]_D^{20} = -158^\circ$ (C=0.432% in methanol).

Example 120

20 3-(R)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-
2-[(R)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-
yl)piperidinocarbonylamino]propanoyl]-1,2,3,4-
tetrahydroquinoline




IR(KBr): 3252, 2968, 1698, 1634, 1489, 1235, 741 cm⁻¹.

$[\alpha]_D^{20} = -128^\circ$ (C=0.505% in methanol).

5 Example 121

3-(S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidinocarbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline




10

IR(KBr): 3196, 2968, 1698, 1634, 1489, 1236, 739 cm⁻¹.

$[\alpha]_D^{20} = -131^\circ$ (C=0.500% in methanol).

Example 122

15 3-(R)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-2-(R)-[4-(2-methyl)phenylpiperazin-1-yl]carbonylaminopropanoyl]-1,2,3,4-tetrahydroquinoline




IR(KBr): 3247, 2818, 1634, 1493, 1227, 762, 741 cm⁻¹.

$[\alpha]_D^{20} = -152^\circ$ (C=0.504% in methanol).

Example 123

3-(S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-
5 2-(R)-[4-(2-methyl)phenyl]piperazin-1-
y1]carbonylamino propanoyl]-1,2,3,4-tetrahydroquinoline




IR(KBr): 3247, 2818, 1634, 1491, 1227, 762, 743 cm⁻¹.

$[\alpha]_D^{20} = -155^\circ$ (C=0.498% in methanol).

10

Example 124

3-(R,S)-(N-Benzyl-N-methylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-(4-phenyl)piperazin-1-
y1]carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline




15

IR(KBr): 3260, 2922, 2849, 1632, 1493, 1233, 741 cm⁻¹.

Example 125


3-(R,S)-(N,N-Dibenzylamino)methyl-1-[3-(indol-3-
20 yl)-2-[(R)-(4-phenyl)piperazin-1-
y1]carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline



IR(KBr): 3281, 2922, 2813, 1636, 1493, 1233, 745 cm⁻¹.

Example 126

5 3-(R,S)-(N,N-Dimethylamino)methyl-1-[2-[(R)-4-phenylbenzotriazol-1-yl]piperidinocarbonylamino]-3-(indol-3-yl)propanoyl]-1,2,3,4-tetrahydroquinoline




IR(KBr): 3260, 2936, 1634, 1491, 1456, 1233, 745 cm⁻¹.

10

Example 127

3-(R,S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-4-[5-(trifluoromethyl)benzotriazol-1-yl]piperidinocarbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline

15




IR(KBr): 2934, 1632, 1493, 1333, 1235, 1163, 1125 cm⁻¹.

Example 128

20 3-(R,S)-(N,N-Dimethylamino)methyl-1-2-[(R)-[4-

(2,3-dimethyl)phenylpiperazin-1-yl]carbonylamino]-3-[indol-3-yl)propanoyl]-1,2,3,4-tetrahydroquinoline




IR(KBr): 3263, 2971, 1632, 1491, 1456, 1235, 741 cm⁻¹.

5

Example 129

3-(R,S)-(N,N-Dimethylamino)methyl-1-2-[(R)-[4-(2,4-dimethyl)phenylpiperazin-1-yl]carbonylamino]-3-[indol-3-yl)propanoyl]-1,2,3,4-tetrahydroquinoline




10

IR(KBr): 3254, 2942, 1632, 1493, 1416, 1225, 741 cm⁻¹.

Example 130

3-(R,S)-(N,N-Dimethylamino)methyl-1-[2-[(R)-[4-(2,5-dimethyl)phenylpiperazin-1-yl]carbonylamino]-3-[indol-3-yl)propanoyl]-1,2,3,4-tetrahydroquinoline




IR(KBr): 3264, 2969, 1632, 1493, 1416, 1242, 741 cm⁻¹.

20 **Example 131**


3-(R,S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-[4-(3-methoxy)phenylpiperazin-1-

y1]carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline

IR(KBr): 3227, 2938, 1632, 1493, 1456, 1250, 1202 cm⁻¹.

5 Example 132


3-(R,S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-(4-(tert-butoxycarbonyl)piperazin-1-yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline

10 IR(KBr): 3316, 2975, 1698, 1634, 1416, 1238, 1169 cm⁻¹.

Example 133

1-[3-(Indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-yl)carbonylamino]propanoyl]-3-(R,S)-(N-

15 methylamino)methyl-1,2,3,4-tetrahydroquinoline




10% Palladium-carbon (50 mg) and concentrated hydrochloric acid (5 drops) were added to a methanol (10 ml) solution of 3-(R,S)-(N-benzyl-N-methylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline (400 mg), and catalytic hydrogenation was conducted at room

temperature under 4 atmospheric pressure of hydrogen for 40 hours. The catalyst was removed by filtration and the filtrate was concentrated. 10% Aqueous potassium carbonate solution was added to the residue, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by alumina column chromatography (eluent: ethyl acetate/hexane=1:1 to ethyl acetate/methanol/triethylamine=5:1:0.1) to obtain the entitled compound (140 mg) as an amorphous powder.

IR(KBr): 3252, 2922, 1636, 1493, 1233, 760, 745 cm⁻¹.

Example 134

15 3-(R,S)-(N-Benzylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline




10% Palladium-carbon (50 mg) and concentrated hydrochloric acid (5 drops) were added to a methanol (10 ml) solution of 3-(R,S)-(N,N-dibenzylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline (400 mg), and catalytic hydrogenation was conducted at room temperature under 4 atmospheric pressure of hydrogen for 8 hours. The catalyst was removed by filtration, and the filtrate was concentrated. 10% Aqueous potassium carbonate solution was added to the residue, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated to obtain the entitled compound (300 mg) as an amorphous powder.

IR(KBr): 3271, 2921, 2840, 1634, 1495, 1233, 743 cm⁻¹.

The following compounds of Examples 135 to 138 were synthesized by similar manner as in Example 147.

5 Example 135


3-(R,S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-[4-(1-naphthyl)piperazin-1-yl]carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline



10 IR(KBr): 3291, 2940, 2820, 1636, 1508, 1491, 1399, 1254, 1011, 775, 743 cm⁻¹.

Example 136

15 3-(R,S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-yl)carbonylamino]propanoyl]-6-methoxy-1,2,3,4-tetrahydroquinoline




20 IR(KBr): 3274, 2940, 2820, 1634, 1499, 1456, 1233, 743 cm⁻¹.

Example 137

25 3-(R,S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidinocarbonylamino]propanoyl]-6-methoxy-

1,2,3,4-tetrahydroquinoline




IR(KBr) : 3247, 2934, 1698, 1628, 1501, 1269, 1244, 741
cm⁻¹.

5

Example 138


3-(R,S)-(N,N-Diméthylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-1-(benzoylpiperidin-4-yl)carbonylamino]propanoyl]-6-methoxy-1,2,3,4-tetrahydroquinoline



IR(KBr) : 3293, 2940, 1628, 1501, 1448, 1279, 743 cm⁻¹.

Example 139

15 6-Chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline



N,N'-Disuccinimidyl carbonate (42 mg) was added to an


acetonitrile (5 ml) solution of 1-[2-(R)-amino-3-(indol-3-yl)propanoyl]-6-chloro-3-(R,S)-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline (101 mg) and N-ethyldiisopropylamine (0.1 ml). The reaction mixture was stirred at room temperature for 30 minutes, to which was added a THF (3 ml) solution of 1-phenylpiperazine (63 mg) and N-ethyldiisopropylamine (0.1 ml). The reaction mixture was further stirred at room temperature for 3 hours, then concentrated. The residue was purified by alumina column chromatography (eluent: ethyl acetate/methanol=10/1) to obtain the entitled compound (55 mg) as an amorphous powder.

IR(KBr) : 2820, 1632, 1489, 1233, 743 cm⁻¹

The following compounds of Examples 140 and 141 were synthesized by similar manner as in Example 139.

Example 140

6-Chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidinocarbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline.




IR(KBr) : 2969, 2938, 1698, 1632, 1485, 741 cm⁻¹.

Example 141

1-Benzoyl-N-[(R)-2-[6-chloro-3-[(N,N-dimethylamino)methyl]-1,2,3,4-tetrahydroquinolin-1-yl]-1-[3-(indol-3-yl)propanoyl]-4-piperidinecarboxamide


methyl)-2-oxoethyl



WSC (68 mg) was added to the mixture of 1-[2-(R)-amino-3-(indol-3-yl)propanoyl]-6-chloro-3-(R,S)-[(N,N-dimethylamino)methyl]-1,2,3,4-tetrahydroquinoline (100 mg), 1-benzoyl-4-piperidinecarboxylic acid (60 mg) and HOBT (41 mg) in acetonitrile (5 ml). The reaction mixture was stirred at room temperature for 16 hours. 10% Aqueous potassium carbonate solution was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by alumina column chromatography (eluent: ethyl acetate/ methanol =10/1) to obtain the entitled compound (151 mg) as an amorphous powder.

IR(KBr): 3281, 2942, 1634, 1487, 1447, 1281, 1231, 741, 710 cm⁻¹.

Example 142
N-[2-(R)-[3-(R,S)-[(N,N-Dimethylamino)methyl]-1,2,3,4-tetrahydroquinolin-1-yl]-1-[3-(indol-3-yl)propanoyl]-3-phenylpropanamide




WSC (84 mg) was added to the mixture of 1-[2-(R)-amino-3-(indol-3-yl)propanoyl]-3-(R,S)-[(N,N-dimethylamino)methyl]-1,2,3,4-tetrahydroquinoline (150

mg); 3-phenylpropionic acid (63 mg) and HOBT (66 mg) in acetonitrile (10 ml). The reaction mixture was stirred at room temperature for 16 hours. 10% Aqueous potassium carbonate solution was added to the reaction mixture, which 5 was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by alumina column chromatography (eluent: ethyl acetate) to obtain the entitled compound (169 mg) as an amorphous 10 powder.

IR(KBr) : 3299, 2938, 1630, 1493, 743 cm⁻¹.

Example 143

15 N-[2-(R)-[3-(R,S)-[(N,N-Dimethylamino)methyl]-1,2,3,4-tetrahydroquinolin-1-yl]-1-[3-(indol-3-yl)propanoyl]-4-phenylbutanamide




Synthesis was conducted by the similar method as in Example 142.

20 IR(KBr) : 3299, 2938, 1632, 1493, 743 cm⁻¹.

Example 144

25 1-[3-(4-Biphenylyl)propanoyl]-3-(R)-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




Synthesis was conducted by the similar method as in Example 1.

m.p. 130-130.5°C (Solvent for recrystallization: 5 ethanol/ethyl acetate).

$[\alpha]_D^{20} = -14.2^\circ$ (C=0.374% in methanol).

Example 145

1-[3-(4-Biphenylyl)propanoyl]-3-(S)-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




Synthesis was conducted by the similar method as in Example 1.

m.p. 130-130.5°C (Solvent for recrystallization: 15 ethanol/ethyl acetate).

$[\alpha]_D^{20} = +12.8^\circ$ (C=0.3825% in methanol).

Example 146

20 1-[2-(R)-Amino-3-(indol-3-yl)propanoyl]-3-(R,S)-(N-benzyloxycarbonylamino)methyl-1,2,3,4-tetrahydroquinoline




A THF (5 ml) solution of oxalyl chloride (0.45 ml) was added dropwise to a THF (20 ml) solution of N-(9-fluorenylmethoxycarbonyl)-D-tryptophan (1.83 g) and DMF (5 drops) at 0°C. The reaction mixture was stirred at room temperature for 30 minutes, then concentrated. The residue was dissolved in ethyl acetate (5 ml), which was added dropwise to the mixture of an ethyl acetate (20 ml) solution of 3-(N-benzyloxycarbonylamino)methyl-1,2,3,4-tetrahydroquinoline (425 mg) and 10% aqueous sodium carbonate solution (20 ml) at 0°C. The reaction mixture was stirred at room temperature for one hour, and the organic layer was separated. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by alumina column chromatography (eluent: ethyl acetate/hexane=1:1) and then silica gel column chromatography (eluent: ethyl acetate/hexane=1:1 to ethyl acetate). The obtained purified product was dissolved in methanol (20 ml). Piperidine (1 ml) was added to the reaction mixture, which was stirred at room temperature for 5 hours. The reaction mixture was concentrated, and the residue was purified by alumina column chromatography (eluent: ethyl acetate to ethyl acetate/methanol=10:1) to obtain the entitled compound (390 mg) as an amorphous powder.

IR(KBr): 3289, 2921, 1705, 1645, 1493, 1248, 745 cm⁻¹.

Example 147

30 3-(R,S)-(N-Benzylloxycarbonylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-

yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline




N,N'-Disuccinimidyl carbonate (160 mg) and N-ethyldiisopropylamine (0.21 ml) were added to an acetonitrile (9 ml) solution of 1-[2-(R)-amino-3-(indol-3-yl)propanoyl]-3-(N-benzyloxycarbonylamino)methyl-1,2,3,4-tetrahydroquinoline (300 mg). The reaction mixture was stirred at room temperature for 30 minutes, to which was added an acetonitrile (1.5 ml) solution of 1-phenylpiperazine (101 mg) and N-ethyldiisopropylamine (0.11 ml). The reaction mixture was further stirred at room temperature for one hour. A saturated aqueous sodium hydrogencarbonate solution was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate/hexane=3:1) to obtain the entitled compound (390 mg) as an amorphous powder.

IR(KBr): 3295, 2921, 1705, 1634, 1495, 1235, 756 cm⁻¹.

Example 148

25 3-(R,S)-Aminomethyl-1-[3-(indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline




10% Palladium-carbon (25 mg) was added to a methanol (5 ml) solution of 3-(N-benzyloxycarbonylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline (250 mg), and catalytic hydrogenation was conducted at room temperature under an atmospheric pressure for 24 hours. The catalyst was removed by filtration, and the filtrate was concentrated to give the entitled compound (200 mg) as an amorphous powder.

IR(KBr): 2915, 2855, 1634, 1599, 1493, 1233, 762 cm⁻¹.

Example 149

1-[3-(4-Biphenylyl)propanoyl]-7-chloro-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




Oxalyl chloride (0.11 ml) and DMF (one drop) were added to a THF (10 ml) solution of 3-(4-biphenylyl)propionic acid (249 mg) at 0°C. The reaction mixture was stirred at room temperature for one hour. The residue was dissolved in THF (5 ml), which was added dropwise to a THF (10 ml) solution of 7-chloro-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline (220 mg) and triethylamine (0.17 ml) at 0°C. The reaction mixture was stirred at room

temperature for one hour. 10% Aqueous potassium carbonate solution was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by silica gel column chromatography (eluent: hexane/ethyl acetate=4/1), which was further converted into its p-toluenesulfonate. The mixture was recrystallized from ethanol-diethyl ether to give the entitled compound (528 mg).

m.p. 144-145°C.

Example 150

1-[2-(R)-Amino-3-(indol-3-yl)propanoyl]-7-chloro-
15 3-(R,S)-(N,N-dimethylamino)methyl-1,2,3,4-
tetrahydroquinoline



A THF (10 ml) solution of oxalyl chloride (1.6 ml) was added dropwise to a THF (50 ml) solution of N-(9-fluorenylmethoxycarbonyl)-D-tryptophan (6.444 g) and DMF (0.14 ml) at 0°C. The reaction mixture was stirred at 0°C for one hour, then concentrated. An ethyl acetate (15 ml) solution of the residue was added dropwise to the mixture of an ethyl acetate (30 ml) solution of 7-chloro-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline (1.128 g) and a saturated aqueous sodium bicarbonate solution (25 ml) at 0°C. The reaction mixture was stirred at room temperature for one hour, and the organic layer was separated. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by alumina column chromatography (eluent: hexane/ethyl acetate=1/1) to


obtain 7-chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[2-(R)-(9-fluorenylmethoxy)carbonylamino-3-(indol-3-yl)propanoyl]-1,2,3,4-tetrahydroquinoline (107.4 g).

Piperidine (1.4 ml) was added to a methanol (30 ml) solution of this compound at room temperature. The reaction mixture was stirred at room temperature for 15 hours, then concentrated. The residue was purified by alumina column chromatography (eluent: ethyl acetate/methanol=10/1) to obtain the entitled compound (1.012 g).

IR(KBr) : 3293, 2938, 1651, 1487, 1456, 1412, 1354, 1094, 743 cm⁻¹.

Example 151

7-Chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline



N,N'-Disuccinimidyl carbonate (96 mg) was added to an acetonitrile (5 ml) solution of 1-[2-(R)-amino-3-(indol-3-yl)propanoyl]-7-chloro-3-(R,S)-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline (153 mg) and N-ethyldiisopropylamine (0.13 ml). The reaction mixture was stirred at room temperature for 30 minutes, to which was added a THF (5 ml) solution of 1-phenylpiperazine (62 mg) and N-ethyldiisopropylamine (0.07 ml). The reaction mixture was further stirred at room temperature for 15 hours. 10% Aqueous potassium carbonate solution was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by alumina column chromatography (eluent: ethyl acetate/methanol=10/1) to

obtain the entitled compound (148 mg) as an amorphous powder.


IR(KBr): 3262, 2971, 1636, 1599, 1489, 1233, 995, 758, 743, 694 cm⁻¹.

5

The following compounds of Examples 152 and 153 were synthesized by similar manner as in Example 151.

Example 152


10 7-Chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidinocarbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline



15 IR(KBr): 3225, 2971, 1694, 1485, 1246, 1235, 741, 696 cm⁻¹.

Example 153

20 1-Benzoyl-N-[(R)-2-[7-chloro-3-[(dimethylamino)methyl]-1,2,3,4-tetrahydroquinolin-1-yl]-1-[3-(indol-3-yl)propanoyl]-4-piperidincarboxamide




WSC (97 mg) was added to the mixture of 1-[2-(R)-amino-3-(indol-3-yl)propanoyl]-7-chloro-3-(R,S)-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline (159

mg), 1-benzoyl-4-piperidinecarboxylic acid (97 mg) and HOBr (66 mg) in acetonitrile (10 ml). The reaction mixture was stirred at room temperature for 16 hours. 10% Aqueous potassium carbonate solution was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, then dried and concentrated. The residue was purified by alumina column chromatography (eluent: ethyl acetate/methanol=10/1) to obtain the entitled compound (239 mg) as an amorphous powder.

IR(KBr) : 3279, 2942, 1634, 1447, 1281, 741, 710 cm⁻¹.

Example 154

15 7-Acetylmino-1-[3-(4-biphenylyl)propanoyl]-3-(N,N-dimethylamino)methyl-1,2,3,4-tetrahydroquinoline p-toluenesulfonate




The entitled compound was synthesized by the similar manner as in Example 1.

20 m.p.: 234-236°C. (Solvent for recrystallization: ethanol).

Example 155

25 1-[3-(4-Biphenylyl)propanoyl]-3-(N,N-dimethylamino)methyl-7-methoxy-1,2,3,4-tetrahydroquinoline



The entitled compound was synthesized by the similar manner as in Example 1.

Amorphous powder

5 ¹H-NMR(CDCl₃) δ: 1.8-2.4(4H, m), 2.18(6H, s),
2.64-3.14(5H, m), 3.16-3.36(1H, m), 3.76(3H, s), 3.92-
4.10(1H, m), 6.67(1H, dd), 7.04(1H, d), 7.14-7.62(1H, m).

Formulation Example 1

10	(1) Compound obtained in Example 56	50.0 mg
	(2) Lactose	34.0 mg
	(3) Corn Starch	10.6 mg
	(4) Corn Starch (pasty)	5.0 mg
	(5) Magnesium Stearate	0.4 mg
15	(6) Carboxymethyl Cellulose Calcium	20.0 mg
	Total	120.0 mg

The above (1) to (6) were admixed in an ordinary manner, and tabletted using a tabletting machine, to obtain 20 tablets.

Experimental Example 1

The followings are some examples of the pharmacological actions of the compounds of the present invention, which should not be construed as being limiting to them. The genetic operation using *E. coli* was conducted in accordance with the method described in the 1989 Edition of Molecular Cloning.

30 (1) Cloning of human somatostatin receptor protein subtype 4 (hSSTR4) DNA

DNA oligomers S4-1 and S4-2 were synthesized based on

the known human SSTR4 DNA sequence (Rohrer et al., Proc. Natl. Acad. Sci., USA 90, 4196-4200, 1993). The sequence of S4-1 is 5'-GGCTCGAGTCACCATGAGCGCCCCCTCG-3' (Sequence No. 1) and that of S4-2 is 5'-GGGCTCGAGCTCCTCAGAAGGTGGTGG-3'.

5 (Sequence No. 2). Human chromosome DNA (Clone Tech Inc. Catalog No. CL6550-1) was used as the template. To 0.5 ng of said DNA was added 25 pmol of each of the above mentioned DNA oligomers and the polymerase chain reaction was carried out using 2.5 units of PfuDNA polymerase (Stratagene). The

10 composition of the reaction mixture was in accordance with the directions attached to said PfuDNA polymerase. The conditions of the reaction were as follows: One cycle consisting of the reactions at 94°C for 1 minute, at 66°C for 1 minute and at 75°C for 2 minutes, and 35 cycles were

15 repeated. The reaction mixture was subjected to electrophoresis on 1 % agarose gel to find that the DNA fragments of the intended size (about 1.2 kb) was specifically amplified. Said DNA fragments were recovered from the agarose gel in the usual manner and connected to

20 pUC118 cleaved at the Hinc II site to transform into the competent cells, *Escherichia coli* JM109. The transformant having plasmid containing said DNA fragments was selected out and the sequence of the intercalated DNA fragments was confirmed by the automatic sequence analyzer employing

25 fluorochroming, ALF DNA Sequencer (Pharmacia). As the results, the amino acid sequence expected from the base sequence was completely in agreement with the sequence described in the above-mentioned reports by Rohrer et al.

(2) Organization of the expression plasmid of human somatostatin receptor protein subtype 4 (hSSTR4). DNA pAKKO-111 was used as the expression vector in CHO (Chinese Hamster Ovary) cells. pAKKO-111 was organized as follows: The 1.4 kb DNA fragment containing SRα promoter and poly A appositional signal was obtained from pTB1417 described in the official gazette JPA-H5(1993)-076385 by treatment with a restriction enzyme (Hind III) and a

restriction enzyme (Cla I). On the other hand, the 4.5 kb DNA fragment containing dihydrofolic acid reductase gene (dhfr) was obtained from pTB348 [Naruo, K. et al., Biochem. Biophys. Res. Commun., 128, 256-264, 1985] by treatment 5 with a restriction enzyme (Cai I) and a restriction enzyme (Sal I). These DNA fragments were treated with T4 polymerase to make the terminal blunt-ended and connected with T4 ligase to organize pAKKO-111 plasmid. Then, 5 µg of the plasmid having human SSTR4 DNA fragment was digested 10 with a restriction enzyme (XhoI) and subjected to electrophoresis on 1 % agarose gel to recover the 1.2 kb DNA fragment coded with human SSTR4. Next, 1 µg of the above-mentioned expression vector pAKKO-111 (5.5 kb) was digested with Sal I to prepare the cloning site for 15 intercalation of human SSTR4 DNA fragment. Said expression vector fragment and the 1.2 kb DNA fragment were combined using T4DNA ligase. The reaction mixture was transduced into *E. coli* JM 109 by the calcium chloride method to obtain the expression plasmid pA1-11-SSTR4 in 20 which human SSTR4 DNA fragment was intercalated from the transformants in regular sequence against the promoter.

This transformant is expressed as *Escherichia coli*

JM109/pA-1-11-hSSTR4.

(3) Transfection and expression of human somatostatin

25 receptor protein subtype 4 (hSSTR4) DNA in CHO (dhfr⁻) cells
1 × 10⁶ CHO (dhfr⁻) cells were cultured for 24 hours in HAM F12 medium containing 10 % bovine fetal serum on a laboratory dish of 8 cm in diameter. To the cells was transfected 10 µg of the human SSTR4 DNA expression plasmid, 30 pA-1-11-hSSTR4 obtained above by the calcium phosphate method (Cell Pfect Transfection Kit; Pharmacia). The medium was switched to Dulbecco's Modified Eagle Medium (DMEM) containing 10 % dialyzed bovine fetal serum 24 hours after the transfection to select the colony-forming cells 35 (i.e. dhfr⁻ cells) in this medium. Further, the selected cells were cloned from a single cell by the limiting

dilution method and the somatostatin receptor protein expression activity of these cells was measured as follows:

Human SSTR4 receptor expression cell strain was diluted with a buffer solution for assay [50 mM of tris

5 hydrochloride, 1 mM of EDTA, 5 mM of magnesium chloride, 0.1% of BSA, 0.2 mg/ml of bacitracin, 10 μ g/ml of leupeptin, 1 μ g/ml of pepstatin and 200 units/ml of aprotinin (pH 7.5)] to adjust the cell count to 2×10^4 /200 μ l. 200 μ l of the

dilution was placed in a tube and to this was added 2 μ l

10 of 5nM [125 I]-somatostatin-14 (2000 Ci/mmol, Amersham). The mixture was incubated at 25°C for 60 minutes. For

measurement of non-specific binding (NSB), the tube to

which 2 μ l of somatostatin-14 (10^{-4} M) was added was also incubated.

To the tube was added 1.5 ml of a buffer solution

15 for washing [50 mM of tris hydrochloride, 1 mM of EDTA and 5 mM of magnesium chloride (pH 7.5)] and the mixture was filtered by GF/F glass fiber filter paper (Whatman) and washed further with 1.5 ml of the same buffer solution.

20 [125 I] of the filter was measured by a γ -counter. Thus, a highly somatostatin-binding cell strain, hSSTR4-1-2, was selected.

(4) Cloning of rat somatostatin receptor protein subtype

25 rSSTR4-DNA

DNA oligomers S4-3 and S4-4 were synthesized based on

the known rat SSTR4-DNA sequence (Bito H et al., J. Biol.

Chem., 269, 12722-12730, 1994). The sequence of S4-3 is

25'-AAGCATGAACACGCCCTGCAACTC-3' (Sequence No. 3) and that of

S4-4 is 5'-GGTTTCAGAAAGTAGTGGTCTT-3'. (Sequence No. 4).

As the template, a chromosome DNA prepared from

30 Sprague-Dawley rats by using Easy-DNA™ KIT (Invitrogen) was used. To 0.5 ng of said DNA was added 25 pmol of each

of the above mentioned DNA oligomers and the polymerase

chain reaction was carried out using TaKaRa LAPCR KIT

(TaKaRa). The conditions of the reaction were as follows:

35 One cycle consisting of the reactions at 95°C for 30 seconds,

at 65°C for 2 minutes and 30 seconds, and 30 cycles were repeated. The reaction mixture was subjected to electrophoresis on 1 % agarose gel to find that the DNA fragments of the intended size (about 1.2 kb) was specifically amplified. Said DNA fragments were recovered from the agarose gel in the usual manner and connected to a vector (pCR™ 2.1 (Trade name)) of ORIGINALTA CLONINGKIT (Invitrogen) to transform into the competent cells, *Escherichia coli* JM109. The transformant having plasmid containing said DNA fragments was selected out and the sequence of the intercalated DNA fragments was confirmed by the automatic sequence analyzer employing fluorescencing, ALF DNA Sequencer (Pharmacia). As the results, the amino acid sequence expected from the base sequence was completely in agreement with the sequence described in the above-mentioned reports by Bito.H et al.

(5) Organization of the expression plasmid of rat somatostatin receptor protein subtype 4 (rSSTR4) DNA pAKKO-111 was used as the expression vector in CHO cells. 5 µg of the plasmid having rat SSTR4 DNA fragment obtained above was digested with a restriction enzyme (EcoRI), treated with T4DNAPolymerase, and subjected to electrophoresis on 1 % agarose gel to recover the 1.2 kb DNA fragment coded with rat SSTR4. Next, 1 µg of the above-mentioned expression vector pAKKO-111 (5.5 kb) was digested with a restriction enzyme (ClaI), treated with T4DNAPolymerase and Alkaline Phosphatase, to prepare the cloning site for intercalation of rat SSTR4 DNA fragment. Said expression vector fragment and the 1.2 kb DNA fragment were combined using T4DNA ligase. The reaction mixture was transduced into *E. coli* JM 109 by the calcium chloride method to obtain the expression plasmid pA1-11-rSSTR4 in which rat SSTR4 DNA fragment was intercalated from the transformants in regular sequence against the promoter. This transformant is expressed as *Escherichia coli* JM109/pA-1-11-rSSTR4.

(6) Transfection and expression of rat somatostatin receptor protein subtype 4 (rSSTR4) DNA in CHO (dhfr⁻) cells

1 × 10⁶ CHO (dhfr⁻) cells were cultured for 24 hours in α-MEM medium (containing ribonucleoside and

5 deoxynucleoside) containing 10 % bovine fetal serum on a laboratory dish of 8 cm in diameter. To the cells was transfected 10 µg of the rat SSTR4 DNA expression plasmid 1, pA-1-11-rSSTR4 obtained above by the calcium phosphate method (Cell Pfect Transfection Kit; Pharmacia). The

10 medium was switched to α-MEM medium (free of ribonucleoside and deoxynucleoside) containing 10 % dialyzed bovine fetal serum 24 hours after the transfection to select the colony-forming cells (i.e. dhfr⁺ cells) in this medium.

Further, the selected cells were cloned from a single cell 15 by the limiting dilution method and the somatostatin receptor protein expression activity of these cells was measured by the binding method mentioned above. Thus, a highly somatostatin-binding cell strain, rSSTR4-20-25, was selected.

20 (7) Preparation of CHO cell membrane fractions containing somatostatin receptor 4

Human and rat somatostatin receptor 4 expression CHO cell strain, hSSTR4-1-2 or rSSTR4-20-25 (1 × 10⁹) was floated on a phosphate buffered saline supplemented with 25 5 mM EDTA (PBS-EDTA) and centrifuged. To the cell pellets was added 10 ml of a homogenate buffer for cells (10 mM NaHCO₃, 5 mM EDTA, pH7.5), which was homogenated using a politron homogenizer. The supernatant obtained by centrifugation at 400 × g for 15 minutes was further centrifuged at 10,000

30 × g for 1 hour to give a precipitate of the membrane fraction.

The precipitates were suspended in 2 ml of a buffer solution for assay [25 mM of Tris-HCl, 1 mM of EDTA (Ethylenediaminetetraacetic Acid), 0.1% of BSA (Bovine Serum Albumin), 0.25 mM of PMSF (Phenylmethylsulfonyl Fluoride), 1 µg/ml pepstatin, 20 µg/ml leupeptin, 10 µg/ml

Phosphoramidone, pH7.5], which was centrifuged at 100,000 × g for 1 hour. The membrane fraction recovered as precipitates was suspended again in 20 ml of the buffer solution for assay, which was placed in tubes and stored at -80°C. The suspension was thawed and used at every use.

Experimental Example 2

(1) Cloning of human somatostatin receptor protein subtype 1 (SSTR1) DNA

10 DNA oligomers S1-1 and S1-2 were synthesized based on the known human SSTR1c DNA sequence (Proc. Natl. Acad. Sci., USA 89, 251-255, 1992). The sequence of S1-1 is 5'-GGTCGACCTCAGCT AGGATGTTCCCCAATG-3' (Sequence No. 5) and that of S1-2 is 5'-GGTCGACCCGGGCTCAGAGCGTCGTGAT-3'

15 Human chromosome DNA (Clone Tech Inc. Catalog No. CL 6550-1) was used as the template. To 0.5 μg of said DNA was added 25 pmol of each of the above mentioned DNA oligomers and the polymerase chain reaction was carried out using 2.5 units of PfuDNA polymerase

20 (Stratagene). The composition of the reaction mixture was in accordance with the directions attached to said PfuDNA polymerase. The conditions of the reaction were as

follows: One cycle consisting of the reactions at 94°C for 1 minute, at 63°C for 1 minute and at 75°C for 2 minutes,

25 and 35 cycles were repeated. The reaction mixture was subjected to electrophoresis on 1 % agarose gel to find that the DNA fragments of the intended size (about 1.2 kb) was specifically amplified. Said DNA fragments were recovered from the agarose gel in the usual manner and connected to

30 pUC118 cleaved at the Hinc II site to transform into the competent cells, *Escherichia coli* JM109. The transformant having plasmid containing said DNA fragments was selected out and the sequence of the intercalated DNA fragments was confirmed by the automatic sequence analyzer employing fluorochroming, ALF DNA Sequencer (Pharmacia). As the results, the amino acid sequence expected from the base

sequence was completely in agreement with the sequence described in the above-mentioned literature.

(2) Organization of the expression plasmid of human somatostatin receptor protein subtype 1 (SSTR1) DNA

5 pAKKO-111 was used as the expression vector in CHO (Chinese Hamster Ovary) cells. PAKKO-111 was organized as follows: The 1.4 kb DNA fragment containing SRα promoter and poly A appositional signal was obtained from pTB1417 described in the official gazette JPA-H5(1993)-076385 by
10 treatment with Hind III and Cla I. On the other hand, the 4.5 kb DNA fragment containing dihydrofolic acid reductase (DHFR) gene was obtained from pTB348 [Biochem. Biophys. Res. Commun., 128, 256-264, 1985] by treatment with Cal I and Sal I. These DNA fragments were treated with T4 polymerase
15 to make the terminal blunt-ended and connected with T4 ligase to organize pAKKO-111 plasmid. Then, 5 µg of the plasmid having human SSTR1 DNA fragment obtained under the above (1) was digested with the restriction enzyme Sal I and subjected to electrophoresis on 1 % agarose gel to
20 recover the 1.2 kb DNA fragment coded with human SSTR1.
Next, 1 µg of the above-mentioned expression vector
pAKKO-111 (5.5 kb) was digested with Sal I to prepare the cloning site for intercalation of human SSTR1 DNA fragment.
Said expression vector fragment and the 1.2 kb DNA fragment
25 were combined using T4DNA ligase. The reaction mixture was transduced into *E. coli* JM 109 by the calcium chloride method to obtain the expression plasmid pA1-11-SSTR1 in which human SSTR1 DNA fragment was intercalated from the transformants in regular sequence against the promoter.
30 This transformant is expressed as *Escherichia coli* JM109/pA-1-11-SSTR1.

(3) Transfection and expression of human somatostatin receptor protein subtype 1 (SSTR1) DNA in CHO (dhfr^r) cells

35 1 × 10⁶ CHO (dhfr^r) cells were cultured for 24 hours in HAM F12 medium containing 10 % bovine fetal serum on a laboratory dish of 8 cm in diameter. To the cells was

transfected 10 µg of the human SSTR1c DNA expression plasmid 1, pA-1-11-SSTR1, obtained under the above (2) by the calcium phosphate method (Cell Pfect Transfection Kit: Pharmacia). The medium was switched to DMEM medium 5 containing 10 % dialyzed bovine fetal serum 24 hours after the transfection to select the colony-forming cells (i.e. DHFR+ cells) in this medium. Further, the selected cells were cloned from a single cell by the limiting dilution method and the somatostatin protein activity was measured 10 as follows: Human SSTRc DNA expression cell strain was diluted with a buffer solution for assay [50 mM of tris hydrochloride, 1 mM of EDTA, 5 mM of magnesium chloride, 0.1% of BSA, 0.2 mg/ml of bacitracin, 10µg/ml of leupeptin, 1µg/ml of pepstatin and 200 units/ml of aprotinin (pH 7.5)] 15 to adjust the cell count to 2×10^4 /200µl. 200 µl of the dilution was placed in a tube and to this was added 2 µl of 5nM [125 I]-somatostatin-14 (2000 Ci/mmol, Amersham). The mixture was incubated at 25°C for 60 minutes. For measurement of non-specific binding (NSB), the tube to 20 which 2µl of somatostatin-14 (10^{-4} M) was added was also incubated. To the tube was added 1.5 ml of a buffer solution for washing [50 mM of tris hydrochloride, 1 mM of EDTA and 5 mM of magnesium chloride (pH 7.5)] and the mixture was filtered by GF/F glass fiber filter paper (Whatman) and washed further with 1.5 ml of the same buffer solution. 25

[125 I] of the filter was measured by a γ -counter. Thus, a highly somatostatin-binding cell strain, SSTR1-8-3, was selected.

(4) Cloning of human somatostatin receptor protein subtype
30 2 (SSTR2) DNA
DNA oligomers PT-1 and PT-2 were synthesized based on the known human SSTR2c DNA sequence (Proc. Natl. Acad. Sci., USA 89: 251- 255, 1992). The sequence of PT-1 is 5'-GGTCGACACCATGGACATGGCGGATGAG-3' (Sequence No. 7) and that 35 of PT-2 is 5'-GGTCGACAGTTCAGATACTGGTTGG-3' (Sequence No.

8). Human pituitary gland cDNA (Clone Tech Inc. Catalog No. 7173-1) was used as the template. To 1 ng of said cDNA was added 25 pmol of each of the above mentioned DNA oligomers and the polymerase chain reaction was carried out

5 using 2.5 units of TaqDNA polymerase (Takara Shuzo). The composition of the reaction mixture was in accordance with the directions attached to said TaqDNA polymerase. The conditions of the reaction were as follows: One cycle consisting of the reactions at 94°C for 30 seconds, at 52°C

10 for 20 seconds and at 72°C for 60 seconds, and 30 cycles were repeated. The reaction mixture was subjected to electrophoresis on 1 % agarose gel to find that the DNA fragments of the intended size (about 1.1 kb) was specifically amplified. Said DNA fragments were recovered

15 from the agarose gel in the usual manner and connected to pUC118 cleaved at the Hinc II site to transform into the competent cells, *Escherichia coli* JM109. Two strains (No. 5 and No. 7) of the transformant having plasmid containing said DNA fragments were selected out and the sequence of

20 the intercalated DNA fragments was confirmed by the automatic sequence analyzer employing fluorochroming, 373A DNA Sequencer (Applied Biosystem). As the results, point mutation was confirmed at one site in the sequence of the 770 base fragment of No. 5 strain between Sal I and Bst PI,

25 and point mutation was also confirmed at one site in the sequence of the 360 base fragment of No. 7 strain between Bst PI and Sal I. Therefore, the fragments remaining after removing the Bst PI-Sal I fragment of No. 5 strain and the Bst PI-Sal I fragment of No. 7 strain were purified by

30 electrophoresis on agarose to organize a plasmid in which these fragments were bound by the ligation reaction.

Confirmation of the insertion sequence of the DNA fragment of this plasmid revealed that it was completely in agreement with the sequence described in the above literature.

35 (5) Organization of the expression plasmid of human somatostatin receptor protein subtype 2 (SSTR2) DNA

pAKKO-111 mentioned under the above (2) was used as the expression vector in CHO (Chinese Hamster Ovary) cells.

5 5 µg of the plasmid having human SSTR2 cDNA fragment obtained under the above (4) was digested with the restriction enzyme Sal I and subjected to electrophoresis on 1 % agarose gel to recover the 1.1 kb DNA fragment coded with human SSTR2. Next, 1 µg of the above-mentioned expression vector pAKKO-111 (5.5 kb) was digested with Sal I to prepare the cloning site for intercalation of human SSTR2 DNA fragment. Said expression vector fragment and the 1.1 kb DNA fragment were combined using T4DNA ligase.

10 The reaction mixture was transduced into *E. coli* JM 109 by the calcium chloride method to obtain the expression plasmid pAC01 in which human SSTR2 DNA fragment was intercalated from the transformants in regular sequence against the promoter. This transformant is expressed as *Escherichia coli* JM109/pAC-01.

15 (6) Transfection and expression of human somatostatin receptor protein subtype 2 (SSTR2) DNA in CHO (dhfr⁻) cells

20 1 × 10⁶ CHO (dhfr⁻) cells were cultured for 24 hours in HAM F12 medium containing 10 % bovine fetal serum on a laboratory dish of 8 cm in diameter. To the cells was transfected 10 µg of the human SSTR2 cDNA expression plasmid, pA-C01, obtained under the above (5) by the calcium phosphate method (Cell Pfect Transfection Kit: Pharmacia).

25 The medium was switched to DMEM medium containing 10 % dialyzed bovine fetal serum 24 hours after the transfection to select the colony-forming cells (i.e. DHFR⁺ cells) in this medium. Further, the selected cells were cloned from a single cell by the limiting dilution method and a cell strain which highly expresses human SSTR2, SSTR2-HS5-9, was selected.

30 (7) Cloning of human somatostatin receptor protein subtype 3 (SSTR3) DNA

35 DNA oligomers S3-1 and S3-2 were synthesized based on the known human SSTR3c DNA sequence (Mol. Endocrinol., 6:

2136-2142, 1992). The sequence of S3-1 is 5'-GGTCGACCTCAACCATGGACATGCTTCATC-3' (Sequence No. 9) and that of S3-2 is 5'-GGTCGACTTCCCCAGGCCCTACAGGTA-3' (Sequence No. 10). Human chromosome DNA (Clone Tech Inc. Catalog No. CL6550-1) was used as the template. To 0.5 ng of said DNA was added 25 pmol of each of the above mentioned DNA oligomers and the polymerase chain reaction was carried out using 2.5 units of PfuDNA polymerase (Strata gene). The composition of the reaction mixture was in accordance with the directions attached to said PfuDNA polymerase. The conditions of the reaction were as follows: One cycle consisting of the reactions at 94°C for 1 minute, at 63°C for 1 minute and at 75°C for 2 minutes, and 35 cycles were repeated. The reaction mixture was subjected to electrophoresis on 1 % agarose gel to find that the DNA fragments of the intended size (about 1.3 kb) was specifically amplified. As the results, the amino acid sequence expected from the base sequence was completely in agreement with the sequence described in the above-mentioned literature.

(8) Organization of the expression plasmid of human somatostatin receptor protein subtype 3 (SSTR3) DNA pAKKO-111 mentioned under the above (2) was used as the expression vector in CHO cells. 5 µg of the plasmid having human SSTR3 DNA fragment obtained under the above (7) was digested with the restriction enzyme Sal I and subjected to electrophoresis on 1 % agarose gel to recover the 1.3 kb DNA fragment coded with human SSTR3. Next, 1 µg of the above-mentioned expression vector pAKKO-111 (5.5 kb) was digested with Sal I to prepare the cloning site for intercalation of human SSTR3 DNA fragment. Said expression vector and the 1.3 kb DNA fragment were combined using T4DNA ligase. The reaction mixture was transduced into *E. coli* JM 109 by the calcium chloride method to obtain the expression plasmid pA1-11-SSTR3 in which human SSTR3 DNA fragment was intercalated from the transformants in

regular sequence against the promoter. This transformant is expressed as *Escherichia coli* JM109/pA-1-11-SSTR3.

(9) Transfection and expression of human somatostatin receptor protein subtype 3 (SSTR3) DNA in CHO (dhfr⁻) cells

5 1×10^6 CHO (dhfr⁻) cells were cultured for 24 hours in HAM F12 medium containing 10 % bovine fetal serum on a laboratory dish of 8 cm in diameter. To the cells was transfected 10 µg of the human SSTR3 DNA expression plasmid, pA-1-11-SSTR3, obtained under the above (5) by the calcium phosphate method. The medium was switched to DMEM medium containing 10 % dialyzed bovine fetal serum 24 hours after the transfection to select the colony-forming cells (i.e. DHFR⁺ cells) in this medium. Further, the selected cells were cloned from a single cell by the limiting dilution 10 method and the somatostatin receptor protein expression activity of these cells was measured by the binding assay 15 mentioned under the above (3). Thus, a highly somatostatin-binding cell strain, SSTR3-15-19, was selected.

20 (10) Cloning of human somatostatin receptor protein subtype (SSTR5) DNA

DNA oligomers S5-1 and S5-2 were synthesized based on the known human SSTR5c DNA sequence (Biochem Biophys. Res. Commun., 195, 844-852, 1993). The sequence of S5-1 is 25 5'-GGTCGACCAACCATGGAGCCCTGTTCCC-3' (Sequence No. 11) and that of S5-2 is 5'-CCGTCGACACTCTCACAGCTTGCTGG-3' (Sequence No. 12). Human chromosome DNA (Clone Tech Inc. Catalog No. CL6550-1) was used as the template. To 0.5 ng of said DNA was added 25 pmol of each of the above mentioned DNA 30 oligomers and the polymerase chain reaction was carried out using 2.5 units of PfuDNA polymerase (Strata gene). The composition of the reaction mixture was in accordance with the directions attached to PfuDNA polymerase. The conditions of the reaction were as follows: One cycle 35 consisting of the reactions at 94°C for 1 minute, at 66°C for 1 minute and at 75°C for 2 minutes, and 35 cycles were

repeated. The reaction mixture was subjected to electrophoresis on 1 % agarose gel to find that the DNA fragments of the intended size (about 1.1 kb) were specifically amplified. Confirmation of the insertion sequence of said DNA fragment by the method mentioned under the above (1) revealed that the amino acid sequence expected from the base sequence was completely in agreement with the sequence described in the above-mentioned literature.

5 10 sequence of said DNA fragment by the method mentioned under the above (1) revealed that the amino acid sequence expected from the base sequence was completely in agreement with the sequence described in the above-mentioned literature.

(11) Organization of the expression plasmid of human somatostatin receptor protein subtype 5 (SSTR5) DNA.

10 15 pAKKO-111 mentioned under the above (2) was used as the expression vector in CHO cells. 5 µg of the plasmid having human SSTR5 DNA fragment obtained under the above (10) was digested with the restriction enzyme Sal I and subjected to electrophoresis on 1 % agarose gel to recover the 1.1 kb DNA fragment coded with human SSTR5. Next, 1 µg of the above-mentioned expression vector pAKKO-111 (5.5 kb) was digested with Sal I to prepare the cloning site for intercalation of human SSTR5 DNA fragment. Said 20 expression vector fragment and the 1.1 kb DNA fragment were combined using T4DNA ligase. The reaction mixture was transduced into *E. coli* JM 109 by the calcium chloride method to obtain the expression plasmid pA1-11-SSTR5 in which human SSTR5 DNA fragment was intercalated from the 25 transformants in regular sequence against the promoter. This transformant is expressed as *Escherichia coli* JM109/pA-1-11-SSTR5, and the name of this plasmid is pA1-11-SSTR5.

(12) Transfection and expression of human somatostatin receptor protein subtype 5 (SSTR5) DNA in CHO (dhfr^r) cells
30 35 1 × 10⁶ CHO (dhfr^r) cells were cultured for 24 hours in HAM F12 medium containing 10 % bovine fetal serum on a laboratory dish of 8 cm in diameter. To the cells was transfected 10 µg of the human SSTR5c DNA expression plasmid, pA-1-11-SSTR5, obtained under the above (11) by the calcium phosphate method. The medium was switched to DMEM medium containing 10 % dialyzed bovine fetal serum 24 hours after

the transfection to select the colony-forming cells (i.e. DHFR⁺ cells) in this medium. Further, the selected cells were cloned from a single cell by the limiting dilution method and the somatostatin receptor protein expression activity of these cells was measured by binding assay mentioned under the above (3). Thus, a highly somatostatin-binding cell strain, SSTR5-3-2-4, was selected.

10 Experimental Example 3

Measurement of the binding inhibition rate of ¹²⁵I-Somatostatin

The receptor binding inhibition rate of the subject compound was calculated using each of the membrane fractions prepared in Experimental Examples 1 and 2. The membrane fraction was diluted with a buffer solution for assay to adjust the concentration to 3 µg/ml. The diluate was placed in tubes each in quantity of 173 µl. To this were simultaneously added 2 µl of a solution of a subject compound in DMSO and 25µl of a 200pM radioisotope-labeled somatostatin-14 (¹²⁵I-somatostatin-14: Amersham). For measurement of the maximum binding, a reaction mixture added with 2 µl of DMSO and 25µl of a 200pM ¹²⁵I-somatostatin was prepared. For measurement of non-specific binding, a reaction mixture added with 2 µl of a 100µM somatostatin solution in DMSO and 25 µl of a 200pM ¹²⁵I-somatostatin solution was prepared at the same time. The mixtures were allowed to react at 25°C for 60 minutes. Then, the reaction mixture was filtered by aspiration using a Whatman glass filter(GF-B) treated with polyethylenimine. After filtration, the radioactivity of ¹²⁵I-somatostatin-14 remaining on the filter paper was measured by a γ-counter.

The binding inhibition rate (%) of each subject compound was calculated by the following formula:

(TB-SB)/(TB-NSB)×100

SB: radioactivity when a compound was added

TB: maximum binding radioactivity

NSB: non-specific binding radioactivity

5 The binding rates were measured by changing the concentrations of the subject compound, and the 50 % inhibiting concentration of the subject compound (IC_{50} value) was calculated by the Hill plots.

Results

10

		IC ₅₀ (μM)		
Example No.	SSTR2	SSTR3	SSTR4	
56			0.007	
88	0.009	0.0008		
15	89	0.003	0.002	

Further, the IC_{50} value of the compound obtained in Example 56 for rat SSTR4 was 10 nM.

This shows that the compound (I) of the present invention have a binding inhibition effect on the human and rat somatostatin receptor.

Experimental Example 4

Inhibitory effect on forskolin-stimulated accumulation of cAMP in rat astrocyte

25 For measurement of the accumulated intracellular adenosine 3',5'-monophosphate (cAMP), newborn rat astrocytes prepared in accordance with the method of McCarthy, K.D. et al. [Cell Biology, 85, 890-920, 1980] were proliferated in 24-well plate until they were confluent.

30 Said cells were washed twice with 1 ml of Medium A [Dulbecco's Modified Eagle Medium (DMEM), 20 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES) (pH 7.5), 0.2 % bovine serum albumin and 0.2 mM 3-isobutyl-1-methylxanthine (IBMX)]. The medium A was placed in wells each in a quantity of 400 μl and incubated at 37°C for an hour. Both 50 μl of a somatostatin-14

solution (final concentration) or a subject compound in various concentrations and 50 μ l of a forskolin solution (final concentration 100 μ M) were placed in each well, which were incubated at 37°C for an hour. The cells were washed 5 twice with 1 ml of Medium A. 500 μ l of Medium A and 100 μ l of a 20% aqueous perchloric acid solution were placed in each well and left standing for 20 minutes at 4°C to lyse the cells. The lyzate was placed in an Eppendorf's tube and centrifuged (15.000 rpm, 10 minutes). The supernatant 10 was placed in another Eppendorf's tube in quantity of 500 μ l and neutralized with 60 mM of a HEPES aqueous solution containing 1.5 M of potassium chloride. The content of cAMP in this extract was determined by the Amersham kit (cAMP EIA system).

15 Results

Somatostatin-14 (10 nM) and the compound obtained in Example 56 (10 nM) inhibit the intracellular accumulation of cAMP at the time of stimulation by forskolin (10 μ M) by 83% and 43%, respectively.

20 This shows that the compound obtained in Example 56 has an agonistic effect on the rat somatostatin receptor.

Industrial Applicability

Compound (I) of the present invention has an excellent 25 somatostatin receptor binding inhibition action with low toxicity.


Compound (I') of the present invention also has an excellent somatostatin receptor binding inhibition action with low toxicity.

30 Therefore, compounds (I) and (I') are useful for disorders of an intracellular signal transduction system (e.g., diseases accompanied by excess sthenia or suppression); diseases accompanied by disorders of regulating cell proliferation; diseases accompanied by 35 disorders of production and(or) secretion of hormones,

growth factors, or physiologically active substances; in a mammal.

CLAIMS

1. A compound of the formula (I):



5 wherein Ar represents an aromatic group which may be substituted;

X represents methylene, S, SO, SO₂ or CO;

Y represents a spacer having a main chain of 2 to 5 atoms;

n represents an integer of 1 to 5;

10 i) R¹ and R² each represents a hydrogen atom or a lower alkyl which may be substituted,

ii) R¹ and R² form, taken together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic ring which may be substituted, or

15 iii) R¹ or R² together with -(CH₂)_n-N= form, bonded to a component atom of Ring B, a spiro-ring, which may be substituted;

Ring A represents an aromatic ring which may be substituted;

Ring B represents a 4- to 7-membered nitrogen-containing non-aromatic ring which may be further substituted by alkyl or acyl, with a proviso that X represents S, SO, SO₂ or CO when Ring A has as a substituent a group represented by the formula: -NHCOR¹¹ where R¹¹ represents alkyl, alkoxyalkyl,

20 25 alkylthioalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or a group represented by the formula: -NHR¹² where R¹² represents alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl, or a salt thereof.

30 2. A compound of claim 1, wherein Ring B represents a 4- to 7-membered nitrogen-containing non-aromatic ring which may be substituted by alkyl.

3. A compound of claim 1, wherein Ar represents an aromatic ring assembly group which may be substituted or a fused aromatic group which may be substituted.

5 4. A compound of claim 1, wherein X represents CO.

5. A compound of claim 1, wherein Y represents a C₂₋₅ alkenylene which may be substituted.

10 6. A compound of claim 5, wherein the substituent of the C₂₋₅ alkenylene represented by Y is acylamino.

7. A compound of claim 1, wherein n represents 1 or 2.


15 8. A compound of claim 1, wherein R¹ and R² each represents a hydrogen atom or a lower alkyl which may be substituted.

9. A compound of claim 1, wherein R¹ and R² form, taken together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic ring which may be substituted.

10 10. A compound of claim 9, wherein the nitrogen-containing heterocyclic ring is pyrrolidine, piperidine, piperazine or morpholine.

25 11. A compound of claim 1, wherein Ring A is a benzene ring which may be substituted.

30 12. A compound of claim 1, which is a compound of the formula:



wherein Ring A' is a benzene ring which may be substituted; Z represents methylene or imino which may be substituted; the other symbols have the same meanings as in claim 1, or a salt thereof.

5

13. A compound of claim 12, wherein Z is methylene.

14. A compound of claim 1, wherein Ar represents

(i) phenyl; 2-, 4- or 5-thiazolyl; 2-, 4- or 5-oxazolyl;

10 2-, 3- or 4-pyridyl; or 1,2,4- or 1,3,4-oxadiazolyl;

(ii) 2-, 3- or 4-biphenyl; 3-(1-naphthyl)-1,2,4-

oxadiazol-5-yl; 3-(2-naphthyl)-1,2,4-oxadiazol-5-yl;

3-(2-benzofuranyl)-1,2,4-oxadiazol-5-yl; 3-phenyl-

1,2,4-oxadiazol-5-yl; 3-(2-benzoxazolyl)-1,2,4-

15 1,2,4-oxadiazol-5-yl; 3-(3-indolyl)-1,2,4-oxadiazol-5-yl; 3-

(2-indolyl)-1,2,4-oxadiazol-5-yl; 4-phenylthiazol-2-yl;

4-(2-benzofuranyl)thiazol-2-yl; 4-phenyl-1,3-oxazol-5-

yl; 5-phenyl-oxazol-2-yl; 4-(2-thienyl)phenyl; 4-(3-

pyridyl)phenyl; 4-(2-naphthyl)phenyl; or 4,4'-terphenyl;

20 or

(iii) 2-, 3- or 4-quinolyl; or 1-, 2- or 3-indolyl;

each of which (i), (ii) and (iii) may be substituted by a group selected from the group consisting of halogen atom; C₁₋₆ alkylenedioxy; optionally halogenated C₁₋₆ alkyl; C₆₋₁₀

aryloxy-C₁₋₆ alkyl; C₁₋₆ alkyl-C₆₋₁₀ aryl-C₂₋₆ alkenyl; C₇₋₁₆

aralkyl optionally substituted by halogen atom or C₁₋₆ alkoxy; hydroxy; C₆₋₁₀ aryloxy optionally substituted by halogen atom or C₁₋₆ alkoxy; optionally halogenated C₁₋₆ alkyl-carbonyl; C₁₋₆ alkoxy-carbonyl; C₆₋₁₀ aryl-carbonyl

25 and C₆₋₁₀ arylsulfonyl optionally substituted by C₁₋₆ alkyl;

X represents methylene, CO or SO₂;


Y represents

(a) C₂₋₅ alkylene which may be substituted by


① cyano,

35 ② C₆₋₁₀ aryl,

③ a group represented by the formula:



wherein J^1 and J^2 each represents CH, C(OH) or N; Q^1 and Q^2 each represents $-(CH_2)_p-$ or $-(CH_2)_p-CO-(CH_2)_q-$ where p and q each represents an integer of 0 to 3;




5 represents (i) a group represented by the formula:



wherein W^1 represents halogen atom, cyano, optionally halogenated C_{1-6} alkyl, optionally halogenated C_{1-6} alkoxy,

10 optionally halogenated C_{1-6} alkyl-carbonyl, nitro or C_{6-10} aryl; (ii) pyridyl, or pyrimidinyl, or
 (iii) a group represented by the formula:



15 wherein W^3 represents hydrogen atom or optionally halogenated C_{1-6} alkyl;


(4) C_{7-16} aralkyloxy-carboxamido;

(5) amino;

(6) C_{7-16} aralkyl-carboxamido;

20 (7) C_{1-6} alkoxy-carbonyl-piperazinyl-carboxamido, or

(8) a group represented by the formula:



wherein W^2 represents optionally halogenated C_{1-6} alkoxy;

(b) C_{2-5} alkenylenè,

(c) $-(CH_2)_m-Y^{1a}-$ wherein m represents an integer of 1 to 4, Y^{1a} represents O or NR^{8a} where R^{8a} represents hydrogen atom or C_{6-10} arylsulfonyl which may be substituted by C_{1-6} alkyl, or

5 (d) $-NH-(CH_2)_r-$ wherein r represents an integer of 1 to 4; n represents 1 or 2;


i) R^1 and R^2 each represents a hydrogen atom or C_{1-6} alkyl which may be substituted by C_{6-10} aryl.

ii) R^1 and R^2 form, taken together with the adjacent

10 nitrogen atom, morpholine, piperidine, piperazine or pyrrolidine, each of which may be substituted by C_{6-10} aryl, or

iii) R^1 together with $-(CH_2)_n-N(R^2)-$ forms, bonded to a component atom of Ring B, a 6-membered spiro-ring


15 represented by the formula:



wherein R^2 represents C_{1-6} alkyl;

Ring A represents benzene ring which may be substituted by C_{1-6} alkoxy, C_{6-10} aryl- C_{7-16} aralkyloxy, halogen atom, or 20 optionally halogenated C_{1-6} alkyl-carboxamido; and

Ring B represents



each of which may be substituted by C_{1-6} alkyl, formyl or C_{1-6} alkyl-carbonyl.

25

15. A compound of claim 14, wherein wherein Y represents

(a) C_{2-5} alkylene which may be substituted by

① cyano,

② C_{6-10} aryl,

30 ③ C_{7-16} aralkyloxy-carboxamido, or

④ amino,

(b) C_{2-5} alkenylene,

(c) $-(CH_2)_m-Y^{1a}-$ wherein m represents an integer of 1 to 4, Y^{1a} represents O or NR^{6a} where R^{6a} represents hydrogen atom

5 or C_{6-10} arylsulfonyl which may be substituted by C_{1-6} alkyl, or

(d) $-NH-(CH_2)_r-$ wherein r represents an integer of 1 to 4.

16. A compound of claim 14, wherein X represents CO;

10 Y represents


(a) C_{2-5} alkylene which may be substituted by

① a group represented by the formula:




wherein J^1 and J^2 each represents CH, C(OH) or N; Q^1 and Q^2

15 each represents $-(CH_2)_p-$ or $-(CH_2)_p-CO-(CH_2)_q-$ where p and q each represents an integer of 0 to 3;





represents (i) a group represented by the formula:



20 wherein W^1 represents halogen atom, "cyano", optionally halogenated C_{1-6} alkyl, optionally halogenated C_{1-6} alkoxy, optionally halogenated C_{1-6} alkyl-carbonyl, nitro, or C_{6-10} aryl;

25 (ii) pyridyl, or pyrimidinyl, or


(iii) a group represented by the formula:




wherein W^3 represents hydrogen atom or optionally halogenated C_{1-6} alkyl.

② C_{7-16} aralkyloxy-carboxamido,

- ③ amino,
- ④ C₇₋₁₆ aralkyl-carboxamido,
- ⑤ C₁₋₆ alkoxy-carbonyl-piperazinyl-carboxamido, or
- ⑥ a group represented by the formula:



5 wherein W² represents optionally halogenated C₁₋₆ alkoxy;
 (b) -(CH)_m-Y^{1a}- wherein m represents an integer of 1 to 4,
 Y^{1a} represents O or NR^{8a} where R^{8a} represents hydrogen atom
 or C₆₋₁₀ arylsulfonyl which may be substituted by C₁₋₆ alkyl,
 10 or
 (c) -NH-(CH₂)_r- wherein r represents an integer of 1 to 4;
 n represents 1;
 i) R¹ and R² each represents a hydrogen atom or C₁₋₆ alkyl;
 Ring A represents benzene ring; and
 15 Ring B represents



17. A compound of claim 16, wherein Ar is 3-indolyl.

20 18. A compound of claim 1, which is
 3-(R)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-
 2-[(R)-(4-phenylpiperazin-1-
 yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline
 or a salt thereof,
 25 3-(S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-
 2-[(R)-(4-phenylpiperazin-1-
 yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline
 or a salt thereof.

3-(R)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-
2-[(R)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-
yl)piperidinocarbonylamino]propanoyl]-1,2,3,4-
tetrahydroquinoline or a salt thereof,

5 3-(S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-
2-[(R)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-
yl)piperidinocarbonylamino]propanoyl]-1,2,3,4-
tetrahydroquinoline or a salt thereof.

10 3-(R)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-
2-(R)-[4-(2-methyl)phenylpiperazin-1-
yl]carbonylaminopropanoyl]-1,2,3,4-tetrahydroquinoline
or a salt thereof,

15 3-(S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-yl)-
2-(R)-[4-(2-methyl)phenylpiperazin-1-
yl]carbonylaminopropanoyl]-1,2,3,4-tetrahydroquinoline
or a salt thereof,

20 3-(R,S)-(N,N-Dimethylamino)methyl-1-[3-(indol-3-
yl)-2-[(R)-1-benzoyl-4-
piperidinocarbonylamino]propanoyl]-6-methoxy-1,2,3,4-
tetrahydroquinoline or a salt thereof.

25 6-Chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[3-
(indol-3-yl)-2-[(R)-4-(2-oxo-2,3-dihydro-1H-
benzimidazol-1-yl)piperidinocarbonylamino]propanoyl]-
1,2,3,4-tetrahydroquinoline or a salt thereof.


30 1-Benzoyl-N-[(R)-2-[6-chloro-3-[(N,N-
dimethylamino)methyl]-1,2,3,4-tetrahydroquinolin-1-yl]-
1-[3-(indol-3-yl)propanoyl]-4-piperidinecarboxamide or a
salt thereof,

35 1-[3-(4-Biphenylyl)propanoyl]-3-(R)-(N,N-
dimethylamino)methyl-1,2,3,4-tetrahydroquinoline or a
salt thereof, or
1-[3-(4-Biphenylyl)propanoyl]-3-(S)-(N,N-
dimethylamino)methyl-1,2,3,4-tetrahydroquinoline or a

salt thereof.

19. A process for producing a compound of claim 1, which comprises:

5 reacting a compound of the formula:



wherein each symbols has the same meanings as in claim 1, or a salt thereof, with a compound of the formula:

10 L-X-Y-Ar

wherein L represents a leaving group, and the other symbols have the same meanings as in claim 1, or a salt thereof.

20 20. A pharmaceutical composition which comprises a compound of claim 1.

21. A pharmaceutical composition of claim 20 which is a somatostatin receptor binding inhibitor.

20 22. A pharmaceutical composition of claim 21 which is a somatostatin receptor agonist.

23. A pharmaceutical composition of claim 21 which is a somatostatin receptor antagonist.


25

24. A prodrug of a compound of claim 1.

25. A pharmaceutical composition which comprises a prodrug of claim 24.

30

26. [A somatostatin receptor binding inhibitor] which comprises a compound of the formula (I'):



wherein Ar represents an aromatic group which may be substituted;

X' represents methylene, S, SO, SO₂ or CO;

5 Y represents a spacer having a main chain of 2 to 5 atoms; n represents an integer of 1 to 5;

i) R¹ and R² each represents a hydrogen atom or a lower alkyl which may be substituted,

10 ii) R¹ and R² form, taken together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic ring which may be substituted, or


iii) R¹ or R² together with -(CH₂)_n-N= form, bonded to a component atom of Ring B, a spiro-ring which may be substituted;

15 Ring A represents an aromatic ring which may be substituted; Ring B represents a 4- to 7-membered nitrogen-containing non-aromatic ring which may be further substituted by alkyl or acyl,
or a salt thereof.

20 27. An inhibitor of claim 26 which is for preventing or treating glaucoma, acromegaly, diabetes, diabetic complication, depression or tumor.

25 28. An inhibitor of claim 26 which is an analgesic agent.

29. Use of a compound of the formula (I'):



wherein Ar represents an aromatic group which may be

30 substituted;

X' represents methylene, S, SO, SO₂ or CO;

Y represents a spacer having a main chain of 2 to 5 atoms;

n represents an integer of 1 to 5;

i) R¹ and R² each represents a hydrogen atom or a lower alkyl
5 which may be substituted,

ii) R¹ and R² form, taken together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic ring which may be substituted, or

iii) R¹ or R² together with -(CH₂)_n-N= form, bonded to a
10 component atom of Ring B, a spiro-ring which may be substituted;

Ring A represents an aromatic ring which may be substituted;
Ring B represents a 4- to 7-membered nitrogen-containing non-aromatic ring which may be further substituted by alkyl
15 or acyl,
or a salt thereof, for manufacturing a pharmaceutical composition which is a somatostatin receptor binding inhibitor.

20 30. Use of a compound of the formula (I'):



wherein Ar represents an aromatic group which may be substituted;

X' represents methylene, S, SO, SO₂ or CO;

25 Y represents a spacer having a main chain of 2 to 5 atoms;

n represents an integer of 1 to 5;

i) R¹ and R² each represents a hydrogen atom or a lower alkyl which may be substituted,

ii) R¹ and R² form, taken together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic ring which may be substituted, or

iii) R¹ or R² together with -(CH₂)_n-N= form, bonded to a
30 component atom of Ring B, a spiro-ring which may be

substituted;


Ring A represents an aromatic ring which may be substituted;

Ring B represents a 4- to 7-membered nitrogen-containing non-aromatic ring which may be further substituted by alkyl or acyl;

or a salt thereof, for manufacturing a pharmaceutical composition for preventing or treating glaucoma, acromegaly, diabetes, diabetic complication, depression or tumor.

10

31. Use of a compound of the formula, (I'):



wherein Ar represents an aromatic group which may be substituted;

15 X' represents methylene, S, SO, SO₂ or CO;

Y represents a spacer having a main chain of 2 to 5 atoms;

n represents an integer of 1 to 5;

i) R¹ and R² each represents a hydrogen atom or a lower alkyl which may be substituted,

20 ii) R¹ and R² form, taken together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic ring which may be substituted, or

iii) R¹ or R² together with -(CH₂)_n-N= form, bonded to a component atom of Ring B, a spiro-ring which may be

25 substituted;


Ring A represents an aromatic ring which may be substituted;

Ring B represents a 4- to 7-membered nitrogen-containing non-aromatic ring which may be further substituted by alkyl or acyl,

30 or a salt thereof, for manufacturing a pharmaceutical composition which is an analgesic agent.

32. A method for inhibiting somatostatin receptor binding

in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of the formula (I'):



5 wherein Ar represents an aromatic group which may be substituted;

X' represents methylene, S, SO, SO₂ or CO;

Y represents a spacer having a main chain of 2 to 5 atoms;

n represents an integer of 1 to 5;

10 i) R¹ and R² each represents a hydrogen atom or a lower alkyl which may be substituted,

ii) R¹ and R² form, taken together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic ring which may be substituted, or

15 iii) R¹ or R² together with -(CH₂)_n-N= form, bonded to a component atom of Ring B, a spiro-ring which may be substituted;


Ring A represents an aromatic ring which may be substituted;

Ring B represents a 4- to 7-membered nitrogen-containing

20 non-aromatic ring which may be further substituted by alkyl or acyl,

or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable excipient, carrier or diluent.

25 33. A method for preventing or treating glaucoma, acromegaly, diabetes, diabetic complication, depression or tumor in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of the formula (I'):



wherein Ar represents an aromatic group which may be substituted;

X' represents methylene, S, SO, SO₂ or CO;

Y represents a spacer having a main chain of 2 to 5 atoms;

5 n represents an integer of 1 to 5;
i) R¹ and R² each represents a hydrogen atom or a lower alkyl which may be substituted,

ii) R¹ and R² form, taken together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic ring

10 which may be substituted, or
iii) R¹ or R² together with -(CH₂)_n-N= form, bonded to a component atom of Ring B, a spiro-ring which may be substituted;

Ring A represents an aromatic ring which may be substituted;

15 Ring B represents a 4- to 7-membered nitrogen-containing non-aromatic ring which may be further substituted by alkyl or acyl,
or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable excipient, carrier or diluent.

1/4

SEQUENCE LISTING

<110> Takeda Chemical Industries, Ltd.
<120> Amine Compounds, Their Production and Use
<130> 2511WOOP
<150> JP 10-096422
<151> 1998-04-08
<150> JP 10-345328
<151> 1998-12-04
<160> 12
<210> 1
<211> 28
<212> DNA
<213> Artificial Sequence
<220>
<223>
<400> 1
GGCTCGAGTC ACCATGAGCG CCCCCCTCG 28
<210> 2
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223>
<400> 2
GGGCTCGAGC TCCTCAGAAG GTGGTGG 27
<210> 3
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223>
<400> 3
AAGCATGAAC ACGCCTGCAA CTC 23

THIS PAGE BLANK USPTO

2/4

<210> 4

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223>

<400> 4

GGTTTTCAGA AAGTAGTGTT CTT 23

<210> 5

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223>

<400> 5

GGTCGACCTC AGCTAGGATG TTCCCCAATG 30

<210> 6

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223>

<400> 6

GGTCGACCCCG GGCTCAGAGAGC GTCGTGAT 28

<210> 7

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223>

<400> 7

GGTCGACACC ATGGACATGG CGGATGAG 28

<210> 8

<211> 26

<212> DNA

THIS PAGE BLANK (NSPTO)

3/4

<213> Artificial Sequence

<220>

<223>

<400> 8

GGTCGACAGT TCAGATACTG GTTTGG 26

<210> 9

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223>

<400> 9

GGTCGACCTC AACCATGGAC ATGCTTCATC 30

<210> 10

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223>

<400> 10

GGTCGACTTT CCCCCAGGCC CTACAGGTA 29

<210> 11

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223>

<400> 11

GGTCGACCAC CATGGAGCCC CTGTTCCC 28

<210> 12

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223>

THIS PAGE BLANK (OPTIONAL)

4/4

<400> 12

CCGTGGACAC TCTCACAGCT TGCTGG 26

THIS PAGE BLANK (USF90)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP 99/01871

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 6 C07D215/12 A61K31/47 C07D215/14 C07D215/18 C07D215/20 C07D215/42 C07D215/58 C07D401/06 C07D401/10 C07D401/14 C07D403/06 C07D405/06 C07D409/10 C07D413/06 C07D413/14					
According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols)					
IPC 6 C07D					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched					
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)					
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category *	Citation of document, with indication, where appropriate, of the relevant passages				Relevant to claim No.
P,X	EP 0 866 059 A (KYOTO PHARMA IND) 23 September 1998 (1998-09-23) cited in the application page 52 - page 53; claim 1				26-28
X	-& WO 97 12860 A (KYOTO PHARMA IND) 10 April 1997 (1997-04-10) cited in the application page 106; claim 1				26-28
A	PAPAGEORGIOU C ET AL: "A non-peptide ligand for the somatostatin receptor having a benzodiazepinone structure" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 3, 6 February 1996 (1996-02-06), pages 267-272, XP004135075 ISSN: 0960-894X the whole document				1-33
-/-					
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.			<input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed					
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family					
Date of the actual completion of the international search		Date of mailing of the international search report			
1 September 1999		10.09.99			
Name and mailing address of the ISA			Authorized officer		
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016			Fink, D		

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 99/01871

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C07D417/06 C07D417/14 C07D471/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 03054 A (SANDOZ LTD ;SANDOZ AG (DE); SANDOZ AG (AT); NEUMANN PETER (CH); PF) 30 January 1997 (1997-01-30) cited in the application the whole document -----	1-33

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
1 September 1999	10.09.99
Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patenttaan 2 NL - 2280 HV Rijswijk Tel: (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Fink, D

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP 99/01871

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 32 and 33 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: 1-11 (in part), 19-23 (in part), 24, 25, 26-33 (in part) because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-11 (in part), 19-23 (in part), 24, 25, 26-33 (in part)

Present claims 1-11 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds of the present claim 1 wherein Ring A represent a benzene ring which may be substituted and wherein Ring B is one of the rings as defined in the present claim 14. Furthermore, it is noted that since the expression "prodrug" has no concrete structural meaning (Article 6 PCT), no search could be performed on the present claims 24 and 25.

Therefore, the present International Search Report should only be considered as being complete as far as the present compound claims 12-18 are concerned.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 99/01871

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0866059	A 23-09-1998	AU 7097796 A		28-04-1997
		NO 981485 A		02-06-1998
		CA 2233842 A		10-04-1997
		CN 1203587 A		30-12-1998
		CZ 9800996 A		12-08-1998
		HU 9900617 A		28-06-1999
		WO 9712860 A		10-04-1997
		PL 326000 A		17-08-1998
-----	-----	-----	-----	-----
WO 9703054	A 30-01-1997	AU 703325 B		25-03-1999
		AU 6612096 A		10-02-1997
		CA 2224436 A		30-01-1997
		CN 1193964 A		23-09-1998
		CZ 9800016 A		15-04-1998
		EP 0839136 A		06-05-1998
		NO 980043 A		05-01-1998
		NZ 313606 A		29-07-1999
		PL 324106 A		11-05-1998
		SK 1798 A		03-06-1998
		US 5885988 A		23-03-1999
-----	-----	-----	-----	-----

THIS PAGE BLANK (USPTO)